Materials with improved biocompatibility

Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.

REFERENCE TO SEQUENCE LISTING

The Sequence Listing submitted as a text file named “MIT_17502_ST25.txt,” created on Nov. 1, 2016, and having a size of 4,941 bytes is hereby incorporated by reference pursuant to 37 C.F.R. § 1.52(e)(5).

FIELD OF THE INVENTION

This invention is in the field of materials with improved properties, e.g., biocompatibility, particularly implantable devices with reduced foreign body response and moieties that confer improved properties, e.g., biocompatibility.

BACKGROUND OF THE INVENTION

The foreign body response is an immune-mediated reaction that impacts the fidelity of implanted biomedical devices (Anderson et al., Semin. Immunol. 20:86-100 (2008); Langer,Adv. Mater.21:3235-3236 (2009); Ward,J. Diabetes Sci. Technol. Online2:768-777 (2008); Harding & Reynolds,Trends Biotechnol.32:140-146 (2014)). Macrophage recognition of biomaterial surfaces in these devices initiate a cascade of inflammatory events that result in the fibrous and collagenous encapsulation of these foreign materials (Anderson et al. (2008); Ward (2008); Harding & Reynolds (2014); Grainger,Nat. Biotechnol.31:507-509 (2013); Williams,Biomaterials29:2941-2953 (2008)). This encapsulation, over time, often leads to device failure and can result in discomfort for the recipient (Anderson et al. (2008); Harding & Reynolds (2014); Williams (2008)). These adverse outcomes emphasize the critical need for biomaterials that do not elicit foreign body responses to overcome this key challenge to long-term biomedical device function.

The foreign body response to implanted biomaterials is the culmination of inflammatory events and wound-healing processes resulting in implant encapsulation (Anderson et al. (2008)). The final pathological product of this response is fibrosis, which is characterized by the accumulation of excessive extracellular matrix at sites of inflammation and is a key obstacle for implantable medical devices as the cellular and collagenous deposition isolate the device from the host (Anderson et al. (2008); Wick et al.,Annu. Rev. Immunol.31:107-135 (2013); Wynn & Ramalingam,Nat. Med.18:1028-1040 (2012)). This device isolation can interfere with sensing of the host environment, lead to painful tissue distortion, cut off nourishment (for implants containing living, cellular components), and ultimately lead to device failure. Materials commonly used for medical device manufacture today elicit a foreign body response that results in fibrous encapsulation of the implanted material (Langer (2009); Ward (2008); Harding & Reynolds (2014); Williams (2008); Zhang et al.,Nat. Biotechnol.31:553-556 (2013)). Overcoming the foreign body response to implanted devices could pave the way for implementing new medical advances, making the development of materials with both anti-inflammatory and anti-fibrotic properties a critical medical need (Anderson et al. (2008); Langer (2009); Harding & Reynolds (2014)).

Macrophages are a key component of material recognition and actively adhere to the surface of foreign objects (Anderson et al. (2008); Ward (2008); Grainger,Nat. Biotechnol.31:507-509 (2013); Sussman et al.,Ann. Biomed. Eng.1-9 (2013) (doi:10.1007/s10439-013-0933-0)). Objects too large for macrophage phagocytosis initiate processes that result in the fusion of macrophages into foreign-body giant cells. These multi-nucleated bodies amplify the immune response by secreting cytokines and chemokines that result in the recruitment of fibroblasts that actively deposit matrix to isolate the foreign material (Anderson et al. (2008); Ward (2008); Rodriguez et al.,J. Biomed. Mater. Res. A89:152-159 (2009); Hetrick et al.,Biomaterials28:4571-4580 (2007)). This response has been described for materials of both natural and synthetic origins that encompass a wide range of physicochemical properties, including alginate, chitosan, dextran, collagen, hyaluronan, poly(ethylene glycol) (PEG), poly(methyl methacrylate) (PMMA), poly(2-hydroxyethyl methacrylate) (PHEMA), polyurethane, polyethylene, silicone rubber, Teflon, gold, titanium, silica, and alumina (Ward (2008); Ratner,J. Controlled Release78:211-218 (2002)).

The development of implantable devices that resist host foreign body responses for protracted periods of time is important for improving the performance and safety of such devices, and remains an unmet need. Accordingly, the search for materials of clinical relevance that address the foreign body response to implantable devices, i.e., ameliorate biocompatibility, remains an area of active research.

Therefore, it is an object of the invention to provide chemical compounds suitable for modifying the surface or a surface of a product to impart a beneficial effect to the product compared to a corresponding product that lacks the chemical modification.

It is also an object of the invention to provide chemical compounds suitable for modifying the surface or a surface of a product, where the chemically modified product has optimized biocompatibility, e.g., greater long term biocompatibility, following implantation of the product compared to a corresponding product that lacks the chemical modification.

It is also an object of the invention to provide chemical compounds suitable for modifying the surface or a surface of a product, where the chemically modified product elicits a lower foreign body response following implantation of the product compared to a corresponding product that lacks the chemical modification.

It is also an object of the invention to provide a chemically modified product with improved biocompatibility and tailored physico-chemical properties, including porosity, roughness, lubricity, hydrophilicity, and hydrophobicity, compared to a corresponding product that lacks the chemical modification.

It is also an object of the invention to provide a chemically modified product that elicits a lower foreign body response, compared to a corresponding product that lacks the chemical modification.

It is also an object of the invention to provide methods for chemically modifying the surface or a surface of a product using compounds, where the chemically modified product has improved biocompatibility compared to a corresponding product that lacks the chemical modification.

It is also an object of the invention to provide methods for chemically modifying the surface or a surface of a product using compounds, where the chemically modified product elicits a lower foreign body response compared to a corresponding product that lacks the chemical modification.

It is also an object of the invention to provide methods for treating a disorder or disease in a subject by transplanting or implanting a product modified with a compound, where the modified product has improved biocompatibility compared to a corresponding product that lacks the chemical modification.

It is also an object of the invention to provide methods for treating a disorder or disease in a subject by transplanting or implanting a product modified with a compound, where the modified product elicits a lower foreign body response compared to a corresponding product that lacks the chemical modification.

SUMMARY OF THE INVENTION

Products, such as devices, prostheses, and materials, having surfaces comprising moieties or compounds that impart beneficial properties to these products are disclosed. The surface-modified products have optimized properties, e.g., improved biocompatibility, compared to a corresponding product that lacks the moieties or compounds on its surface. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.

In some embodiments, the surfaces of the products can be covalently modified using chemical compounds. In some embodiments, the chemical compounds contain hydrophobic groups. In preferred embodiments, the chemical compounds contain aryl/heteroaryl groups. In currently preferred embodiments for improving biocompatibility, the chemical compounds contain a triazole linked to a moiety or compound that can provide anti-fibrotic properties. In preferred embodiments, the moiety can be tetrahydropyran, thiomorpholine-1,1-dioxide, or aniline.

In one aspect, the products described herein can be implanted or administered to a subject comprising a human or an animal including, but not limited to, a mouse, dog, cat, horse, bovine or ovine and the like, that is in need thereof, e.g., in need of alleviation or amelioration from a disorder, e.g., a recognized medical condition.

Disclosed are products, such as devices, prostheses, and materials, where the surface or a surface of the product includes one or more of the moieties or compounds described herein. In some embodiments, the product can be formed from a starting material or intermediate which includes the moiety or compound. In some embodiments, the product can be formed by covalently modifying a starting material or the surface of a starting material, intermediate, or an otherwise finished object. For example, the surface or a surface of the product can be chemically modified after formation of the product with one or more compounds. The compounds are preferably compounds that confer a beneficial effect, such as lower foreign body response and improved biocompatibility, on the product. In some embodiments, the modifying compounds can provide anti-fibrotic properties. Also disclosed are methods of chemically modifying products and methods of using the chemically modified products, such as by implantation into a subject.

In some embodiments, the compound can have a structure —X—R1, whereX is oxygen, sulfur, NR2, or another group compatible with attachment or coupling of the compound to a product or surface;R1is hydrogen, or an organic grouping containing any number of carbon atoms, preferably 1-30 carbon atoms, more preferably 1-20 carbon atoms, more preferably 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R1organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q2+Q3); andR2is hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R2organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q3).

In some embodiments, R1is, independently in one or more sites of chemical modification,
-A-B(—C)δ,   Formula XII
whereinA is hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q3);B, and C are, independently, absent, hydrogen, or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q3); andδ is an integer from, as valency permits, 0 to 30.

In some embodiments, R1is, independently in one or more sites of chemical modification,
—R3—Rb,   Formula II
whereinR3is hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R3organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q3); andRbis absent, hydrogen, or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative Rborganic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q3).

Independently in some embodiments of A and R3, and independently in combination with any embodiments of any other relevant substituent classes, A and R3can be, independently, hydrogen, U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q3).

Independently in some embodiments of A and R3, and independently in combination with any embodiments of any other relevant substituent classes, A and R3can be, independently, hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or J1.

Independently in some embodiments of A and R3, and independently in combination with any embodiments of any other relevant substituent classes, A and R3can be, independently, hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or J2.

Independently in some embodiments of B, C, and Rb, and independently in combination with any embodiments of any other relevant substituent classes, B, C, and Rbcan be, independently, absent, hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or J1.

Independently in some embodiments of B, C, and Rb, and independently in combination with any embodiments of any other relevant substituent classes, B, C, and Rbcan be, independently, absent, hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or J2.

Independently in some embodiments of A and R3, and independently in combination with any embodiments of any other relevant substituent classes, A and R3can be, independently,

Independently in some embodiments of B, and independently in combination with any embodiments of any other relevant substituent classes, B can be

Independently in some embodiments of Rb, and independently in combination with any embodiments of any other relevant substituent classes, Rbcan be

Independently in some embodiments of C, and independently in combination with any embodiments of any other relevant substituent classes C can be

Independently in some embodiments of A and R3, and independently in combination with any embodiments of any other relevant substituent classes, A and R3can be, independently,

Independently in some embodiments of B, and independently in combination with any embodiments of any other relevant substituent classes, B can be

Independently in some embodiments of Rb, and independently in combination with any embodiments of any other relevant substituent classes, Rbcan be

Independently in some embodiments of C, and independently in combination with any embodiments of any other relevant substituent classes, C can be

Independently in some embodiments of A and R3, and independently in combination with any embodiments of any other relevant substituent classes, A and R3can be, independently,

Independently in some embodiments of B, and independently in combination with any embodiments of any other relevant substituent classes, B can be

Independently in some embodiments of Rb, and independently in combination with any embodiments of any other relevant substituent classes, Rbcan be

Independently in some embodiments of C, and independently in combination with any embodiments of any other relevant substituent classes, C can be

Independently in some embodiments of A and R3, and independently in combination with any embodiments of any other relevant substituent classes, A and R3can be, independently,

Independently in some embodiments of B, and independently in combination with any embodiments of any other relevant substituent classes, B can be

Independently in some embodiments of Rb, and independently in combination with any embodiments of any other relevant substituent classes, Rbcan be

Independently in some embodiments of C, and independently in combination with any embodiments of any other relevant substituent classes, C can be

Independently in some embodiments of A and R3, and independently in combination with any embodiments of any other relevant substituent classes, A and R3can be, independently,

Independently in some embodiments of B, and independently in combination with any embodiments of any other relevant substituent classes, B can be

Independently in some embodiments of Rb, and independently in combination with any embodiments of any other relevant substituent classes, Rbcan be

Independently in some embodiments of C, and independently in combination with any embodiments of any other relevant substituent classes, C can be

Independently in some embodiments of A and R3, and independently in combination with any embodiments of any other relevant substituent classes, A and R3can be, independently,

Independently in some embodiments of B, and independently in combination with any embodiments of any other relevant substituent classes, B can be

Independently in some embodiments of Rb, and independently in combination with any embodiments of any other relevant substituent classes, Rbcan be

Independently in some embodiments of C, and independently in combination with any embodiments of any other relevant substituent classes, C can be

Independently in some embodiments of A and R3, and independently in combination with any embodiments of any other relevant substituent classes, A and R3can be, independently,

Independently in some embodiments of B, and independently in combination with any embodiments of any other relevant substituent classes, B can be

Independently in some embodiments of Rb, and independently in combination with any embodiments of any other relevant substituent classes, Rbcan be

Independently in some embodiments of C, and independently in combination with any embodiments of any other relevant substituent classes, C can be

Independently in some embodiments of A and R3, and independently in combination with any embodiments of any other relevant substituent classes, A and R3can be, independently,

Independently in some embodiments of B, and independently in combination with any embodiments of any other relevant substituent classes, B can be

Independently in some embodiments of Rb, and independently in combination with any embodiments of any other relevant substituent classes, Rbcan be

Independently in some embodiments of C, and independently in combination with any embodiments of any other relevant substituent classes, C can be

In some embodiments, R1is, independently in one or more sites of chemical modification,

where a is an integer from 1 to 30, z is an integer from 0-5, n is an integer from 1 to 12, m is an integer from 3 to 16, and Raand Rbare independently selected from U2, U2+Q1, U2+Q2, U2+Q3, U2+Q1+Q2, U2+Q1+Q3, U2+Q2+Q3, U2+Q1+Q2+Q3, U3, U3+Q1, U3+Q2, U3+Q3, U3+Q1+Q2, U3+Q1+Q3, U3+Q2+Q3, or U3+Q1+Q2+Q3(preferably, in these embodiments, U3+Q1+Q2+Q3), and Rbis

andR3, R4, and R5are, independently, hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1+Q2+Q3).

In some embodiments, the compound can have a structure —X—R1, whereX is oxygen, sulfur, NR2, or another group compatible with attachment or coupling of the compound to a product or surface;R1is, independently in one or more sites of chemical modification, hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1+Q2+Q3);R2is hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R2organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1+Q3).

In some embodiments, R1is, independently in one or more sites of chemical modification,

or —R3—Rb,where a is an integer from 1 to 30, z is an integer from 0-5, n is an integer from 1 to 12, m is an integer from 3 to 16, Rais independently selected from U2, U2+Q1, U2+Q2, U2+Q3, U2+Q1+Q2, U2+Q1+Q3, U2+Q2+Q3, U2+Q1+Q2+Q3, U3, U3+Q1, U3+Q2, U3+Q3, U3+Q1+Q2, U3+Q1+Q3, U3+Q2+Q3, or U3+Q1+Q2+Q3(preferably, in these embodiments, U3+Q1+Q2+Q3), and Rbis

andR3, R4, and R5are, independently, hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R3, R4, and R5organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1+Q2+Q3).

Independently in some embodiments of a, and independently in combination with any embodiments of any other relevant substituent classes, a can be an integer from 1 to 10, 2 to 10, 3 to 10, 4 to 10, 5 to 10, 6 to 10, 7 to 10, 8 to 10, 9 to 10, 1 to 9, 2 to 9, 3 to 9, 4 to 9, 5 to 9, 6 to 9, 7 to 9, 8 to 9, 1 to 8, 2 to 8, 3 to 8, 4 to 8, 5 to 8, 6 to 8, 7 to 8, 1 to 7, 2 to 7, 3 to 7, 4 to 7, 5 to 7, 6 to 7, 1 to 6, 2 to 6, 3 to 6, 4 to 6, 5 to 6, 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2. Independently in some embodiments of a, and independently in combination with any embodiments of any other relevant substituent classes, a can be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

Independently in some embodiments of a, and independently in combination with any embodiments of any other relevant substituent classes, a can be an integer from 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2. In preferred embodiments, a is 1, 2, 3, 4, or 5.

Independently in some embodiments of m, and independently in combination with any embodiments of any other relevant substituent classes, m can be an integer from 3 to 10, 4 to 10, 5 to 10, 6 to 10, 7 to 10, 8 to 10, 9 to 10, 3 to 9, 4 to 9, 5 to 9, 6 to 9, 7 to 9, 8 to 9, 3 to 8, 4 to 8, 5 to 8, 6 to 8, 7 to 8, 3 to 7, 4 to 7, 5 to 7, 6 to 7, 3 to 6, 4 to 6, 5 to 6, 3 to 5, 4 to 5, and 3 to 4. Independently in some embodiments of m, and independently in combination with any embodiments of any other relevant substituent classes, m can be 3, 4, 5, 6, 7, 8, 9, or 10.

Independently in some embodiments of m, and independently in combination with any embodiments of any other relevant substituent classes, m can be an integer from 3 to 5, 4 to 5, or 3 to 4. In preferred embodiments, m is 3, 4, or 5.

Independently in some embodiments of n, and independently in combination with any embodiments of any other relevant substituent classes, n can be an integer from 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2. In preferred embodiments, n is 1, 2, 3, 4, or 5.

In some embodiments, X is oxygen or NR2, wherein R2is hydrogen, methyl, or —CH2—CH3; and R1is —CH2—CH2—CH2—CH2—OH, —CH2—CH2—(O—CH2—CH2)n—O—CH3, where n is an integer from 3 to 16, —CH2—CH2—O—CH2—CH2—OH, —(CH2—CH2)3—NH—CH3,

Independently in some embodiments of Formula I, X is oxygen, sulfur, or NR2, wherein R2is hydrogen, alkyl, or substituted alkyl, wherein R1is
-A-B(—C)δ,   Formula XIIwherein A is

Independently in some embodiments of Formula I, X is oxygen, sulfur, or NR2, wherein R2is hydrogen, alkyl, or substituted alkyl,

wherein R1is
-A-B(—C)δ,   Formula XIIwherein A is

R18in B is —(CH2)p—; p is an integer from 0 to 5; each Rdis independently alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, alkoxy, alkylamino, dialkylamino, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C3-C20cyclic, substituted C3-C20cyclic, heterocyclic, or substituted heterocyclic; w is an integer from 0 to 4; each R12, R13, R14, R15, and R16, are independently C or N, wherein the bonds between adjacent R12to R16are double or single according to valency, and wherein R12to R16are bound to none, one, or two hydrogens according to valency, and R14is bound to C;wherein C is

Independently in some embodiments of Formula I, X is oxygen, sulfur, or NR2, wherein R2is hydrogen, alkyl, or substituted alkyl,wherein R1is
-A-B(—C)δ,   Formula XIIwherein A is

Independently in some embodiments of Formula I, X is oxygen, sulfur, or NR2, wherein R2is hydrogen, alkyl, or substituted alkyl,wherein R1is
-A-B(—C)δ,   Formula XIIwherein A is

In some embodiments, the compound is

In some embodiments, the product includes a cargo or payload, such as a biological material. For example, the biological material can be cells or tissue. In some embodiments, the cargo is disposed within an outer member (e.g. a coating or encapsulating layer) that includes compounds as described herein on its surface.

In some embodiments, the product can be a cardiac pacemaker, a catheter, a needle injection catheter, a blood clot filter, a vascular transplant, a balloon, a stent transplant, a biliary stent, an intestinal stent, a bronchial stent, an esophageal stent, a ureteral stent, an aneurysm-filling coil or other coil device, a surgical repair mesh, a transmyocardial revascularization device, a percutaneous myocardial revascularization device, a prosthesis, an organ, a vessel, an aorta, a heart valve, a tube, an organ replacement part, an implant, a fiber, a hollow fiber, a membrane, a textile, banked blood, a blood container, a titer plate, an adsorber media, a dialyzer, a connecting piece, a sensor, a valve, an endoscope, a filter, a pump chamber, or another medical device intended to have hemocompatible properties.

In some embodiments, the product includes cells or tissues encapsulated or coated with a polymer, where the surface or a surface of the polymeric product includes compounds as described herein. In some embodiments of such products:(a) the polymer comprises polydimethylsiloxane (PDMS);(b) the compound comprises the formula -A-B(—C)δ(Formula XIII), where A is Formula VIII or Formula VI, B is Formula IX, δ is 1, C is Formula VI;(c) the product is spherical or spheroidal in shape;(d)) the product has an average diameter of 1.5 mm;(e) the cell is a cell producing a recombinant product; and, optionally,(f) the product has a pore size of 0.1 to 1 μm.

In some embodiments, the product is provided as a preparation of products and the products in the preparation have one or more of the following characteristics:(1) at least 50% of the products in the preparation have a surface with a concentration of 1 to 5% surface modifications as measured by X-ray photoelectron spectroscopy (XPS);(2) at least 50% of the products in the preparation have the shape specified in (c); (3) at least 50% of the products in the preparation have a the diameter specified in (d); and(4) at least 50% of the products in the preparation have the pore size of (f).

In some embodiments, the product has properties (1) and (2).

In some embodiments, the product has properties (1) and (3).

In some embodiments, the product has properties (1) and (4).

In some embodiments, the product has properties (2) and (3).

In some embodiments, the product has properties (2) and (4).

In some embodiments, the product has properties (3) and (4).

In some embodiments, the product has properties (1), (2), and (3).

In some embodiments, the product has properties (1), (2), (3). and (4).

In some embodiments, when implanted into the subject, at least 5% of the cells are alive after 30 days.

In some embodiments, when implanted into the subject, the cells respond to an increase in blood glucose by secreting insulin.

In some embodiments, the product is singularly modified with the compound of (b).

In some embodiments, the product is encapsulated or coated with a polymer, wherein the polymer comprises a compound with a structure-X—R1, wherein X is oxygen, sulfur, NR2, or another group compatible with attachment or coupling of the compound to a product or surface; R2is hydrogen, alkyl, or substituted alkyl; and R1is
-A-B(—C)δ,   Formula XIIwherein A is

R18in B is —(CH2)p—; p is an integer from 0 to 5; each Rdis independently alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, alkoxy, alkylamino, dialkylamino, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C3-C20cyclic, substituted C3-C20cyclic, heterocyclic, or substituted heterocyclic; w is an integer from 0 to 4; each R12, R13, R14, R15, and R16, are independently C or N, wherein the bonds between adjacent R12to R16are double or single according to valency, and wherein R12to R16are bound to none, one, or two hydrogens according to valency, and R14is bound to C.wherein C is

R18in C is —(CR19R19)p—Xb—(CR19R19)q—, p is 1 and q is 0; Xbis —O—; each R19is hydrogen; Rdare independently alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, alkoxy, alkylamino, dialkylamino, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C3-C20cyclic, substituted C3-C20cyclic, heterocyclic, or substituted heterocyclic; z is an integer from 0 to 11; each R12, R13, R14, R15, R16, and R17are independently C, O, N, or S, wherein the bonds between adjacent R12to R17are double or single according to valency, and wherein R12to R17are bound to none, one, or two hydrogens according to valency;wherein δ is 1; andwherein the product has one or more characteristics selected from:(a) a spherical or spheroidal shape;(b) a mean diameter between 1 mm and 4 mm;(c) a mean pore size ranging from 0.1 μm to 10 μm;(d) a density of chemical derivatizations between 100 and 1000 per μm2on the surface or a surface of the products, in the interior of the products, or both; and(e) a concentration of between 10 and 100 percent surface modifications.

In some embodiments, the product is encapsulated or coated with a polymer, wherein the polymer comprises a compound with a structure-X—R1, wherein X is oxygen, sulfur, NR2, or another group compatible with attachment or coupling of the compound to a product or surface; R2is hydrogen, alkyl, or substituted alkyl; and R1is
-A-B(—C)δ,   Formula XIIwherein A is

R18in C is —(CR19R19)p—; p is an integer from 0 to 5; each R19is hydrogen; Rdare independently alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkynyl, alkoxy, alkylamino, dialkylamino, hydroxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted alkoxy, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, C3-C20cyclic, substituted C3-C20cyclic, heterocyclic, or substituted heterocyclic; z is an integer from 0 to 11; wherein R12, R13, R14, R15, R16, and R17are independently C, N, or S(O)2, wherein the bonds between adjacent R12to R17are double or single according to valency, and wherein R12to R17are bound to none, one, or two hydrogens according to valency;wherein δ is 1; andwherein the product has one or more characteristics selected from:(a) a spherical or spheroidal shape;(b) a mean diameter between 1 mm and 4 mm;(c) a mean pore size ranging from 0.1 μm to 10 μm;(d) a density of chemical derivatizations between 100 and 1000 per μm2on the surface or a surface of the products, in the interior of the products, or both; and(e) a concentration of between 10 and 100 percent surface modifications.

In some embodiments, the product is multiply modified with the compound of (b) and another compound of different structure (for example, another compound as disclosed herein).

In some embodiments, the product is purified after chemical modification to remove any unreacted or partially reacted contaminants present with the chemically modified product, wherein the purified chemically modified product induces a lower foreign body response than a similar product that has not been chemically modified.

DETAILED DESCRIPTION OF THE INVENTION

It has been discovered that certain classes of chemical compounds confer beneficial effects, such as lower foreign body response, when used to chemically modify products for implantation into the body of a subject. In tests of a range of product materials, the disclosed chemical modifications improve the in vivo performance of implantable biomedical devices through chemical surface modification of commonly and widely used materials for device manufacture.

“Biocompatible,” as used herein, refers to a substance or object that performs its desired function when introduced into an organism without inducing significant inflammatory response, immunogenicity, or cytotoxicity to native cells, tissues, or organs. For example, a biocompatible product is a product that performs its desired function when introduced into an organism without inducing significant inflammatory response, immunogenicity, or cytotoxicity to native cells, tissues, or organs. Biocompatibility, as used herein, can be quantified using the in vivo biocompatibility assay described below.

In this assay, a material or product as disclosed can be considered biocompatible if it produces, in a test of biocompatibility related to immune system reaction less than 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 8%, 6%, 5%, 4%, 3%, 2%, or 1% of the reaction, in the same test of biocompatibility, produced by a material or product the same as the test material or product except for a lack of the surface modification on the test material or product. Examples of useful biocompatibility tests include measuring and assessing cytotoxicity in cell culture, inflammatory response after implantation (such as by fluorescence detection of cathepsin activity), and immune system cells recruited to implant (for example, macrophages and neutrophils).

“Foreign body response” as used herein, refers to the immunological response of biological tissue to the presence of any foreign material in the tissue which can include protein adsorption, macrophages, multinucleated foreign body giant cells, fibroblasts, and angiogenesis.

“Contacting” as used herein in the context of coating refers to any way for coating a product, using one or more of the compounds disclosed herein, on a substrate such as a product. Contacting can include, but is not limited to, intraoperative dip-coating, spraying, wetting, immersing, dipping, painting, bonding or adhering, stepwise surface derivatization, or otherwise providing a substrate or surface with a compound. The compound can be covalently attached, non-covalently attached, or both, to the substrate or surface.

“Coating” as used herein, refers to any temporary, semi-permanent or permanent layer, covering or surface. A coating can be applied as a gas, vapor, liquid, paste, semi-solid, or solid. In addition a coating can be applied as a liquid and solidified into a hard coating. Elasticity can be engineered into coatings to accommodate pliability, e.g. swelling or shrinkage, of the substrate or surface to be coated.

“Chemical modification” and related terms, as used herein in the context of the disclosed products, refers to chemical modification of the product. Generally, such chemical modification is by direct attachment, coupling, or adherence of a compound to the surface material of the product. Preferably, the chemical modification involves modification with one or more of the disclosed compounds. Chemical modification, as defined herein in the context of the disclosed products, can be accomplished at any time and in any manner, including, for example, synthesis or production of the modified form of the product or material when the product or material is formed, addition of the chemical modification after the final product or material is formed, or at any time in between. The terms “replaced,” “replace,” “modified,” “singularly modified,” “singular modification,” “multiply modified,” “multiple modifications,” “chemically modified,” “surface modified,” “modification,” “chemical modification,” “surface modification,” “substituted,” “substitution,” “derived from,” “based on,” or “derivatized,” and similar terms, as used herein to describe a structure, do not limit the structure to one made from a specific starting material or by a particular synthetic route. Except where specifically and expressly provided to the contrary, the terms refer to a structural property, regardless of how the structure was formed, and the structure is not limited to a structure made by any specific method.

In some embodiments, where explicitly indicated, addition or application of a material, compound, or composition to a starting material or intermediate before it is made into or incorporated into the final product can be specifically excluded. Thus, for example, chemical modification of alginate or another polymer prior to the polymer being incorporated into a capsule or other structure can be, in some embodiments, specifically excluded as the manner of producing a chemical modification of the capsule or structure. As another example, coating a device, prosthesis, or other product with a material that was chemically modified prior to being applied as a coating can be, in some embodiments, specifically excluded as the manner of producing a chemical modification of the device, prosthesis, or product. However, for such embodiments where such specific exclusions are used, so long as the product was itself chemically modified, coating of or addition to the product of another material that has chemical modifications does not alter the fact that the product was chemically modified according to the meaning of the term used herein.

“Surface modification” and related terms, as used herein in the context of a product, e.g., the disclosed products, refers to chemical modification of the surface or a surface of the product. Generally, such surface modification is by direct attachment, coupling, or adherence of a compound to the surface material of the product. Preferably, the surface modification involves modification with one or more of the disclosed compounds. Surface modification, as defined herein in the context of the disclosed products, can be accomplished at any time and in any manner, including, for example, synthesis or production of the modified form of the product or material when the product or material is formed, addition of the chemical modification after the final product or material is formed, or at any time in between. Except where specifically and expressly provided to the contrary, the term “surface modification” refers to a structural property, regardless of how the structure was formed, and the structure is not limited to a structure made by any specific method.

In some embodiments, where explicitly indicated, addition or application of a material, compound, or composition to a starting material or intermediate before it is made into or incorporated into the final product can be specifically excluded. Thus, for example, chemical or surface modification of alginate or another polymer prior to the polymer being incorporated into a capsule or other structure can be, in some embodiments, specifically excluded as the manner of producing a surface modification of the capsule or structure. As another example, coating a device, prosthesis, or other product with a material that was chemically modified prior to being applied as a coating can be, in some embodiments, specifically excluded as the manner of producing a surface modification of the device, prosthesis, or product. However, for such embodiments where such specific exclusions are used, so long as the product was itself surface modified, coating of or addition to the product of another material that has chemical modifications does not alter the fact that the product was surface modified according to the meaning of the term used herein.

In some embodiments, the moieties or compounds modifying the product can be present on the surface or a surface of the product, and are not present, or are not present in a significant amount, elsewhere in the product, e.g., on internal or interior surfaces. In some embodiments, at least 50, 60, 70, 80, 90, 95, or 99% of the moieties or compounds are present on the surface or a surface of the product. In some embodiments, the moieties or compounds are present on the exterior face of the surface or a surface of the product, and are not present, or not present in a significant amount, elsewhere in the product, e.g., on internal or interior surfaces. In some embodiments, at least 50, 60, 70, 80, 90, 95, or 99% of the moieties or compounds are present on the external face of the surface or a surface of the product.

In some embodiments, the moieties or compounds modifying the product can be present on a portion or component of the product, and are not present, or are not present in a significant amount, elsewhere in the product. Such differences can be referred to as asymmetry of the modification or coating. In some embodiments, at least 50, 60, 70, 80, 90, 95, or 99% of the moieties or compounds are present on the portion or component of the product. In some embodiments, the moieties or compounds are present on the exterior face of the portion or component of the product, and are not present, or not present in a significant amount, elsewhere in the product. In some embodiments, at least 50, 60, 70, 80, 90, 95, or 99% of the moieties or compounds are present on the external face of the portion or component of the product.

“Surface,” as used herein in the context of the disclosed products, refers to the exterior or outer boundary of a product. Generally, the surface or a surface of a product corresponds to the idealized surface of a three dimensional solid that is topological homeomorphic with the product. The surface or a surface of the product can be an exterior surface or an interior surface of the product. An exterior surface forms the outermost layer of a product or device. An interior surface surrounds an inner cavity of a product or device, such as the inner cavity of a tube. As an example, both the outside surface of a tube and the inside surface of a tube are part of the surface or a surface of the tube. However, internal surfaces of the product that are not in topological communication with the exterior surface, such as a tube with closed ends, can be excluded as the surface or a surface of a product. Preferred surfaces to be chemically modified are the outside surface and surfaces that can contact immune system components. Where the product is porous or has holes in its mean (idealized or surface, the internal faces of passages and holes would not be considered part of the surface or a surface of the product if its opening on the mean surface of the product is less than 5 nm.

“Corresponding product” and “similar product,” as used herein, refers a product that has, as far as is practical or possible, the same composition, structure, and construction as a reference product. The terms “corresponding” and “similar” can be used for the same meaning with any particular or subgroup of products or other materials described herein. For example, a “similar surface modification” refers a surface modification that has, as far as is practical or possible, the same composition, structure, and construction as a reference surface modification.

“Control corresponding product” and “control similar product,” as used herein, refers a product that has, as far as is practical or possible, the same composition, structure, and construction as a reference product except for one or more specified parameters. For example, a control corresponding product that lacks the chemical modification in reference to a chemically modified product refers to a product that has, as far as is practical or possible, the same composition, structure, and construction as a reference product except for the chemical modification. Generally, a product prior to chemical modification constitutes a control corresponding product to the chemically modified form of the product. The terms “control corresponding” and “control similar” can be used for the same meaning with any particular or subgroup of products or other materials described herein. For example, a “control similar surface modification” refers a surface modification that has, as far as is practical or possible, the same composition, structure, and construction as a reference surface modification except for one or more specified parameters. Components that are “control corresponding” or “control similar” relative to a reference component are useful as controls in assays assessing the effect of independent variables.

“Preparation,” as used herein in reference to products, compounds, and other objects and components themselves (as opposed to their production or preparation), refers to a plurality of the product, compound, or other object or component, each such product, compound, or other object or component having a set of common properties and structure but also having some differences in properties or structure. For example, a preparation of capsules with capsules having the same composition, structure, and functional properties, can include, for example, capsules having a variance in shape, size, pore size, generally around a desired mean. It is not necessary that such variance be intended or purposely designed, although that is contemplated. Rather, such variance generally is a consequence of the variability in production or preparation of the products, compounds, and other objects and components (as is exemplified by production of capsules).

“Implanting,” as used herein, refers to the insertion or grafting into the body of a subject a product or material.

“Administering,” as used herein, refers to contacting a substance or product to the body of a subject. For example, administering a substance or a product includes contacting the skin of a subject and injecting or implanting a substance or product into the subject.

“Chemical compound,” as used herein, refers to an organic compound. The disclosed compounds for chemically modifying products are examples of chemical compounds.

“High,” “higher,” “increases,” “elevates,” and “elevation,” as used herein, refer to increases above a reference level, e.g., a basal level, e.g., as compared to a control. “Low,” “lower,” “reduces,” and “reduction,” as used herein, refer to decreases below a reference level, e.g., a basal level, e.g., as compared to a control. “Improved,” as used herein, refers to a change that is desirable, which may be a higher or lower value of some measure.

“Long term,” as used herein, refers to a state or situation that extends for longer than days or weeks. Preferred long term effects last several months or years.

“Monitoring” as used herein refers to any method in the art by which an activity can be measured.

“Providing,” as used herein, refers to any method, device, or means of adding a compound or molecule to something, e.g., a method or device known in the art. Examples of providing can include the use of pipettes, pipettemen, syringes, needles, tubing, guns, etc. This can be manual or automated. It can include transfection by any mean or any other means of providing nucleic acids to dishes, cells, tissue, cell-free systems and can be in vitro or in vivo.

“Preventing,” as used herein, refers to administering or applying a treatment or therapy prior to the onset of clinical symptoms of a disease or conditions so as to prevent a physical manifestation of aberrations associated with the disease or condition.

“In need of treatment,” as used herein, refers to a subject that would benefit from the treatment. In some embodiments, it comprises a judgment made by a caregiver (e.g. physician, nurse, nurse practitioner, or individual in the case of humans; veterinarian in the case of animals, including non-human mammals) that a subject requires or will benefit from treatment. This judgment can be made based on a variety of factors that are in the realm of a care giver's expertise, but that includes the knowledge that the subject is ill, or will be ill, as the result of a condition that is treatable by the compounds of the invention.

“Subject,” as used herein, includes, but is not limited to, animals, plants, bacteria, viruses, parasites and any other organism or entity. The subject can be a vertebrate, more specifically a mammal (e.g., a human, horse, pig, rabbit, dog, sheep, goat, non-human primate, cow, cat, guinea pig or rodent), a fish, a bird or a reptile or an amphibian. The subject can be an invertebrate, more specifically an arthropod (e.g., insects and crustaceans). The term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be covered. A patient refers to a subject afflicted with a disease or disorder. The term “patient” includes human and veterinary subjects.

“Treatment” and “treating,” as used herein, refer to the medical management of a subject with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder. This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder. In addition, this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder. It is understood that treatment, while intended to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder, need not actually result in the cure, ameliorization, stabilization or prevention. The effects of treatment can be measured or assessed as described herein and as known in the art as is suitable for the disease, pathological condition, or disorder involved. Such measurements and assessments can be made in qualitative and/or quantitative terms. Thus, for example, characteristics or features of a disease, pathological condition, or disorder and/or symptoms of a disease, pathological condition, or disorder can be reduced to any effect or to any amount.

A cell can be in vitro. Alternatively, a cell can be in vivo and can be found in a subject. A “cell” can be a cell from any organism including, but not limited to, a bacterium.

“Beneficial effect,” as used herein, refers to any effect that is desired. In the context of the disclosed chemically modified products, beneficial effects include lower foreign body response, improved biocompatibility, and reduced immune response or reaction.

“Independently” as used herein in the context of chemical formulae (and unless the context clearly indicates otherwise), means that each instance of the group referred to is chosen independently of the other instances of that group. For example, each instance of the group could be different from every other instance, some other instances, or no other instances of the group. Where multiple groups are referred to, “independently” means that each instance of each given group is chosen independently of the other instances of the respective group and that each of the groups are chosen independently of the other groups. For example, each instance of a first group could be different from every instance, some other instances, or no other instances of a second group (or third, or fourth, etc., group).

“Component” as used herein in the context of a product, e.g., medical products, such as medical devices, is a part of a product that is structurally integrated with that product. A component may be applied to a substrate or to the surface or a surface of a product, contained within the substance of the product, retained in the interior of the product, or any other arrangement whereby that part is an integral element of the structure of the product. As an example, the silicone covering surrounding the mechanical part of a pacemaker is a component of the pacemaker. A component may be the lumen of a product where the lumen performs some function essential to the overall function of the product. The lumen of a tissue expander port is a component of the tissue expander. A component can refer to a reservoir or a discrete area within the product specifically adapted for the delivery of a fluid to a surface of the product. A reservoir within an implantable drug delivery device is a component of that device.

The phrase “effective amount,” as used herein in the context of a coating, generally refers to the amount of the coating applied to the implant in order to provide one or more clinically measurable endpoints, such as reduced foreign body response compared to an uncoated implant, an implant coated with an unmodified coating, or another suitable control. The phrase “effective amount,” as used herein in the context of a cell, capsule, product, device, material, composition, or compound, refers to a nontoxic but sufficient amount of the cell, capsule, product, device, material, composition, or compound to provide the desired result. The exact amount required may vary from subject to subject, depending on the species, age, and general condition of the subject; the severity of the disease that is being treated; the particular cell, capsule, product, device, material, composition, or compound used; its mode of administration; and other routine variables. An appropriate effective amount can be determined by one of ordinary skill in the art using only routine experimentation.

“Singularly modified,” as used herein, refers to a modified product that contains one or more covalently attached compounds, non-covalently attached compounds, or both, wherein substantially all of the covalently attached compounds, non-covalently attached compounds, or both are the same compound. A singularly modified device includes, for example, a modified device wherein all the modifications are carried out using Z1-Y15 (see below).

“Multiply modified,” as used herein, refers to a modified product that contains one or more covalently attached compounds, non-covalently attached compounds, or both, wherein substantially all of the covalently attached compounds, non-covalently attached compounds, or both are not formed using the same compound. A multiply modified device includes, for example, a modified device wherein the modifications are carried out using Z2-Y12, Z1-Y15 and Z1-Y19 (see below).

“Capsule,” as used herein, refers to a particle having a mean diameter of about 150 μm to about 5 cm, formed of a cross-linked hydrogel, having a cross-linked hydrogel core that is surrounded by one or more polymeric shells, having one or more cross-linked hydrogel layers, having a cross-linked hydrogel coating, or a combination thereof. The capsule may have any shape suitable for, for example, cell encapsulation. The capsule may contain one or more cells dispersed in the cross-linked hydrogel, thereby “encapsulating” the cells. Reference to “capsules” herein refers to and includes microcapsules unless the context clearly indicates otherwise. Preferred capsules have a mean diameter of about 150 μm to about 8 mm.

“Microcapsule” and “microgel,” as used herein, are used interchangeably to refer to a particle or capsule having a mean diameter of about 150 μm to about 1000 μm.

“Cell,” as used herein, refers to individual cells, cell lines, primary cultures, or cultures derived from such cells unless specifically indicated. “Culture,” as used herein, refers to a composition including cells, such as isolated cells, which can be of the same or a different type. “Cell line,” as used herein, refers to a permanently established cell culture that will proliferate indefinitely given appropriate fresh medium and space, thus making the cell line “immortal.” “Cell strain,” as used herein, refers to a cell culture having a plurality of cells adapted to culture, but with finite division potential. “Cell culture,” as used herein, is a population of cells grown on a medium such as agar.

Cells can be, for example, xenogeneic, autologous, or allogeneic. Cells can also be primary cells. Cells can also be cells derived from the culture and expansion of a cell obtained from a subject. For example, cells can also be stem cells or derived from stem cells. Cells can also be immortalized cells. Cells can also be genetically engineered to express or produce a protein, nucleic acid, or other product.

“Mammalian cell,” as used herein, refers to any cell derived from a mammalian subject.

“Autologous,” as used herein, refers to a transplanted biological material, such as cells, taken from the same individual.

“Allogeneic,” as used herein, refers to a transplanted biological material, such as cells, taken from a different individual of the same species.

“Xenogeneic,” as used herein, refers to a transplanted biological material, such as cells, taken from a different species.

“Endocrine cell,” as used herein, refers to a cell of the endocrine system.

“Secreting endocrine cell,” as used herein, refers to an endocrine cell that secretes one or more hormones.

“Islet cell,” as used herein, refers to an endocrine cell derived from a mammalian pancreas. Islet cells include alpha cells that secrete glucagon, beta cells that secrete insulin and amylin, delta cells that secrete somatostatin, PP cells that secrete pancreatic polypeptide, or epsilon cells that secrete ghrelin. The term includes homogenous and heterogeneous populations of these cells. In preferred embodiments, a population of islet cells contains at least beta cells. In certain embodiments, an islet cell is a human islet cell.

“Hormone-producing cell,” as used herein, refers to a cell that produces one or more hormones. Preferred hormone-producing cells produce hormone in response to physiological stimulus, such as the physiological stimulus that cause secretion of the hormone from an endocrine cell that naturally secretes the hormone. Secreting endocrine cells, hormone-producing cells derived from stem cells, and cells genetically engineered to produce hormone are examples of hormone-producing cells.

“Insulin-producing cell,” as used herein, refers to a cell that produces insulin. Preferred insulin-producing cells produce insulin in response to glucose levels. Islet beta cells, insulin-producing cells derived from stem cells, and cells genetically engineered to produce insulin are examples of insulin-producing cells.

“Transplant,” as used herein, refers to the transfer of a cell, tissue, or organ to a subject from another source. The term is not limited to a particular mode of transfer. Encapsulated cells may be transplanted by any suitable method, such as by injection or surgical implantation.

“Primary cells,” “primary cell lines,” and “primary cultures,” as used herein, are used interchangeably to refer to cells and cells cultures that have been derived from a subject and allowed to grow in vitro for a limited number of passages, that is, splittings, of the culture.

“Mesenchymal stem cell” or “MSC,” as used herein, refer to multipotent stem cells present in or derived from mesenchymal tissue that can differentiate into a variety of cell types, including: osteoblasts, chondrocytes, and adipocytes.

“Derived from,” as used herein, with respect to cells, refer to cells obtained from tissue, cell lines, or cells, which optionally are then cultured, passaged, differentiated, induced, etc., to produce the derived cells. For example, induced pluripotent stem cells are derived from somatic cells.

“Pluripotency,” as used herein, refers to the ability of cells to differentiate into multiple types of cells in an organism. By “pluripotent stem cells,” it is meant cells that can self-renew and differentiate to produce all types of cells in an organism. By “multipotency” it is meant the ability of cells to differentiate into some types of cells in an organism but not all, typically into cells of a particular tissue or cell lineage.

“Multi-potent cells” and “adult stem cells,” as used herein, refer to any type of stem cell that is not derived from an embryo or fetus and generally has a limited capacity to generate new cell types (referred to as “multipotency”) and being committed to a particular lineage.

“Induced pluripotent stem cell,” as used herein, encompasses pluripotent stem cells, that, like embryonic stem (ES) cells, can be cultured over a long period of time while maintaining the ability to differentiate into all types of cells in an organism, but that, unlike ES cells (which are derived from the inner cell mass of blastocysts), are derived from somatic cells.

“Analog” and “Derivative,” in the context of chemical compounds, are used herein interchangeably, and refer to a compound having a structure similar to that of a parent compound, but varying from the parent compound by a difference in one or more certain components. (Designation as a parent compound does not mean that the parent compound is used as a starting material or intermediate but is rather a structural relationship.) Analogs or derivatives differ from the parent compound in one or more atoms, functional groups, or substructures, which are replaced with other atoms, groups, or substructures. An analog or derivative can be imagined to be formed, at least theoretically, from the parent compound via some chemical or physical process. The terms analog and derivative encompass compounds which retain the same basic ring structure as the parent compound, but possess one or more different substituents on the ring(s). For example, an analog or derivative of Z2-Y12 refers to a compound that retains the core of Z2-Y12, e.g., but differs in or more substituents on any of the rings. In some embodiments, an analog or derivative retains at least, 20, 30, 40, 50, 60, 70, 80, 90, or 100% of a selected activity of a reference compound, e.g., a parent compound.

“Substantially,” as used herein, specifies an amount of 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more.

“Click chemistry,” as used herein, refers to chemical reactions used to couple two compounds together which are high yielding, wide in scope, create only byproducts that can be removed without chromatography, are stereospecific, simple to perform, and can be conducted in easily removable or benign solvents. Examples of reactions which fulfill these criteria include the nucleophilic ring opening of epoxides and aziridines, non-aldol type carbonyl reactions, including the formation of hydrazones and heterocycles, additions to carbon-carbon multiple bonds, including Michael Additions, and cycloaddition reactions, such as a 1,3-dipolar cycloaddition reaction (i.e., a Huisgen cycloaddition reaction). See, for example, Moses, and Moorhouse,Chem Soc. Rev.36:1249-1262 (2007); Kolb and Sharpless,Drug Discovery Today.8(24): 1128-1137 (2003); and Kolb et al.,Angew. Chem. Int. Ed.40:2004-2021 (2001).

Heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. It is understood that “substitution” or “substituted” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, i.e. a compound that does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.

Except where specifically and expressly provided to the contrary, the term “substituted” refers to a structure, e.g., a chemical compound or a moiety on a larger chemical compound, regardless of how the structure was formed. The structure is not limited to a structure made by any specific method.

“Aryl” further encompasses polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (i.e., “fused rings”) wherein at least one of the rings is aromatic, e.g., the other cyclic ring or rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocycles.

“Heterocycle,” “heterocyclic” and “heterocyclyl” are used interchangeably, and refer to a cyclic radical attached via a ring carbon or nitrogen atom of a monocyclic or bicyclic ring containing 3-10 ring atoms, and preferably from 5-6 ring atoms, consisting of carbon and one to four heteroatoms each selected from the group consisting of non-peroxide oxygen, sulfur, and N(Y) wherein Y is absent or is H, O, C1-C10alkyl, phenyl or benzyl, and optionally containing 1-3 double bonds and optionally substituted with one or more substituents. Heterocyclyl are distinguished from heteroaryl by definition. Examples of heterocycles include, but are not limited to piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, dihydrofuro[2,3-b]tetrahydrofuran, morpholinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pyranyl, 2H-pyrrolyl, 4H-quinolizinyl, quinuclidinyl, tetrahydrofuranyl, 6H-1,2,5-thiadiazinyl. Heterocyclic groups can optionally be substituted with one or more substituents as defined above for alkyl and aryl.

“Alkyl,” as used herein, refers to the radical of saturated aliphatic groups, including straight-chain alkyl, alkenyl, or alkynyl groups, branched-chain alkyl, cycloalkyl (alicyclic), alkyl substituted cycloalkylgroups, and cycloalkyl substituted alkyl. In preferred embodiments, a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C1-C30for straight chains, C3-C30for branched chains), preferably 20 or fewer, more preferably 15 or fewer, most preferably 10 or fewer. Likewise, preferred cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably have 5, 6 or 7 carbons in the ring structure. The term “alkyl” (or “lower alkyl”) as used throughout the specification, examples, and claims is intended to include both “unsubstituted alkyls” and “substituted alkyls,” the latter of which refers to alkyl moieties having one or more substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents include, but are not limited to, halogen, hydroxyl, carbonyl (such as a carboxyl, alkoxycarbonyl, formyl, or an acyl), thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, a hosphinate, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfoxide, sulfonamido, sulfonyl, heterocyclyl, aralkyl, or an aromatic or heteroaromatic moiety.

It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate. For instance, the substituents of a substituted alkyl may include halogen, hydroxy, nitro, thiols, amino, azido, imino, amido, phosphoryl (including phosphonate and phosphinate), sulfonyl (including sulfate, sulfonamido, sulfamoyl, sulfoxide, and sulfonate), and silyl groups, as well as ethers, alkylthios, carbonyls (including ketones, aldehydes, carboxylates, and esters), haloalkyls, —CN and the like. Cycloalkyls can be substituted in the same manner.

The term “phenyl” is art recognized, and refers to the aromatic moiety —C6H5, i.e., a benzene ring without one hydrogen atom.

“Amino” and “Amine,” as used herein, are art-recognized and refer to both substituted and unsubstituted amines, e.g., a moiety that can be represented by the general formula:

wherein, R, R′, and R″ each independently represent a hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, —(CH2)m—R′″, or R and R′ taken together with the N atom to which they are attached complete a heterocycle having from 3 to 14 atoms in the ring structure; R′″ represents a hydroxy group, substituted or unsubstituted carbonyl group, an aryl, a cycloalkyl ring, a cycloalkenyl ring, a heterocycle, or a polycycle; and m is zero or an integer ranging from 1 to 8. In preferred embodiments, only one of R and R′ can be a carbonyl, e.g., R and R′ together with the nitrogen do not form an imide. In preferred embodiments, R and R′ (and optionally R″) each independently represent a hydrogen atom, substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, or —(CH2)m—R′″. Thus, the term ‘alkylamine’ as used herein refers to an amine group, as defined above, having a substituted or unsubstituted alkyl attached thereto (i.e. at least one of R, R′, or R″ is an alkyl group).

“Carbonyl,” as used herein, is art-recognized and includes such moieties as can be represented by the general formula:

wherein X is a bond, or represents an oxygen or a sulfur, and R represents a hydrogen, a substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, —(CH2)m—R″, or a pharmaceutical acceptable salt, R′ represents a hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl or —(CH2)m—R″; R″ represents a hydroxy group, substituted or unsubstituted carbonyl group, an aryl, a cycloalkyl ring, a cycloalkenyl ring, a heterocycle, or a polycycle; and m is zero or an integer ranging from 1 to 8. Where X is oxygen and R is defines as above, the moiety is also referred to as a carboxyl group. When X is oxygen and R is hydrogen, the formula represents a ‘carboxylic acid’. Where X is oxygen and R′ is hydrogen, the formula represents a ‘formate’. Where X is oxygen and R or R′ is not hydrogen, the formula represents an “ester”. In general, where the oxygen atom of the above formula is replaced by a sulfur atom, the formula represents a ‘thiocarbonyl’ group. Where X is sulfur and R or R′ is not hydrogen, the formula represents a ‘thioester.’ Where X is sulfur and R is hydrogen, the formula represents a ‘thiocarboxylic acid.’ Where X is sulfur and R′ is hydrogen, the formula represents a ‘thioformate.’ Where X is a bond and R is not hydrogen, the above formula represents a ‘ketone.’ Where X is a bond and R is hydrogen, the above formula represents an ‘aldehyde.’

The term “substituted carbonyl” refers to a carbonyl, as defined above, wherein one or more hydrogen atoms in R, R′ or a group to which the moiety

The term “carboxyl” is as defined above for the formula

and is defined more specifically by the formula —RivCOOH, wherein Rivis an alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, alkylaryl, arylalkyl, aryl, or heteroaryl. In preferred embodiments, a straight chain or branched chain alkyl, alkenyl, and alkynyl have 30 or fewer carbon atoms in its backbone (e.g., C1-C30for straight chain alkyl, C3-C30for branched chain alkyl, C2-C30for straight chain alkenyl and alkynyl, C3-C30for branched chain alkenyl and alkynyl), preferably 20 or fewer, more preferably 15 or fewer, most preferably 10 or fewer. Likewise, preferred cycloalkyls, heterocyclyls, aryls and heteroaryls have from 3-10 carbon atoms in their ring structure, and more preferably have 5, 6 or 7 carbons in the ring structure.

“Heteroalkyl,” as used herein, refers to straight or branched chain, or cyclic carbon-containing radicals, or combinations thereof, containing at least one heteroatom. Suitable heteroatoms include, but are not limited to, O, N, Si, P and S, wherein the nitrogen, phosphorous and sulfur atoms are optionally oxidized, and the nitrogen heteroatom is optionally quaternized.

The terms “alkoxyl” or “alkoxy” as used herein refer to an alkyl group, as defined above, having an oxygen radical attached thereto. Representative alkoxyl groups include methoxy, ethoxy, propyloxy, tert-butoxy and the like. An “ether” is two hydrocarbons covalently linked by an oxygen. Accordingly, the substituent of an alkyl that renders that alkyl an ether is or resembles an alkoxyl, such as can be represented by one of —O-alkyl, —O-alkenyl, and —O-alkynyl. The term alkoxy also includes cycloalkyl, heterocyclyl, cycloalkenyl, heterocycloalkenyl, and arylalkyl having an oxygen radical attached to at least one of the carbon atoms, as valency permits.

The term “phenoxy” is art recognized, and refers to a compound of the formula —ORvwherein Rvis (i.e., —O—C6H5). One of skill in the art recognizes that a phenoxy is a species of the aroxy genus.

The terms “aroxy” and “aryloxy,” as used interchangeably herein, are represented by —O-aryl or —O-heteroaryl, wherein aryl and heteroaryl are as defined herein.

The term “alkylthio” refers to an alkyl group, as defined above, having a sulfur radical attached thereto. The “alkylthio” moiety is represented by —S-alkyl. Representative alkylthio groups include methylthio, ethylthio, and the like. The term “alkylthio” also encompasses cycloalkyl groups having a sulfur radical attached thereto.

The term “phenylthio” is art recognized, and refers to —S—C6H5, i.e., a phenyl group attached to a sulfur atom.

“Arylthio” refers to —S-aryl or —S-heteroaryl groups, wherein aryl and heteroaryl as defined herein.

“Arylalkyl,” as used herein, refers to an alkyl group that is substituted with a substituted or unsubstituted aryl or heteroaryl group.

“Alkylaryl,” as used herein, refers to an aryl group (e.g., an aromatic or hetero aromatic group), substituted with a substituted or unsubstituted alkyl group.

The terms “amide” or “amido” are used interchangeably, refer to both “unsubstituted amido” and “substituted amido” and are represented by the general formula:

wherein, E is absent, or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, wherein independently of E, R and R′ each independently represent a hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, —(CH2)m—R′″, or R and R′ taken together with the N atom to which they are attached complete a heterocycle having from 3 to 14 atoms in the ring structure; R′″ represents a hydroxy group, substituted or unsubstituted carbonyl group, an aryl, a cycloalkyl ring, a cycloalkenyl ring, a heterocycle, or a polycycle; and m is zero or an integer ranging from 1 to 8. In preferred embodiments, only one of R and R′ can be a carbonyl, e.g., R and R′ together with the nitrogen do not form an imide. In preferred embodiments, R and R′ each independently represent a hydrogen atom, substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, or —(CH2)m—R′. When E is oxygen, a carbamate is formed. The carbamate cannot be attached to another chemical species, such as to form an oxygen-oxygen bond, or other unstable bonds, as understood by one of ordinary skill in the art.

The term “sulfonyl” is represented by the formula

wherein E is absent, or E is alkyl, alkenyl, alkynyl, aralkyl, alkylaryl, cycloalkyl, aryl, heteroaryl, heterocyclyl, wherein independently of E, R represents a hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted amine, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, —(CH2)m—R′″, or E and R taken together with the S atom to which they are attached complete a heterocycle having from 3 to 14 atoms in the ring structure; R′″ represents a hydroxy group, substituted or unsubstituted carbonyl group, an aryl, a cycloalkyl ring, a cycloalkenyl ring, a heterocycle, or a polycycle; and m is zero or an integer ranging from 1 to 8. In preferred embodiments, only one of E and R can be substituted or unsubstituted amine, to form a “sulfonamide” or “sulfonamido.” The substituted or unsubstituted amine is as defined above.

The term “sulfonic acid” refers to a sulfonyl, as defined above, wherein R is hydroxyl, and E is absent, or E is substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

The term “sulfate” refers to a sulfonyl, as defined above, wherein E is absent, oxygen, alkoxy, aroxy, substituted alkoxy or substituted aroxy, as defined above, and R is independently hydroxyl, alkoxy, aroxy, substituted alkoxy or substituted aroxy, as defined above. When E is oxygen, the sulfate cannot be attached to another chemical species, such as to form an oxygen-oxygen bond, or other unstable bonds, as understood by one of ordinary skill in the art.

The term “sulfonate” refers to a sulfonyl, as defined above, wherein E is oxygen, alkoxy, aroxy, substituted alkoxy or substituted aroxy, as defined above, and R is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted amine, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, —(CH2)m—R′″, R′″ represents a hydroxy group, substituted or unsubstituted carbonyl group, an aryl, a cycloalkyl ring, a cycloalkenyl ring, a heterocycle, or a polycycle; and m is zero or an integer ranging from 1 to 8. When E is oxygen, sulfonate cannot be attached to another chemical species, such as to form an oxygen-oxygen bond, or other unstable bonds, as understood by one of ordinary skill in the art.

The term “sulfamoyl” refers to a sulfonamide or sulfonamide represented by the formula

wherein E is absent, or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, wherein independently of E, R and R′ each independently represent a hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, —(CH2)m—R′″, or R and R′ taken together with the N atom to which they are attached complete a heterocycle having from 3 to 14 atoms in the ring structure; R′″ represents a hydroxy group, substituted or unsubstituted carbonyl group, an aryl, a cycloalkyl ring, a cycloalkenyl ring, a heterocycle, or a polycycle; and m is zero or an integer ranging from 1 to 8. In preferred embodiments, only one of R and R′ can be a carbonyl, e.g., R and R′ together with the nitrogen do not form an imide.

The term “sulfoxide” is represented by the formula

wherein E is absent, or E is alkyl, alkenyl, alkynyl, aralkyl, alkylaryl, cycloalkyl, aryl, heteroaryl, heterocyclyl, wherein independently of E, R represents a hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted amine, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, —(CH2)m—R′″, or E and R taken together with the S atom to which they are attached complete a heterocycle having from 3 to 14 atoms in the ring structure; R′″ represents a hydroxy group, substituted or unsubstituted carbonyl group, an aryl, a cycloalkyl ring, a cycloalkenyl ring, a heterocycle, or a polycycle; and m is zero or an integer ranging from 1 to 8.

The term “phosphonyl” is represented by the formula

wherein E is absent, or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, wherein, independently of E, Rviand Rviiare independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, —(CH2)m—R′″, or R and R′ taken together with the P atom to which they are attached complete a heterocycle having from 3 to 14 atoms in the ring structure; R′″ represents a hydroxy group, substituted or unsubstituted carbonyl group, an aryl, a cycloalkyl ring, a cycloalkenyl ring, a heterocycle, or a polycycle; and m is zero or an integer ranging from 1 to 8.

The term “polyaryl” refers to a chemical moiety that includes two or more aryls, heteroaryls, and combinations thereof. The aryls, heteroaryls, and combinations thereof, are fused, or linked via a single bond, ether, ester, carbonyl, amide, sulfonyl, sulfonamide, alkyl, azo, and combinations thereof.

The term “C3-C20cyclic” refers to a substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocyclyl that have from three to 20 carbon atoms, as geometric constraints permit. The cyclic structures are formed from single or fused ring systems. The substituted cycloalkyls, cycloalkenyls, cycloalkynyls and heterocyclyls are substituted as defined above for the alkyls, alkenyls, alkynyls and heterocyclyls, respectively.

The terms “hydroxyl” and “hydroxy” are used interchangeably and are represented by —OH.

The terms “thiol” and “sulfhydryl” are used interchangeably and are represented by —SH.

The term “oxo” refers to ═O bonded to a carbon atom.

The terms “cyano” and “nitrile” are used interchangeably to refer to —CN.

The term “nitro” refers to —NO2.

The term “phosphate” refers to —O—PO3.

The term “azide” or “azido” are used interchangeably to refer to —N3.

The term “substituted C1-Cxalkyl” refers to alkyl groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten. The term “unsubstituted C1-Cxalkyl” refers to alkyl groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.

The term “substituted C1-Cxalkylene” refers to alkylene groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten. The term “unsubstituted C1-Cxalkylene” refers to alkylene groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten. The term “alkylene” as used herein, refers to a moiety with the formula —(CH2)a—, wherein “a” is an integer from one to ten.

The term “substituted C2-Cxalkenyl” refers to alkenyl groups having from two to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from two to ten. The term “unsubstituted C2-Cxalkenyl” refers to alkenyl groups having from two to x carbon atoms that are not substituted, wherein “x” is an integer from two to ten.

The term “substituted C2-Cxalkynyl” refers to alkynyl groups having from two to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from two to ten. The term “unsubstituted C2-Cxalkynyl” refers to alkynyl groups having from two to x carbon atoms that are not substituted, wherein “x” is an integer from two to ten.

The term “substituted C1-Cxalkoxy” refers to alkoxy groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten. The term “unsubstituted C1-Cxalkoxy” refers to alkoxy groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.

The term “substituted C1-Cxalkylamino” refers to alkylamino groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten. The term “unsubstituted C1-Cxalkylamino” refers to alkyl groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten. The terms “alkylamine” and “alkylamino” are used interchangeably. In any alkylamino, where the nitrogen atom is substituted with one, two, or three substituents, the nitrogen atom can be referred to as a secondary, tertiary, or quartenary nitrogen atom, respectively.

The term “substituted C1-Cxalkylthio” refers to alkylthio groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten. The term “unsubstituted C1-Cxalkylthio” refers to alkylthio groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.

The term “substituted C1-Cxcarbonyl” refers to carbonyl groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten. The term “unsubstituted C1-Cxcarbonyl” refers to carbonyl groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.

The term “substituted C1-Cxcarboxyl” refers to carboxyl groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten. The term “unsubstituted C1-Cxcarboxyl” refers to carboxyl groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.

The term “substituted C1-Cxamido” refers to amido groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten. The term “unsubstituted C1-Cxamido” refers to amido groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.

The term “substituted C1-Cxsulfonyl” refers to sulfonyl groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten. The term “unsubstituted C1-Cxsulfonyl” refers to sulfonyl groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.

The term “substituted C1-Cxsulfonic acid” refers to sulfonic acid groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten. The term “unsubstituted C1-Cxsulfonic acid” refers to sulfonic acid groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.

The term “substituted C1-Cxsulfamoyl” refers to sulfamoyl groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten. The term “unsubstituted C1-Cxsulfamoyl” refers to sulfamoyl groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.

The term “substituted C1-Cxsulfoxide” refers to sulfoxide groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten. The term “unsubstituted C1-Cxsulfoxide” refers to sulfoxide groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.

The term “substituted C1-Cxphosphoryl” refers to phosphoryl groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten. The term “unsubstituted C1-Cxphosphoryl” refers to phosphoryl groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.

The term “substituted C1-Cxphosphonyl” refers to phosphonyl groups having from one to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from one to ten. The term “unsubstituted C1-Cxphosphonyl” refers to phosphonyl groups having from one to x carbon atoms that are not substituted, wherein “x” is an integer from one to ten.

The term “substituted C0-Cxsulfonyl” refers to sulfonyl groups having from zero to x carbon atoms, wherein, if present, at least one carbon atom is substituted, wherein “x” is an integer from zero to ten. The term “unsubstituted C0-Cxsulfonyl” refers to sulfonyl groups having from zero to x carbon atoms that are not substituted, wherein “x” is an integer from zero to ten.

The term “substituted C0-Cxsulfonic acid” refers to sulfonic acid groups having from zero to x carbon atoms, wherein, if present, at least one carbon atom is substituted, wherein “x” is an integer from zero to ten. The term “unsubstituted C0-Cxsulfonic acid” refers to sulfonic acid groups having from zero to x carbon atoms that are not substituted, wherein “x” is an integer from zero to ten.

The term “substituted C0-Cxsulfamoyl” refers to sulfamoyl groups having from zero to x carbon atoms, wherein, if present, at least one carbon atom is substituted, wherein “x” is an integer from zero to ten. The term “unsubstituted C0-Cxsulfamoyl” refers to sulfamoyl groups having from zero to x carbon atoms that are not substituted, wherein “x” is an integer from zero to ten.

The term “substituted C0-Cxsulfoxide” refers to sulfoxide groups having from zero to x carbon atoms, wherein at least one carbon atom is substituted, wherein “x” is an integer from zero to ten. The term “unsubstituted C0-Cxsulfoxide” refers to sulfoxide groups having from zero to x carbon atoms that are not substituted, wherein “x” is an integer from zero to ten.

The term “substituted C0-Cxphosphoryl” refers to phosphoryl groups having from zero to x carbon atoms, wherein, if present, at least one carbon atom is substituted, wherein “x” is an integer from zero to ten. The term “unsubstituted C0-Cxphosphoryl” refers to phosphoryl groups having from zero to x carbon atoms that are not substituted, wherein “x” is an integer from zero to ten.

The term “substituted C0-Cxphosphonyl” refers to phosphonyl groups having from zero to x carbon atoms, wherein, if present, at least one carbon atom is substituted, wherein “x” is an integer from zero to ten. The term “unsubstituted C0-Cxphosphonyl” refers to phosphonyl groups having from zero to x carbon atoms that are not substituted, wherein “x” is an integer from zero to ten.

As used herein, Q1represents the organic groups arylalkyl and substituted arylalkyl.

As used herein, Q3represents the organic group poly(lactic-co-glycolic acid).

As used herein, Q4represents the organic groups phenyl and substituted phenyl.

As used herein, Q5represents the organic groups alkylamino, dialkylamino, and hydroxy.

As used herein, Q8represents the organic groups amino acid, peptide, and polypeptide group.

In some embodiments, groups Q1, Q2, Q3, or any combination thereof, can be used along with any one of U1, U2, and U3. For example, U1can be combined with Q1, with Q2, with Q3, with Q1and Q2, with Q1and Q3, with Q2and Q3, and with Q1, Q2, and Q3. Such combinations can be referred to as U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, and U1+Q1+Q2+Q3, respectively. Similarly, U2can be combined with Q1, with Q2, with Q3, with Q1and Q2, with Q1and Q3, with Q2and Q3, and with Q1, Q2, and Q3. Such combinations can be referred to as U2+Q1, U2+Q2, U2+Q3, U2+Q1+Q2, U2+Q1+Q3, U2+Q2+Q3, and U2+Q1+Q2+Q3, respectively. Similarly, U3can be combined with Q1, with Q2, with Q3, with Q1and Q2, with Q1and Q3, with Q2and Q3, and with Q1, Q2, and Q3. Such combinations can be referred to as U3+Q1, U3+Q2, U3+Q3, U3+Q1+Q2, U3+Q1+Q3, U3+Q2+Q3, and U3+Q1+Q2+Q3, respectively.

Described herein, are compounds, such as chemical compounds, for use to modify a product, such as the surface of a product, a surface of a product, the surface of the product, a surface of the product, the face of a surface of a product, a face of a surface of a product, the face of the surface of a product, a face of the surface of a product, the face of a surface of the product, a face of a surface of the product, the face of the surface of the product, and a face of the surface of the product. Generally, the surface(s) and face(s) of the product to be modified can be those that, when the device is administered to (e.g., implanted in) a subject, would be in contact with fluid, cells, or other components of the subjects body. The compounds are represented by the general formula:
—X—R1Formula Iwherein X is oxygen, sulfur, NR2, or another group compatible with attachment or coupling of the compound to a product or surface;R1is hydrogen, or an organic grouping containing any number of carbon atoms, preferably 1-30 carbon atoms, more preferably 1-20 carbon atoms, more preferably 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R1organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1+Q2+Q3); andR2is hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R2organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1+Q3).

X is preferably oxygen, sulfur, or NR2.

In some embodiments, R1is, independently in one or more sites of chemical modification,
-A-B(—C)δ,   Formula XII
whereinA is hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1+Q3);B, and C are, independently, absent, hydrogen, or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1+Q3); andδ is an integer from, as valency permits, 0 to 30.X is preferably oxygen, sulfur, or NR2.

In some embodiments, R1is, independently in one or more sites of chemical modification,
—R3—Rb,   Formula II
whereinR3is hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R3organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1+Q3); andRbis absent, hydrogen, or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative Rborganic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1+Q3).

Independently in some embodiments of A and R3, and independently in combination with any embodiments of any other relevant substituent classes, A and R3can be, independently, hydrogen, U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1+Q3).

Independently in some embodiments of A and R3, and independently in combination with any embodiments of any other relevant substituent classes, A and R3can be, independently, hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or J1.

Independently in some embodiments of A and R3, and independently in combination with any embodiments of any other relevant substituent classes, A and R3can be, independently, hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or J2.

Independently in some embodiments of B, C, and Rb, and independently in combination with any embodiments of any other relevant substituent classes, B, C, and Rbcan be, independently, absent, hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or J1.

Independently in some embodiments of B, C, and Rb, and independently in combination with any embodiments of any other relevant substituent classes, B, C, and Rbcan be, independently, absent, hydrogen, amino, hydroxyl, thiol, oxo, phosphate, or J2.

Independently in some embodiments of A and R3, and independently in combination with any embodiments of any other relevant substituent classes, A and R3can be, independently,

Independently in some embodiments of B, and independently in combination with any embodiments of any other relevant substituent classes, B can be

Independently in some embodiments of Rb, and independently in combination with any embodiments of any other relevant substituent classes, Rbcan be

Independently in some embodiments of C, and independently in combination with any embodiments of any other relevant substituent classes C can be

Independently in some embodiments of A and R3, and independently in combination with any embodiments of any other relevant substituent classes, A and R3can be, independently,

Independently in some embodiments of B, and independently in combination with any embodiments of any other relevant substituent classes, B can be

Independently in some embodiments of Rb, and independently in combination with any embodiments of any other relevant substituent classes, Rbcan be

Independently in some embodiments of C, and independently in combination with any embodiments of any other relevant substituent classes, C can be

Independently in some embodiments of A and R3, and independently in combination with any embodiments of any other relevant substituent classes, A and R3can be, independently,

Independently in some embodiments of B, and independently in combination with any embodiments of any other relevant substituent classes, B can be

Independently in some embodiments of Rb, and independently in combination with any embodiments of any other relevant substituent classes, Rbcan be

Independently in some embodiments of C, and independently in combination with any embodiments of any other relevant substituent classes, C can be

Independently in some embodiments of A and R3, and independently in combination with any embodiments of any other relevant substituent classes, A and R3can be, independently,

Independently in some embodiments of B, and independently in combination with any embodiments of any other relevant substituent classes, B can be

Independently in some embodiments of Rb, and independently in combination with any embodiments of any other relevant substituent classes, Rbcan be

Independently in some embodiments of C, and independently in combination with any embodiments of any other relevant substituent classes, C can be

Independently in some embodiments of A and R3, and independently in combination with any embodiments of any other relevant substituent classes, A and R3can be, independently,

Independently in some embodiments of B, and independently in combination with any embodiments of any other relevant substituent classes, B can be

Independently in some embodiments of Rb, and independently in combination with any embodiments of any other relevant substituent classes, Rbcan be

Independently in some embodiments of C, and independently in combination with any embodiments of any other relevant substituent classes, C can be

Independently in some embodiments of A and R3, and independently in combination with any embodiments of any other relevant substituent classes, A and R3can be, independently,

Independently in some embodiments of B, and independently in combination with any embodiments of any other relevant substituent classes, B can be

Independently in some embodiments of Rb, and independently in combination with any embodiments of any other relevant substituent classes, Rbcan be

Independently in some embodiments of C, and independently in combination with any embodiments of any other relevant substituent classes, C can be

Independently in some embodiments of A and R3, and independently in combination with any embodiments of any other relevant substituent classes, A and R3can be, independently,

Independently in some embodiments of B, and independently in combination with any embodiments of any other relevant substituent classes, B can be

Independently in some embodiments of Rb, and independently in combination with any embodiments of any other relevant substituent classes, Rbcan be

Independently in some embodiments of C, and independently in combination with any embodiments of any other relevant substituent classes, C can be

In some embodiments, A is

In some embodiments, B is

wherein R4is hydrogen and R5is C;A is hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1+Q3); andeach C is, independently, absent, hydrogen, or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1+Q3).

In some embodiments, C is

A is hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1+Q3); andB is absent, hydrogen, or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1+Q3).

In some embodiments

In some embodiments, R4is hydrogen; and R5and C are

In some embodiments, R4is hydrogen; and R5and C are

In some embodiments, R5and C are methyl, —COCH3, or —CH2—N(CH2—CH3)2.

where n is an integer from 3 to 16.

Independently in some embodiments of Rc, and independently in combination with any embodiments of any other relevant substituent classes, Rccan be B, C, —B(—C)δ, Rb, amino, hydroxyl, thiol, oxo, phosphate, or J1.

Independently in some embodiments of Rc, and independently in combination with any embodiments of any other relevant substituent classes, Rccan be B, C, —B(—C)δ, Rb, amino, hydroxyl, thiol, oxo, phosphate, or J2.

Independently in some embodiments of δ, and independently in combination with any embodiments of any other relevant substituent classes, δ can be an integer from 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2. Independently in some embodiments of δ, and independently in combination with any embodiments of any other relevant substituent classes, δ can be 1, 2, 3, 4, or 5.

Independently in some embodiments of k, and independently in combination with any embodiments of any other relevant substituent classes, k can be an integer from 1 to 10, 2 to 10, 3 to 10, 4 to 10, 5 to 10, 6 to 10, 7 to 10, 8 to 10, 9 to 10, 1 to 9, 2 to 9, 3 to 9, 4 to 9, 5 to 9, 6 to 9, 7 to 9, 8 to 9, 1 to 8, 2 to 8, 3 to 8, 4 to 8, 5 to 8, 6 to 8, 7 to 8, 1 to 7, 2 to 7, 3 to 7, 4 to 7, 5 to 7, 6 to 7, 1 to 6, 2 to 6, 3 to 6, 4 to 6, 5 to 6, 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2. Independently in some embodiments of k, and independently in combination with any embodiments of any other relevant substituent classes, k can be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

Independently in some embodiments of w, and independently in combination with any embodiments of any other relevant substituent classes, w can be an integer from 1 to 9, 2 to 9, 3 to 9, 4 to 9, 5 to 9, 6 to 9, 7 to 9, 8 to 9, 1 to 8, 2 to 8, 3 to 8, 4 to 8, 5 to 8, 6 to 8, 7 to 8, 1 to 7, 2 to 7, 3 to 7, 4 to 7, 5 to 7, 6 to 7, 1 to 6, 2 to 6, 3 to 6, 4 to 6, 5 to 6, 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2. Independently in some embodiments of w, and independently in combination with any embodiments of any other relevant substituent classes, w can be 1, 2, 3, 4, 5, 6, 7, 8, or 9.

Independently in some embodiments of w, and independently in combination with any embodiments of any other relevant substituent classes, w can be an integer from 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2. In preferred embodiments, w is 1, 2, 3, 4, or 5.

Independently in some embodiments of z, and independently in combination with any embodiments of any other relevant substituent classes, z can be an integer from 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2. Independently in some embodiments of z, and independently in combination with any embodiments of any other relevant substituent classes, z can be 1, 2, 3, 4, or 5.

Independently in some embodiments of p and q, and independently in combination with any embodiments of any other relevant substituent classes, p and q can be, independently, an integer from 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2. Independently in some embodiments of p and q, and independently in combination with any embodiments of any other relevant substituent classes, p and q can be, independently, 1, 2, 3, 4, or 5.

In some embodiments, R1is, independently in one or more sites of chemical modification,

or —R3—RbFormula II,wherein a is an integer from 1 to 30, z is an integer from 0-5, n is an integer from 1 to 12, m is an integer from 3 to 16,Rais independently selected from U2, U2+Q1, U2+Q2, U2+Q3, U2+Q1+Q2, U2+Q1+Q3, U2+Q2+Q3, U2+Q1+Q2+Q3, U3, U3+Q1, U3+Q2, U3+Q3, U3+Q1+Q2, U3+Q1+Q3, U3+Q2+Q3, or U3+Q1+Q2+Q3(preferably, in these embodiments, U3+Q1+Q2+Q3), andRb, as valence permits, is

R2is hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R2organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1+Q3); andR3, R4, and R5are, independently, hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R3, R4, and R5organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1+Q2+Q3).

In some embodiments, the surface or a surface of the product includes one or more covalent modifications defined by Formula I
—X—R1Formula I
wherein,

X is oxygen, sulfur, NR2, or another group compatible with attachment or coupling of the compound to a product or surface;

R1is, independently in the one or more modified monomers,

wherein R6, R7, R8, R9, R10, and R11are, independently, hydrogen, U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1);wherein R6, R9, R10, and R11are independently present or absent according to valency, and wherein the ring bonds are double or single according to valency;wherein z is an integer from 0 to 11; wherein w is an integer from 0-9; wherein Rdand Reare each independently U2, U2+Q1, U2+Q2, U2+Q3, U2+Q1+Q2, U2+Q1+Q3, U2+Q2+Q3, U2+Q1+Q2+Q3, U3, U3+Q1, U3+Q2, U3+Q3, U3+Q1+Q2, U3+Q1+Q3, U3+Q2+Q3, or U3+Q1+Q2+Q3(preferably, in these embodiments, U3+Q1); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring;wherein R12, R13, R14, R15, R16, and R17are independently C, O, N, or S, wherein the bonds between adjacent R12to R17are double or single according to valency, and wherein R12to R17are bound to none, one, or two hydrogens according to valency; andwherein R18is independently —(CR19R19)p— or —(CR19R19)p—Xb—(CR19R19)q—, wherein p and q are independently integers from 0 to 5, wherein Xbis absent, —O—, —S—, —SO2—, or NR2, wherein each R19is independently absent, hydrogen, ═O, ═S, —OH, —SH, —NR2, wherein R2is U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1);wherein R4, and R5are not both hydrogen; wherein at least one Rbor Rcis defined by Formula III;
whereinR2is hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1).X is preferably oxygen, sulfur, or NR2.

In some embodiments, z in Formula VI is 2, R12is N, R13, R14, R15, R16, or R17is S, both Rdare oxo and are bonded to the S, and all of the bonds between adjacent R12to R17are single.

In some embodiments, z in Formula VI is 2, both Rdare oxo and are bonded to R15, R12is N, R15is S, and all of the bonds between adjacent R12to R17are single.

In some embodiments, z in Formula VI is 2, both Rdare oxo and are bonded to R15, R12is N, R15is S, and all of the bonds between adjacent R12to R17are single, Xbis absent, q is 0, p is 1, and each R19is hydrogen.

In some embodiments, z in Formula VI is 1, Redis amino, and three of the bonds between adjacent R12to R17are double and three of the bonds between adjacent R12to R17are single.

In some embodiments, z in Formula VI is 1, Rdis amino and is bonded to R15, and three of the bonds between adjacent R12to R17are double and three of the bonds between adjacent R12to R17are single.

In some embodiments, z in Formula VI is 1, Rdis amino and is bonded to R15, and three of the bonds between adjacent R12to R17are double and three of the bonds between adjacent R12to R17are single, Xbis absent, p is 0 and q is 0.

In some embodiments, z in Formula VI is 0, R13, R14, R15, R16, or R17is O, and all of the bonds between adjacent R12to R17are single.

In some embodiments, z in Formula VI is 0, R13is O, and all of the bonds between adjacent R12to R17are single.

In some embodiments, z in Formula VI is 0, R13is O, all of the bonds between adjacent R12to R17are single, Xbis oxygen, p is 1, q is 0 and each R19is hydrogen.

In some embodiments, R13and R17of Formula VI are O and all of the bonds between adjacent R12to R17are single.

In some embodiments, R13and R17of Formula VI are 0, the bonds between R12and R13, and between R15and R16are double bonds, and the rest of the bonds in the ring are single bonds.

In some embodiments, z in Formula VI is 1, Rdis alkoxy and is bonded to R13, R14, R15, R15, R16, or R17, three of the bonds between adjacent R12to R17are double and three of the bonds between adjacent R12to R17are single.

In some embodiments, z in Formula VI is 1, Rdis alkoxy and is bonded to R13, three of the bonds between adjacent R12to R17are double and three of the bonds between adjacent R12to R17are single.

In some embodiments, z in Formula VI is 1, Rdis methoxy, and is bonded to R13, R12to R17are carbon atoms, three of the bonds between adjacent R12to R17are double and three of the bonds between adjacent R12to R17are single, Xbis absent, p is 0 and q is 0.

In some embodiments, z in Formula VI is 1, Rdis hydroxyl.

In some embodiments, z in Formula VI is 1 and Rdis hydroxyl bonded at the position para- to the methylene group.

In some embodiments, z in Formula VI is 1, Rdis Formula III shown below:

wherein R4is a substituted alkyl and R5is a dialkylamino, or R4is a dialkylamino and R5is a substituted alkyl, wherein the substituted alkyl is hydroxymethyl and the dialkylamino is N,N-diethylamino.

In some embodiments, z in Formula VI is 1, Rdis Formula III, wherein R4is hydrogen and R5is Formula VI shown below:

or R4is Formula VI and R5is hydrogen. In some embodiments, z in Formula VI is 0, R13, R14, R15, R16, or R17is O, and all of the bonds between adjacent R12to R17are single. In some embodiments, z in Formula VI is 0, R13is O, and all of the bonds between adjacent R12to R17are single. In some embodiments, z in Formula VI is 0, R13is O, all of the bonds between adjacent R12to R17are single, Xbis oxygen, p is 1, q is 0 and each R19is hydrogen.

In some embodiments, z in Formula VI is 1, Rdis Formula III, wherein R4is hydrogen and R5is Formula IV or Formula V shown below:

In some embodiments R6of Formula IV is alkyl. In some embodiments, R6is methyl.

In some embodiments, z in Formula VI is 1 and Rdis hydroxyl bonded at the position para- to the methylene group.

In some embodiments of Formula VIII, k is 1 and Rcis hydroxyl.

In some embodiments of Formula VIII, k is 1, Rcis hydroxyl, and Xdis absent.

In some embodiments of Formula VIII, k is 1, Rcis hydroxyl, Xdis absent, and R21—R28are hydrogen.

In some embodiments of Formula VIII, Rcis alkoxy.

In some embodiments of Formula VIII, Rcis methoxy and Xdis O.

In some embodiments of Formula VIII, k is 2 and Rcis alkylamino.

In some embodiments of Formula VIII, k is 2, Rcis methylamino, and Xdis absent.

In some embodiments of Formula VIII, k is 2, Rcis methylamino, Xdis absent, and R21—R28are hydrogen.

In some embodiments of Formula VIII, k is 3, Xdis O and Rcis Formula III shown below:

In some embodiments of Formula VIII, k is 3, Xdis O and Rcis Formula III, wherein R4is hydrogen, and R5is carbonyl, or R4is carbonyl, and R5is hydrogen.

In some embodiments of Formula VIII, k is 3, Xdis O and Rcis Formula III, wherein R4is hydrogen, and R5is acetyl, or R4is acetyl, and R5is hydrogen.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, R4is hydrogen, and R5is Formula VI shown below:

or R4is hydrogen and R5is Formula VI.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula VI, or R4is hydrogen and R5is Formula VI, wherein z in Formula VI is 2, R12is N, R13, R14, R15, R16, or R17is S, both Rdare oxo and are bonded to the S, and all of the bonds between adjacent R12to R17are single.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula VI, or R4is hydrogen and R5is Formula VI, wherein z in Formula VI is 2, both Rdare oxo and are bonded to R15, R12is N, R15is S, and all of the bonds between adjacent R12to R17are single.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula VI, or R4is hydrogen and R5is Formula VI, wherein z in Formula VI is 2, both Rdare oxo and are bonded to R15, R12is N, R15is S, and all of the bonds between adjacent R12to R17are single, Xbis absent, q is 0, p is 1, and each R19is hydrogen.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula VI, or R4is hydrogen and R5is Formula VI, wherein z in Formula VI is 1, Rdis amino, and three of the bonds between adjacent R12to R17are double and three of the bonds between adjacent R12to R17are single.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula VI, or R4is hydrogen and R5is Formula VI, wherein z in Formula VI is 1, Rdis amino and is bonded to R15, and three of the bonds between adjacent R12to R17are double and three of the bonds between adjacent R12to R17are single.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula VI, or R4is hydrogen and R5is Formula VI, wherein z in Formula VI is 1, Rdis amino and is bonded to R15, and three of the bonds between adjacent R12to R17are double and three of the bonds between adjacent R12to R17are single, Xbis absent, p is 0 and q is 0.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula VI, or R4is hydrogen and R5is Formula VI, wherein z in Formula VI is 0, R13, R14, R15, R16, or R17is O, and all of the bonds between adjacent R12to R17are single.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula VI, or R4is hydrogen and R5is Formula VI, wherein z in Formula VI is 0, R13is O, and all of the bonds between adjacent R12to R17are single.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula VI, or R4is hydrogen and R5is Formula VI, wherein z in Formula VI is 0, R13is O, all of the bonds between adjacent R12to R17are single, Xbis oxygen, p is 1, q is 0 and each R19is hydrogen.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula VI, or R4is hydrogen and R5is Formula VI, wherein z in Formula VI is 1, Rdis alkoxy and is bonded to R13, R14, R15, R15, R16, or R17, three of the bonds between adjacent R12to R17are double and three of the bonds between adjacent R12to R17are single.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula VI, or R4is hydrogen and R5is Formula VI, wherein z in Formula VI is 1, Rdis alkoxy and is bonded to R13, three of the bonds between adjacent R12to R17are double and three of the bonds between adjacent R12to R17are single.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula VI, or R4is hydrogen and R5is Formula VI, wherein z in Formula VI is 1, Rdis alkoxy such as methoxy, and is bonded to R13, R12to R17are carbon atoms, three of the bonds between adjacent R12to R17are double and three of the bonds between adjacent R12to R17are single, Xbis absent, p is 0 and q is 0.

In some embodiments, w in Formula IX is 0, R13, R14, R15, R15, or R16is O, and, as valency permits, two of the bonds between adjacent R12to R16are double bonds, and three of the bonds between adjacent R12to R16are single bonds.

In some embodiments, w in Formula IX is 0, R13is O, R12, R14, R15and R16are C, the bonds between R12and R16, and between R14and R15, are double bonds, and the rest of the bonds in the ring are single bonds.

In some embodiments, w in Formula IX is 0, R13is O, R12, R14, R15and R16are C, the bonds between R12and R16, and between R14and R15, are double bonds, the rest of the bonds in the ring are single bonds, Xbis absent, p is 1, q is 0, and each R19is hydrogen.

In some embodiments, w in Formula IX is 0, R13, R14, R15, or R16is O, and, the bonds between adjacent R12to R16are single bonds.

In some embodiments, w in Formula IX is 0, R13is O, R12, R14, R15and R16are C, and the bonds between adjacent R12to R16are single bonds.

In some embodiments, w in Formula IX is 0, R13and R16are O, and the bonds between adjacent R12to R16are single bonds.

In some embodiments, w in Formula IX is 0, R13, R14, R15, R15, or R16is N, and, as valency permits, two of the bonds between adjacent R12to R16are double bonds, and three of the bonds between adjacent R12to R16are single bonds.

In some embodiments, w in Formula IX is 0, R13is N, R12, R14, R15and R16are C, the bonds between R12and R16, and between R14and R15, are double bonds, and the rest of the bonds in the ring are single bonds.

In some embodiments, w in Formula IX is 0, R13is N, R12, R14, R15and R16are C, the bonds between R12and R16, and between R14and R15, are double bonds, the rest of the bonds in the ring are single bonds, Xbis absent, p is 1, q is 0, and each R19is hydrogen.

In some embodiments, w in Formula IX is 0, R13, R14, R15, or R16is N, and, the bonds between adjacent R12to R16are single bonds.

In some embodiments, w in Formula IX is 0, R13is N, R12, R14, R15and R16are C, and the bonds between adjacent R12to R16are single bonds.

In some embodiments, w in Formula IX is 0, R13and R16are N, and the bonds between adjacent R12to R16are single bonds.

In some embodiments, w in Formula IX is 0, R13, R14, R15, R15, or R16is S, and, as valency permits, two of the bonds between adjacent R12to R16are double bonds, and three of the bonds between adjacent R12to R16are single bonds.

In some embodiments, w in Formula IX is 0, R13is S, R12, R14, R15and R16are C, the bonds between R12and R16, and between R14and R15, are double bonds, and the rest of the bonds in the ring are single bonds.

In some embodiments, w in Formula IX is 0, R13is S, R12, R14, R15and R16are C, the bonds between R12and R16, and between R14and R15, are double bonds, the rest of the bonds in the ring are single bonds, Xbis absent, p is 1, q is 0, and each R19is hydrogen.

In some embodiments, w in Formula IX is 0, R13, R14, R15, or R16is S, and, the bonds between adjacent R12to R16are single bonds.

In some embodiments, w in Formula IX is 0, R13is S, R12, R14, R15and R16are C, and the bonds between adjacent R12to R16are single bonds.

In some embodiments, w in Formula IX is 0, R13and R16are S, and the bonds between adjacent R12to R16are single bonds.

In some embodiments R29of Formula X is Si, and Xgis alkynyl.

In some embodiments R29of Formula X is Si, Xgis ethynyl, and R30is alkylene.

Products can be either singularly modified or multiply modified. Singularly modified product s are products that contain one or more covalent modifications, wherein substantially all of the covalently modified products possess the same covalent modification (i.e. the product contains one ‘type’ or species of covalent modification). Multiply modified products are products that contain covalent modifications, wherein substantially all of the covalently modified products do not possess the same covalent modification (i.e. the product contains two or more ‘types’ or species of covalent modifications).

In some embodiments, the surface modified product is singularly modified. In some embodiments, the surface modification is:

In preferred embodiments, the surface modified product is multiply modified containing a first species or type of covalent modification defined by Formula I, and a second species or type of covalent modification defined by Formula I. In some embodiments, the surface modifications are combinations of the modifications shown above. Example combinations include:

In some embodiments, R1is

In some embodiments, the surface modified products contain one or more covalent modifications described by Formula I, wherein for each formula R2, R3, R4, and R5are independently hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1); and wherein R1is not hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1).

In some embodiments, the surface modified products contain one or more covalent modifications described by Formula I, wherein for each formula R1, R2, R3, R4, and R5are independently hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1).

In some embodiments, the surface modified products contain one or more covalent modifications described by Formula I, wherein for each formula R1, R3, R4, and R5are independently hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1); and wherein R2is not hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1).

In some embodiments, the surface modified products contain one or more covalent modifications described by Formula I, wherein for each formula R1, R2, R4, and R5are independently hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1); and wherein R3is not hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1).

In some embodiments, the surface modified products contain one or more covalent modifications described by Formula I, wherein for each formula R1, R2, R3, and R5are independently hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1); and wherein R4is not hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1).

In some embodiments, the surface modified products contain one or more covalent modifications described by Formula I, wherein for each formula R1, R2, R3, and R4are independently hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1); and wherein R5is not hydrogen or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1).

Independently in some embodiments of R4and R5, and independently in combination with any embodiments of any other relevant substituent classes, R4and R5can be, independently,

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, all of R12, R13, R14, R15, R16, and R17are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, R16, and R17are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, R16, and R17are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, R16, and R17are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, R16, and R17is C.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, all of R12, R13, R14, R15, and R16are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, and R16are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, and R16are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, and R16are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, and R16is C.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, all of R12, R13, R14, R15, R16, and R17are N. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are N. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, R16, and R17are N. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, R16, and R17are N. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, R16, and R17are N. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, R16, and R17is N.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, all of R12, R13, R14, R15, and R16are N. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, and R16are N. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, and R16are N. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, and R16are N. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, and R16is N.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, all of R12, R13, R14, R15, R16, and R17are O. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are O. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, R16, and R17are O. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, R16, and R17are O. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, R16, and R17are O. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, R16, and R17is O.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, all of R12, R13, R14, R15, and R16are O. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, and R16are O. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, and R16are O. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, and R16are O. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, and R16is O.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, all of R12, R13, R14, R15, R16, and R17are S. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are S. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, R16, and R17are S. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, R16, and R17are S. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, R16, and R17are S. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, R16, and R17is S.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, all of R12, R13, R14, R15, and R16are S. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, and R16are S. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, and R16are S. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, and R16are S. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, and R16is S.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, all of R12, R13, R14, R15, R16, and R17are S(O)2. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are S(O)2. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, R16, and R17are S(O)2. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, R16, and R17are S(O)2. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, R16, and R17are S(O)2. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, R16, and R17is S(O)2.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, all of R12, R13, R14, R15, and R16are S(O)2. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, and R16are S(O)2. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, and R16are S(O)2. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, and R16are S(O)2. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, and R16is S(O)2.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are N and one of R12, R13, R14, R15, R16, and R17is O. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, R16, and R17are N and one or two of R12, R13, R14, R15, R16, and R17are O. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, R16, and R17are N and one, two, or three of R12, R13, R14, R15, R16, and R17are O. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, R16, and R17are N and one, two, three, or four of R12, R13, R14, R15, R16, and R17are O. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, R16, and R17is N and one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are 0.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, and R16are N and one of R12, R13, R14, R15, and R16is O. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, and R16are N and one or two of R12, R13, R14, R15, and R16are O. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, and R16are N and one, two, or three of R12, R13, R14, R15, and R16are O. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, and R16is N and one, two, three, or four of R12, R13, R14, R15, and R16are O.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are N and one of R12, R13, R14, R15, R16, and R17is S. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, R16, and R17are N and one or two of R12, R13, R14, R15, R16, and R17are S. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, R16, and R17are N and one, two, or three of R12, R13, R14, R15, R16, and R17are S. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, R16, and R17are N and one, two, three, or four of R12, R13, R14, R15, R16, and R17are S. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, R16, and R17is N and one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are S.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, and R16are N and one of R12, R13, R14, R15, and R16is S. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, and R16are N and one or two of R12, R13, R14, R15, and R16are S. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, and R16are N and one, two, or three of R12, R13, R14, R15, and R16are S. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, and R16is N and one, two, three, or four of R12, R13, R14, R15, and R16are S.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are N and one of R12, R13, R14, R15, R16, and R17is S(O)2. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, R16, and R17are N and one or two of R12, R13, R14, R15, R16, and R17are S(O)2. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, R16, and R17are N and one, two, or three of R12, R13, R14, R15, R16, and R17are S(O)2. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, R16, and R17are N and one, two, three, or four of R12, R13, R14, R15, R16, and R17are S(O)2. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, R16, and R17is N and one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are S(O)2.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, and R16are N and one of R12, R13, R14, R15, and R16is S(O)2. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, and R16are N and one or two of R12, R13, R14, R15, and R16are S(O)2. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, and R16are N and one, two, or three of R12, R13, R14, R15, and R16are S(O)2. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, and R16is N and one, two, three, or four of R12, R13, R14, R15, and R16are S(O)2.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are O and one of R12, R13, R14, R15, R16, and R17is S. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, R16, and R17are O and one or two of R12, R13, R14, R15, R16, and R17are S. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, R16, and R17are O and one, two, or three of R12, R13, R14, R15, R16, and R17are S. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, R16, and R17are O and one, two, three, or four of R12, R13, R14, R15, R16, and R17are S. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, R16, and R17is N and one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are S.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, and R16are O and one of R12, R13, R14, R15, and R16is S. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, and R16are O and one or two of R12, R13, R14, R15, and R16are S. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, and R16are O and one, two, or three of R12, R13, R14, R15, and R16are S. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, and R16is O and one, two, three, or four of R12, R13, R14, R15, and R16are S.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are O and one of R12, R13, R14, R15, R16, and R17is S(O)2. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, R16, and R17are O and one or two of R12, R13, R14, R15, R16, and R17are S(O)2. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, R16, and R17are O and one, two, or three of R12, R13, R14, R15, R16, and R17are S(O)2. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, R16, and R17are O and one, two, three, or four of R12, R13, R14, R15, R16, and R17are S(O)2. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, R16, and R17is O and one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are S(O)2.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, and R16are O and one of R12, R13, R14, R15, and R16is S(O)2. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, and R16are O and one or two of R12, R13, R14, R15, and R16are S(O)2. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, and R16are O and one, two, or three of R12, R13, R14, R15, and R16are S(O)2. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, and R16is O and one, two, three, or four of R12, R13, R14, R15, and R16are S(O)2.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are S and one of R12, R13, R14, R15, R16, and R17is S(O)2. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, R16, and R17are S and one or two of R12, R13, R14, R15, R16, and R17are S(O)2. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, R16, and R17are S and one, two, or three of R12, R13, R14, R15, R16, and R17are S(O)2. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, R16, and R17are S and one, two, three, or four of R12, R13, R14, R15, R16, and R17are S(O)2. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, R16, and R17is S and one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are S(O)2.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, and R16are S and one of R12, R13, R14, R15, and R16is S(O)2. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, and R16are S and one or two of R12, R13, R14, R15, and R16are S(O)2. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, and R16are S and one, two, or three of R12, R13, R14, R15, and R16are S(O)2. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, and R16is S and one, two, three, or four of R12, R13, R14, R15, and R16are S(O)2.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are N and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, R16, and R17are N and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, R16, and R17are N and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, R16, and R17are N and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, R16, and R17is N and the others are C.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, and R16are N and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, and R16are N and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, and R16are N and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, and R16is N and the others are C.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are O and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, R16, and R17are O and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, R16, and R17are O and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, R16, and R17are O and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, R16, and R17is O and the others are C.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, and R16are O and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, and R16are O and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, and R16are O and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, and R16is O and the others are C.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are S and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, R16, and R17are S and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, R16, and R17are S and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, R16, and R17are S and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, R16, and R17is S and the others are C.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, and R16are S and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, and R16are S and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, and R16are S and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, and R16is S and the others are C.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are S(O)2and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, R16, and R17are S(O)2and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, R16, and R17are S(O)2and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, R16, and R17are S(O)2and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, R16, and R17is S(O)2and the others are C.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, and R16are S(O)2and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, and R16are S(O)2and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, and R16are S(O)2and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, and R16is S(O)2and the others are C.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, five, or six of R12, R13, R14, R15, R16, and R17are N, none, one, two, three, four, five, or six of R12, R13, R14, R15, R16, and R17is O, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are N, none, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17is O, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, or four of R12, R13, R14, R15, R16, and R17are N, none, one, two, three, or four of R12, R13, R14, R15, R16, and R17is O, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, or three of R12, R13, R14, R15, R16, and R17are N, none, one, two, or three of R12, R13, R14, R15, R16, and R17is O, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, or two of R12, R13, R14, R15, R16, and R17are N, none, one, or two of R12, R13, R14, R15, R16, and R17is O, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none or one of R12, R13, R14, R15, R16, and R17are N, none or one of R12, R13, R14, R15, R16, and R17is O, and the others are C.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, or five of R12, R13, R14, R15, and R16are N, none, one, two, three, four, or five of R12, R13, R14, R15, and R16is O, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, or four of R12, R13, R14, R15, and R16are N, none, one, two, three, or four of R12, R13, R14, R15, and R16is O, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, or three of R12, R13, R14, R15, and R16are N, none, one, two, or three of R12, R13, R14, R15, and R16are O, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one or two of R12, R13, R14, R15, and R16are N, none, one or two of R12, R13, R14, R15, and R16are O, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none or one of R12, R13, R14, R15, and R16is N, none or one of R12, R13, R14, R15, and R16are O, and the others are C.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are N, one of R12, R13, R14, R15, R16, and R17is O, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, R16, and R17are N, one or two of R12, R13, R14, R15, R16, and R17are O, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, R16, and R17are N, one, two, or three of R12, R13, R14, R15, R16, and R17are O, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, R16, and R17are N, one, two, three, or four of R12, R13, R14, R15, R16, and R17are O, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, R16, and R17is N, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are O, and the others are C.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, and R16are N, one of R12, R13, R14, R15, and R16is O, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, and R16are N, one or two of R12, R13, R14, R15, and R16are O, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, and R16are N, one, two, or three of R12, R13, R14, R15, and R16are O, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, and R16is N, one, two, three, or four of R12, R13, R14, R15, and R16are O, and the others are C.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, five, or six of R12, R13, R14, R15, R16, and R17are N, none, one, two, three, four, five, or six of R12, R13, R14, R15, R16, and R17is S, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are N, none, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17is S, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, or four of R12, R13, R14, R15, R16, and R17are N, none, one, two, three, or four of R12, R13, R14, R15, R16, and R17is S, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, or three of R12, R13, R14, R15, R16, and R17are N, none, one, two, or three of R12, R13, R14, R15, R16, and R17is S, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, or two of R12, R13, R14, R15, R16, and R17are N, none, one, or two of R12, R13, R14, R15, R16, and R17is S, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none or one of R12, R13, R14, R15, R16, and R17are N, none or one of R12, R13, R14, R15, R16, and R17is S, and the others are C.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, or five of R12, R13, R14, R15, and R16are N, none, one, two, three, four, or five of R12, R13, R14, R15, and R16is S, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, or four of R12, R13, R14, R15, and R16are N, none, one, two, three, or four of R12, R13, R14, R15, and R16is S, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, or three of R12, R13, R14, R15, and R16are N, none, one, two, or three of R12, R13, R14, R15, and R16are S, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one or two of R12, R13, R14, R15, and R16are N, none, one or two of R12, R13, R14, R15, and R16are S, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none or one of R12, R13, R14, R15, and R16is N, none or one of R12, R13, R14, R15, and R16are S, and the others are C.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are N, one of R12, R13, R14, R15, R16, and R17is S, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, R16, and R17are N, one or two of R12, R13, R14, R15, R16, and R17are S, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, R16, and R17are N, one, two, or three of R12, R13, R14, R15, R16, and R17are S, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, R16, and R17are N, one, two, three, or four of R12, R13, R14, R15, R16, and R17are S, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, R16, and R17is N, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are S, and the others are C.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, and R16are N, one of R12, R13, R14, R15, and R16is S, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, and R16are N, one or two of R12, R13, R14, R15, and R16are S, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, and R16are N, one, two, or three of R12, R13, R14, R15, and R16are S, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, and R16is N, one, two, three, or four of R12, R13, R14, R15, and R16are S, and the others are C.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, five, or six of R12, R13, R14, R15, R16, and R17are N, none, one, two, three, four, five, or six of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are N, none, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, or four of R12, R13, R14, R15, R16, and R17are N, none, one, two, three, or four of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, or three of R12, R13, R14, R15, R16, and R17are N, none, one, two, or three of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, or two of R12, R13, R14, R15, R16, and R17are N, none, one, or two of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none or one of R12, R13, R14, R15, R16, and R17are N, none or one of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, or five of R12, R13, R14, R15, and R16are N, none, one, two, three, four, or five of R12, R13, R14, R15, and R16is S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, or four of R12, R13, R14, R15, and R16are N, none, one, two, three, or four of R12, R13, R14, R15, and R16is S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, or three of R12, R13, R14, R15, and R16are N, none, one, two, or three of R12, R13, R14, R15, and R16are S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one or two of R12, R13, R14, R15, and R16are N, none, one or two of R12, R13, R14, R15, and R16are S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none or one of R12, R13, R14, R15, and R16is N, none or one of R12, R13, R14, R15, and R16are S(O)2, and the others are C.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are N, one of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, R16, and R17are N, one or two of R12, R13, R14, R15, R16, and R17are S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, R16, and R17are N, one, two, or three of R12, R13, R14, R15, R16, and R17are S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, R16, and R17are N, one, two, three, or four of R12, R13, R14, R15, R16, and R17are S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, R16, and R17is N, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are S(O)2, and the others are C.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, and R16are N, one of R12, R13, R14, R15, and R16is S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, and R16are N, one or two of R12, R13, R14, R15, and R16are S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, and R16are N, one, two, or three of R12, R13, R14, R15, and R16are S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, and R16is N, one, two, three, or four of R12, R13, R14, R15, and R16are S(O)2, and the others are C.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, five, or six of R12, R13, R14, R15, R16, and R17are O, none, one, two, three, four, five, or six of R12, R13, R14, R15, R16, and R17is S, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are O, none, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17is S, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, or four of R12, R13, R14, R15, R16, and R17are O, none, one, two, three, or four of R12, R13, R14, R15, R16, and R17is S, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, or three of R12, R13, R14, R15, R16, and R17are O, none, one, two, or three of R12, R13, R14, R15, R16, and R17is S, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, or two of R12, R13, R14, R15, R16, and R17are O, none, one, or two of R12, R13, R14, R15, R16, and R17is S, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none or one of R12, R13, R14, R15, R16, and R17are O, none or one of R12, R13, R14, R15, R16, and R17is S, and the others are C.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, or five of R12, R13, R14, R15, and R16are O, none, one, two, three, four, or five of R12, R13, R14, R15, and R16is S, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, or four of R12, R13, R14, R15, and R16are O, none, one, two, three, or four of R12, R13, R14, R15, and R16is S, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, or three of R12, R13, R14, R15, and R16are O, none, one, two, or three of R12, R13, R14, R15, and R16are S, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one or two of R12, R13, R14, R15, and R16are O, none, one or two of R12, R13, R14, R15, and R16are S, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none or one of R12, R13, R14, R15, and R16is O, none or one of R12, R13, R14, R15, and R16are S, and the others are C.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are O, one of R12, R13, R14, R15, R16, and R17is S, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, R16, and R17are O, one or two of R12, R13, R14, R15, R16, and R17are S, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, R16, and R17are O, one, two, or three of R12, R13, R14, R15, R16, and R17are S, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, R16, and R17are O, one, two, three, or four of R12, R13, R14, R15, R16, and R17are S, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, R16, and R17is N, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are S, and the others are C.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, and R16are O, one of R12, R13, R14, R15, and R16is S, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, and R16are O, one or two of R12, R13, R14, R15, and R16are S, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, and R16are O, one, two, or three of R12, R13, R14, R15, and R16are S, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, and R16is O, one, two, three, or four of R12, R13, R14, R15, and R16are S, and the others are C.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, five, or six of R12, R13, R14, R15, R16, and R17are O, none, one, two, three, four, five, or six of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are O, none, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, or four of R12, R13, R14, R15, R16, and R17are O, none, one, two, three, or four of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, or three of R12, R13, R14, R15, R16, and R17are O, none, one, two, or three of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, or two of R12, R13, R14, R15, R16, and R17are O, none, one, or two of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none or one of R12, R13, R14, R15, R16, and R17are O, none or one of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, or five of R12, R13, R14, R15, and R16are O, none, one, two, three, four, or five of R12, R13, R14, R15, and R16is S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, or four of R12, R13, R14, R15, and R16are O, none, one, two, three, or four of R12, R13, R14, R15, and R16is S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, or three of R12, R13, R14, R15, and R16are O, none, one, two, or three of R12, R13, R14, R15, and R16are S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one or two of R12, R13, R14, R15, and R16are O, none, one or two of R12, R13, R14, R15, and R16are S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none or one of R12, R13, R14, R15, and R16is O, none or one of R12, R13, R14, R15, and R16are S(O)2, and the others are C.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are O, one of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, R16, and R17are O, one or two of R12, R13, R14, R15, R16, and R17are S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, R16, and R17are O, one, two, or three of R12, R13, R14, R15, R16, and R17are S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, R16, and R17are O, one, two, three, or four of R12, R13, R14, R15, R16, and R17are S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, R16, and R17is O, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are S(O)2, and the others are C.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, and R16are O, one of R12, R13, R14, R15, and R16is S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, and R16are O, one or two of R12, R13, R14, R15, and R16are S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, and R16are O, one, two, or three of R12, R13, R14, R15, and R16are S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, and R16is O, one, two, three, or four of R12, R13, R14, R15, and R16are S(O)2, and the others are C.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, five, or six of R12, R13, R14, R15, R16, and R17are S, none, one, two, three, four, five, or six of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are S, none, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, or four of R12, R13, R14, R15, R16, and R17are S, none, one, two, three, or four of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, or three of R12, R13, R14, R15, R16, and R17are S, none, one, two, or three of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, or two of R12, R13, R14, R15, R16, and R17are S, none, one, or two of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none or one of R12, R13, R14, R15, R16, and R17are S, none or one of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, or five of R12, R13, R14, R15, and R16are S, none, one, two, three, four, or five of R12, R13, R14, R15, and R16is S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, or four of R12, R13, R14, R15, and R16are S, none, one, two, three, or four of R12, R13, R14, R15, and R16is S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, or three of R12, R13, R14, R15, and R16are S, none, one, two, or three of R12, R13, R14, R15, and R16are S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one or two of R12, R13, R14, R15, and R16are S, none, one or two of R12, R13, R14, R15, and R16are S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none or one of R12, R13, R14, R15, and R16is S, none or one of R12, R13, R14, R15, and R16are S(O)2, and the others are C.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are S, one of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, R16, and R17are S, one or two of R12, R13, R14, R15, R16, and R17are S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, R16, and R17are S, one, two, or three of R12, R13, R14, R15, R16, and R17are S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, R16, and R17are S, one, two, three, or four of R12, R13, R14, R15, R16, and R17are S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, R16, and R17is S, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are S(O)2, and the others are C.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, three, or four of R12, R13, R14, R15, and R16are S, one of R12, R13, R14, R15, and R16is S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one, two, or three of R12, R13, R14, R15, and R16are S, one or two of R12, R13, R14, R15, and R16are S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one or two of R12, R13, R14, R15, and R16are S, one, two, or three of R12, R13, R14, R15, and R16are S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, one of R12, R13, R14, R15, and R16is S, one, two, three, or four of R12, R13, R14, R15, and R16are S(O)2, and the others are C.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, five, or six of R12, R13, R14, R15, R16, and R17are N, none, one, two, three, four, five, or six of R12, R13, R14, R15, R16, and R17are S, none, one, two, three, four, five, or six of R12, R13, R14, R15, R16, and R17is O, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are N, none, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are S, none, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17is O, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, or four of R12, R13, R14, R15, R16, and R17are N, none, one, two, three, or four of R12, R13, R14, R15, R16, and R17are S, none, one, two, three, or four of R12, R13, R14, R15, R16, and R17is O, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, or three of R12, R13, R14, R15, R16, and R17are N, none, one, two, or three of R12, R13, R14, R15, R16, and R17are S, none, one, two, or three of R12, R13, R14, R15, R16, and R17is O, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, or two of R12, R13, R14, R15, R16, and R17are N, none, one, or two of R12, R13, R14, R15, R16, and R17are S, none, one, or two of R12, R13, R14, R15, R16, and R17is O, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none or one of R12, R13, R14, R15, R16, and R17are N, none or one of R12, R13, R14, R15, R16, and R17are S, none or one of R12, R13, R14, R15, R16, and R17is O, and the others are C.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, or five of R12, R13, R14, R15, or R16are N, none, one, two, three, four, or five of R12, R13, R14, R15, or R16are S, none, one, two, three, four, or five of R12, R13, R14, R15, or R16is O, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, or four of R12, R13, R14, R15, or R16are N, none, one, two, three, or four of R12, R13, R14, R15, or R16are S, none, one, two, three, or four of R12, R13, R14, R15, or R16is O, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, or three of R12, R13, R14, R15, or R16are N, none, one, two, or three of R12, R13, R14, R15, or R16are S, none, one, two, or three of R12, R13, R14, R15, or R16is O, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, or two of R12, R13, R14, R15, or R16are N, none, one, or two of R12, R13, R14, R15, or R16are S, none, one, or two of R12, R13, R14, R15, or R16is O, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none or one of R12, R13, R14, R15, or R16are N, none or one of R12, R13, R14, R15, or R16are S, none or one of R12, R13, R14, R15, or R16is O, and the others are C.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, five, or six of R12, R13, R14, R15, R16, and R17are N, none, one, two, three, four, five, or six of R12, R13, R14, R15, R16, and R17are S(O)2, none, one, two, three, four, five, or six of R12, R13, R14, R15, R16, and R17is O, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are N, none, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are S(O)2, none, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17is O, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, or four of R12, R13, R14, R15, R16, and R17are N, none, one, two, three, or four of R12, R13, R14, R15, R16, and R17are S(O)2, none, one, two, three, or four of R12, R13, R14, R15, R16, and R17is O, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, or three of R12, R13, R14, R15, R16, and R17are N, none, one, two, or three of R12, R13, R14, R15, R16, and R17are S(O)2, none, one, two, or three of R12, R13, R14, R15, R16, and R17is O, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, or two of R12, R13, R14, R15, R16, and R17are N, none, one, or two of R12, R13, R14, R15, R16, and R17are S(O)2, none, one, or two of R12, R13, R14, R15, R16, and R17is O, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none or one of R12, R13, R14, R15, R16, and R17are N, none or one of R12, R13, R14, R15, R16, and R17are S(O)2, none or one of R12, R13, R14, R15, R16, and R17is O, and the others are C.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, or five of R12, R13, R14, R15, or R16are N, none, one, two, three, four, or five of R12, R13, R14, R15, or R16are S(O)2, none, one, two, three, four, or five of R12, R13, R14, R15, or R16is O, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, or four of R12, R13, R14, R15, or R16are N, none, one, two, three, or four of R12, R13, R14, R15, or R16are S(O)2, none, one, two, three, or four of R12, R13, R14, R15, or R16is O, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, or three of R12, R13, R14, R15, or R16are N, none, one, two, or three of R12, R13, R14, R15, or R16are S(O)2, none, one, two, or three of R12, R13, R14, R15, or R16is O, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, or two of R12, R13, R14, R15, or R16are N, none, one, or two of R12, R13, R14, R15, or R16are S(O)2, none, one, or two of R12, R13, R14, R15, or R16is O, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none or one of R12, R13, R14, R15, or R16are N, none or one of R12, R13, R14, R15, or R16are S(O)2, none or one of R12, R13, R14, R15, or R16is O, and the others are C.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, five, or six of R12, R13, R14, R15, R16, and R17are N, none, one, two, three, four, five, or six of R12, R13, R14, R15, R16, and R17are S, none, one, two, three, four, five, or six of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are N, none, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are S, none, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, or four of R12, R13, R14, R15, R16, and R17are N, none, one, two, three, or four of R12, R13, R14, R15, R16, and R17are S, none, one, two, three, or four of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, or three of R12, R13, R14, R15, R16, and R17are N, none, one, two, or three of R12, R13, R14, R15, R16, and R17are S, none, one, two, or three of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, or two of R12, R13, R14, R15, R16, and R17are N, none, one, or two of R12, R13, R14, R15, R16, and R17are S, none, one, or two of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none or one of R12, R13, R14, R15, R16, and R17are N, none or one of R12, R13, R14, R15, R16, and R17are S, none or one of R12, R13, R14, R15, R16, and R17is S(O)2, and the others are C.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, or five of R12, R13, R14, R15, or R16are N, none, one, two, three, four, or five of R12, R13, R14, R15, or R16are S, none, one, two, three, four, or five of R12, R13, R14, R15, or R16is S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, or four of R12, R13, R14, R15, or R16are N, none, one, two, three, or four of R12, R13, R14, R15, or R16are S, none, one, two, three, or four of R12, R13, R14, R15, or R16is S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, or three of R12, R13, R14, R15, or R16are N, none, one, two, or three of R12, R13, R14, R15, or R16are S, none, one, two, or three of R12, R13, R14, R15, or R16is S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, or two of R12, R13, R14, R15, or R16are N, none, one, or two of R12, R13, R14, R15, or R16are S, none, one, or two of R12, R13, R14, R15, or R16is S(O)2, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none or one of R12, R13, R14, R15, or R16are N, none or one of R12, R13, R14, R15, or R16are S, none or one of R12, R13, R14, R15, or R16is S(O)2, and the others are C.

Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, five, or six of R12, R13, R14, R15, R16, and R17are S(O)2, none, one, two, three, four, five, or six of R12, R13, R14, R15, R16, and R17are S, none, one, two, three, four, five, or six of R12, R13, R14, R15, R16, and R17is O, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are S(O)2, none, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17are S, none, one, two, three, four, or five of R12, R13, R14, R15, R16, and R17is O, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, or four of R12, R13, R14, R15, R16, and R17are S(O)2, none, one, two, three, or four of R12, R13, R14, R15, R16, and R17are S, none, one, two, three, or four of R12, R13, R14, R15, R16, and R17is O, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, or three of R12, R13, R14, R15, R16, and R17are S(O)2, none, one, two, or three of R12, R13, R14, R15, R16, and R17are S, none, one, two, or three of R12, R13, R14, R15, R16, and R17is O, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none, one, or two of R12, R13, R14, R15, R16, and R17are S(O)2, none, one, or two of R12, R13, R14, R15, R16, and R17are S, none, one, or two of R12, R13, R14, R15, R16, and R17is O, and the others are C. Independently in some embodiments of Formula VI, and independently in combination with any embodiments of any other relevant substituent classes, none or one of R12, R13, R14, R15, R16, and R17are S(O)2, none or one of R12, R13, R14, R15, R16, and R17are S, none or one of R12, R13, R14, R15, R16, and R17is O, and the others are C.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, or five of R12, R13, R14, R15, or R16are S(O)2, none, one, two, three, four, or five of R12, R13, R14, R15, or R16are S, none, one, two, three, four, or five of R12, R13, R14, R15, or R16is O, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, or four of R12, R13, R14, R15, or R16are S(O)2, none, one, two, three, or four of R12, R13, R14, R15, or R16are S, none, one, two, three, or four of R12, R13, R14, R15, or R16is O, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, or three of R12, R13, R14, R15, or R16are S(O)2, none, one, two, or three of R12, R13, R14, R15, or R16are S, none, one, two, or three of R12, R13, R14, R15, or R16is O, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, or two of R12, R13, R14, R15, or R16are S(O)2, none, one, or two of R12, R13, R14, R15, or R16are S, none, one, or two of R12, R13, R14, R15, or R16is O, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none or one of R12, R13, R14, R15, or R16are S(O)2, none or one of R12, R13, R14, R15, or R16are S, none or one of R12, R13, R14, R15, or R16is O, and the others are C.

Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, four, or five of R12, R13, R14, R15, or R16are N, none, one, two, three, four, or five of R12, R13, R14, R15, or R16are S, none, one, two, three, four, or five of R12, R13, R14, R15, or R16are S(O)2, none, one, two, three, four, or five of R12, R13, R14, R15, or R16is O, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, three, or four of R12, R13, R14, R15, or R16are N, none, one, two, three, or four of R12, R13, R14, R15, or R16are S, none, one, two, three, or four of R12, R13, R14, R15, or R16are S(O)2, none, one, two, three, or four of R12, R13, R14, R15, or R16is O, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, two, or three of R12, R13, R14, R15, or R16are N, none, one, two, or three of R12, R13, R14, R15, or R16are S, none, one, two, or three of R12, R13, R14, R15, or R16are S(O)2, none, one, two, or three of R12, R13, R14, R15, or R16is O, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none, one, or two of R12, R13, R14, R15, or R16are N, none, one, or two of R12, R13, R14, R15, or R16are S, none, one, or two of R12, R13, R14, R15, or R16are S(O)2, none, one, or two of R12, R13, R14, R15, or R16is O, and the others are C. Independently in some embodiments of Formula IX, and independently in combination with any embodiments of any other relevant substituent classes, none or one of R12, R13, R14, R15, or R16are N, none or one of R12, R13, R14, R15, or R16are S, none or one of R12, R13, R14, R15, or R16are S(O)2, none or one of R12, R13, R14, R15, or R16is O, and the others are C.

Independently in some embodiments of R18, and independently in combination with any embodiments of any other relevant substituent classes, R18can be

Independently in some embodiments of R18, and independently in combination with any embodiments of any other relevant substituent classes, R18can be

Independently in some embodiments of R18, and independently in combination with any embodiments of any other relevant substituent classes, R18can be

Independently in some embodiments of R18, and independently in combination with any embodiments of any other relevant substituent classes, R18can be absent or —(CR19R19)p—, wherein p is 1.

In some embodiments, the compounds are represented by Formula Iwherein X is oxygen, sulfur, or NR2,R1is, independently in one or more sites of chemical modification,

In some embodiments, z in Formula VI is 2, R12is N, R13, R14, R15, R16, or R17is S, both Rdare oxo and are bonded to the S, and all of the bonds between adjacent R12to R17are single.

In some embodiments, z in Formula VI is 2, both Rdare oxo and are bonded to R15, R12is N, R15is S, and all of the bonds between adjacent R12to R17are single.

In some embodiments, z in Formula VI is 2, both Rdare oxo and are bonded to R15, R12is N, R15is S, and all of the bonds between adjacent R12to R17are single, Xbis absent, q is 0, p is 1, and each R19is hydrogen.

In some embodiments, z in Formula VI is 1, Rdis amino, and three of the bonds between adjacent R12to R17are double and three of the bonds between adjacent R12to R17are single.

In some embodiments, z in Formula VI is 1, Rdis amino and is bonded to R15, and three of the bonds between adjacent R12to R17are double and three of the bonds between adjacent R12to R17are single.

In some embodiments, z in Formula VI is 1, Rdis amino and is bonded to R15, and three of the bonds between adjacent R12to R17are double and three of the bonds between adjacent R12to R17are single, Xbis absent, p is 0 and q is 0.

In some embodiments, z in Formula VI is 0, R13, R14, R15, R16, or R17is O, and all of the bonds between adjacent R12to R17are single.

In some embodiments, z in Formula VI is 0, R13is O, and all of the bonds between adjacent R12to R17are single.

In some embodiments, z in Formula VI is 0, R13is O, all of the bonds between adjacent R12to R17are single, Xbis oxygen, p is 1, q is 0 and each R19is hydrogen.

In some embodiments, R13and R17of Formula VI are O and all of the bonds between adjacent R12to R17are single.

In some embodiments, z in Formula VI is 1, Rdis alkoxy and is bonded to R13, R14, R15, R16, or R17, three of the bonds between adjacent R12to R17are double and three of the bonds between adjacent R12to R17are single.

In some embodiments, z in Formula VI is 1, Rdis alkoxy and is bonded to R13, three of the bonds between adjacent R12to R17are double and three of the bonds between adjacent R12to R17are single.

In some embodiments, z in Formula VI is 1, Rdis methoxy, and is bonded to R13, R12to R17are carbon atoms, three of the bonds between adjacent R12to R17are double and three of the bonds between adjacent R12to R17are single, Xbis absent, p is 0 and q is 0.

In some embodiments, z in Formula VII is 1, Reis hydroxyl.

In some embodiments, z in Formula VII is 1 and Reis hydroxyl bonded at the position para- to the methylene group.

In some embodiments, z in Formula VII is 1, Reis Formula III shown below:

wherein R4is a substituted alkyl and R5is a dialkylamino, or R4is a dialkylamino and R5is a substituted alkyl, wherein the substituted alkyl is hydroxymethyl and the dialkylamino is N,N-diethylamino.

In some embodiments, z in Formula VII is 1, Reis Formula III, wherein R4is hydrogen and R5is Formula VI shown below:

or R4is Formula VI and R5is hydrogen. In some embodiments, z in Formula VI is 0, R13, R15, R15, R16, or R17is O, and all of the bonds between adjacent R12to R17are single. In some embodiments, z in Formula VI is 0, R13is O, and all of the bonds between adjacent R12to R17are single. In some embodiments, z in Formula VI is 0, R13is O, all of the bonds between adjacent R12to R17are single, Xbis oxygen, p is 1, q is 0 and each R19is hydrogen.

In some embodiments, z in Formula VI is 1, Reis Formula III, wherein R4is hydrogen and R5is Formula IV or Formula V shown below:

In some embodiments R6of Formula IV is alkyl. In some embodiments, R6is methyl.

In some embodiments, z in Formula VII is 1 and Reis hydroxyl bonded at the position para- to the methylene group.

In some embodiments of Formula VIII, k is 1 and Rcis hydroxyl.

In some embodiments of Formula VIII, k is 1, Rcis hydroxyl, and Xdis absent.

In some embodiments of Formula VIII, k is 1, Rcis hydroxyl, Xdis absent, and R21—R28are hydrogen.

In some embodiments of Formula VIII, Rcis alkoxy.

In some embodiments of Formula VIII, Rcis methoxy and Xdis O.

In some embodiments of Formula VIII, k is 2 and Rcis alkylamino.

In some embodiments of Formula VIII, k is 2, Rcis methylamino, and Xdis absent.

In some embodiments of Formula VIII, k is 2, Rcis methylamino, Xdis absent, and R21—R28are hydrogen.

In some embodiments of Formula VIII, k is 3, Xdis O and Rcis Formula III shown below:

In some embodiments of Formula VIII, k is 3, Xdis O and Rcis Formula III, wherein R4is hydrogen, and R5is carbonyl, or R4is carbonyl, and R5is hydrogen.

In some embodiments of Formula VIII, k is 3, Xdis O and Rcis Formula III, wherein R4is hydrogen, and R5is acetyl, or R4is acetyl, and R5is hydrogen.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, R4is hydrogen, and R5is Formula VI shown below:

or R4is hydrogen and R5is Formula VI.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula IX, or R5is hydrogen and R4is Formula VI, wherein z in Formula VI is 2, R12is N, R13, R14, R15, R16, or R17is S, both Rdare oxo and are bonded to the S, and all of the bonds between adjacent R12to R17are single.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula VI, or R5is hydrogen and R4is Formula VI, wherein z in Formula VI is 2, both Rdare oxo and are bonded to R15, R12is N, R15is S, and all of the bonds between adjacent R12to R17are single.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula VI, or R5is hydrogen and R4is Formula VI, wherein z in Formula VI is 2, both Rdare oxo and are bonded to R15, R12is N, R15is S, and all of the bonds between adjacent R12to R17are single, Xbis absent, q is 0, p is 1, and each R19is hydrogen.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula VI, or R5is hydrogen and R4is Formula VI, wherein z in Formula VI is 1, Rdis amino, and three of the bonds between adjacent R12to R17are double and three of the bonds between adjacent R12to R17are single.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula VI, or R5is hydrogen and R4is Formula VI, wherein z in Formula VI is 1, Rdis amino and is bonded to R15, and three of the bonds between adjacent R12to R17are double and three of the bonds between adjacent R12to R17are single.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula VI, or R5is hydrogen and R4is Formula VI, wherein z in Formula VI is 1, Rdis amino and is bonded to R15, and three of the bonds between adjacent R12to R17are double and three of the bonds between adjacent R12to R17are single, Xbis absent, p is 0 and q is 0.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula VI, or R5is hydrogen and R4is Formula VI, wherein w in Formula IX is 0, R13, R14, R15, or R16is O, and all of the bonds between adjacent R12to R16are single.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula VI, or R5is hydrogen and R4is Formula VI, wherein z in Formula VI is 0, R13is O, and all of the bonds between adjacent R12to R17are single.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula VI, or R5is hydrogen and R4is Formula VI, wherein z in Formula VI is 0, R13is O, all of the bonds between adjacent R12to R17are single, Xbis oxygen, p is 1, q is 0 and each R19is hydrogen.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula VI, or R5is hydrogen and R4is Formula VI, wherein z in Formula VI is 1, Rdis alkoxy and is bonded to R13, R14, R15, R16, R17, or R18, three of the bonds between adjacent R12to R17are double and three of the bonds between adjacent R12to R17are single.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula VI, or R5is hydrogen and R4is Formula VI, wherein z in Formula VI is 1, Rdis alkoxy and is bonded to R13, three of the bonds between adjacent R12to R17are double and three of the bonds between adjacent R12to R17are single.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula VI, or R5is hydrogen and R4is Formula VI, wherein z in Formula VI is 1, Rdis alkoxy such as methoxy, and is bonded to R13, R12to R17are carbon atoms, three of the bonds between adjacent R12to R17are double and three of the bonds between adjacent R12to R17are single, Xbis absent, p is 0 and q is 0.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula IV or Formula V, or R5is hydrogen and R4is Formula IV or Formula V, wherein R6is alkyl.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula IV or Formula V, or R5is hydrogen and R4is Formula IV or Formula V, wherein R6is alkyl.

In some embodiments of Formula VIII, k is 3 and Rcis Formula III, wherein R4is hydrogen, and R5is Formula IV, or R5is hydrogen and R4is Formula IV, wherein R6is an alkyl such as a methyl, R7and R8are hydrogen.

In some embodiments, w in Formula IX is 0, R13, R14, R15, or R16is O, and, as valency permits, two of the bonds between adjacent R12to R16are double bonds, and three of the bonds between adjacent R12to R16are single bonds.

In some embodiments, w in Formula IX is 0, R13is O, R12, R14, R15and R16are C, the bonds between R12and R16, and between R14and R15, are double bonds, and the rest of the bonds in the ring are single bonds.

In some embodiments, w in Formula IX is 0, R13is O, R12, R14, R15and R16are C, the bonds between R12and R16, and between R15and R15, are double bonds, the rest of the bonds in the ring are single bonds, R18is —(CR19R19)p—Xb—(CR19R19)q—, Xbis absent, p is 1, q is 0, and each R19is hydrogen.

In some embodiments, w in Formula IX is 0, R13, R14, R15, or R16is O, and, the bonds between adjacent R12to R16are single bonds.

In some embodiments, w in Formula IX is 0, R13is O, R12, R14, R15and R16are C, and the bonds between adjacent R12to R16are single bonds.

In some embodiments, w in Formula IX is 0, R13and R16are O, and the bonds between adjacent R12to R16are single bonds.

In some embodiments R30of Formula X is Si, and Xgis alkynyl.

In some embodiments R30of Formula X is Si, Xgis ethynyl, and R29is alkylene.

In preferred embodiments, the surface or a surface of the product described herein, is covalently modified.

In some embodiments the modified product is singularly modified. In specific embodiments, the singularly modified product contains one or more covalent modifications defined by Formula I, wherein R1includes an azide group, an alkyne group, or a 1,2,3-triazole ring.

In some embodiments, the surface or a surface of the product is modified with a compound that contains an azide group. The azide group is further reacted with a second molecule containing a terminal or internal alkyne. Upon reaction, the azide and the alkyne groups undergo an intramolecular 1,3-dipolar cycloaddition reaction forming a 1,2,3-triazole ring, coupling the second molecule to the modified surface.

In alternative embodiments, the surface or a surface of the product is modified with a compound that contains an alkyne group. The alkyne group is further reacted with a second molecule containing an azide group. Upon reaction, the azide and the alkyne groups undergo an intramolecular 1,3-dipolar cycloaddition reaction forming a 1,2,3-triazole ring, coupling the second molecule to the modified surface.

Alkynes for use as reagents in 1,3-dipolarcycloaddition reactions include alkynes having side groups corresponding to of the moieties described herein for any of the organic groups, R groups, and substituents. For example, the alkynes can have side groups corresponding to of the moieties described herein for R4and R5.

In some embodiments, alkynes for use as reagents in 1,3-dipolarcycloaddition reactions can be
R59—C≡C—R60,   Formula XIIIwherein R59and R60are independently hydrogen, or an organic grouping containing any number of carbon atoms, 1-30 carbon atoms, 1-20 carbon atoms, or 1-14 carbon atoms, and optionally including one or more heteroatoms such as oxygen, sulfur, or nitrogen grouping in linear, branched, or cyclic structural formats, representative R59and R60organic groupings being those present in U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1+Q3).

In some embodiments of R5, and independently in combination with any embodiments of any other relevant substituent classes, R5can be —CH2—OH, —CH3, —O—CH3, or —CO—CH3, preferably —CH2—OH. Preferably in these embodiments, R4is hydrogen.

In some embodiments of C, and independently in combination with any embodiments of any other relevant substituent classes, C can be —CH2—OH, —CH3, —O—CH3, or —CO—CH3, preferably —CH2—OH. Preferably in these embodiments, C is in Formula XII, B is triazole, and δ is 1.

In some embodiments of Rd, and independently in combination with any embodiments of any other relevant substituent classes, Rdcan be —CH2—OH, —CH3, —O—CH3, or —CO—CH3, preferably —CH2—OH. Preferably in these embodiments, R12, R13, and R14are N, R15and R16are C, and w is 1.

Preferred alkynes for use as reagents in 1,3-dipolarcycloaddition reactions include those shown below.

In alternative embodiments, the modified product is multiply modified. In preferred embodiments, the multiply modified product is covalently modified with a first species or type of a compound defined by Formula I, and also covalently modified with a second different species or type of compound by Formula I. In other embodiments, the multiply modified product is covalently modified with three or more different types of compounds defined by Formula I.

In some embodiments, the multiply product contains two different species of compounds defined by Formula I, which covalently modify a surface of the product, wherein in both species X is NR2.

In some embodiments, the multiply product contains two different species of compounds defined by Formula I, which covalently modify a surface of the product, wherein in both species X is oxygen.

In some embodiments, the multiply product contains two different species of compounds defined by Formula I, which covalently modify a surface of the product, wherein in both species X is sulfur.

In some embodiments, the multiply modified product contains two different species of compounds defined by Formula I, which covalently modify a surface of the product, wherein in one species X is oxygen, and in the second species X is NR2or sulfur.

In some embodiments, the multiply modified product contains two different species of compounds defined by Formula I, which covalently modify a surface of the product, wherein in one species X is sulfur, and in the second species X is NR2.

In some embodiments, the multiply modified product contains three different species of compounds defined by Formula I, which covalently modify a surface of the product, wherein in the first species X is oxygen, in the second species X is sulfur, and in the third species X is NR2.

In some embodiments, the multiply modified product contains two different species of compounds defined by Formula I, wherein in at least one of the species of compounds, R1includes one or more cyclic moieties. In preferred embodiments, the multiply modified product contains two different species of covalent modifications defined by Formula I, wherein in one or more sites of chemical modification, R1includes a phenyl ring, furan ring, oxolane ring, dioxolane ring, or a 1,2,3-triazole ring.

In certain embodiments, the multiply modified product contains two different species of compounds defined by Formula I, wherein in one or more sites of chemical modification, R1includes one or more halogen moieties, an azide group, or an alkyne.

Independently in some embodiments of j, and independently in combination with any embodiments of any other relevant substituent classes, j can be an integer from 1 to 10, 2 to 10, 3 to 10, 4 to 10, 5 to 10, 6 to 10, 7 to 10, 8 to 10, 9 to 10, 1 to 9, 2 to 9, 3 to 9, 4 to 9, 5 to 9, 6 to 9, 7 to 9, 8 to 9, 1 to 8, 2 to 8, 3 to 8, 4 to 8, 5 to 8, 6 to 8, 7 to 8, 1 to 7, 2 to 7, 3 to 7, 4 to 7, 5 to 7, 6 to 7, 1 to 6, 2 to 6, 3 to 6, 4 to 6, 5 to 6, 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2. Independently in some embodiments of j, and independently in combination with any embodiments of any other relevant substituent classes, j can be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

Independently in some embodiments of j, and independently in combination with any embodiments of any other relevant substituent classes, j can be an integer from 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2. In preferred embodiments, j is 1, 2, 3, 4, or 5.

Independently in some embodiments of jx, and independently in combination with any embodiments of any other relevant substituent classes, jx can be an integer from 1 to 10, 2 to 10, 3 to 10, 4 to 10, 5 to 10, 6 to 10, 7 to 10, 8 to 10, 9 to 10, 1 to 9, 2 to 9, 3 to 9, 4 to 9, 5 to 9, 6 to 9, 7 to 9, 8 to 9, 1 to 8, 2 to 8, 3 to 8, 4 to 8, 5 to 8, 6 to 8, 7 to 8, 1 to 7, 2 to 7, 3 to 7, 4 to 7, 5 to 7, 6 to 7, 1 to 6, 2 to 6, 3 to 6, 4 to 6, 5 to 6, 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2. Independently in some embodiments of jx, and independently in combination with any embodiments of any other relevant substituent classes, jx can be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

Independently in some embodiments of jx, and independently in combination with any embodiments of any other relevant substituent classes, jx can be an integer from 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2. In preferred embodiments, jx is 1, 2, 3, 4, or 5.

Independently in some embodiments of jy, and independently in combination with any embodiments of any other relevant substituent classes, jy can be an integer from 1 to 10, 2 to 10, 3 to 10, 4 to 10, 5 to 10, 6 to 10, 7 to 10, 8 to 10, 9 to 10, 1 to 9, 2 to 9, 3 to 9, 4 to 9, 5 to 9, 6 to 9, 7 to 9, 8 to 9, 1 to 8, 2 to 8, 3 to 8, 4 to 8, 5 to 8, 6 to 8, 7 to 8, 1 to 7, 2 to 7, 3 to 7, 4 to 7, 5 to 7, 6 to 7, 1 to 6, 2 to 6, 3 to 6, 4 to 6, 5 to 6, 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2. Independently in some embodiments of jy, and independently in combination with any embodiments of any other relevant substituent classes, jy can be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

Independently in some embodiments of jy, and independently in combination with any embodiments of any other relevant substituent classes, jy can be an integer from 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2. In preferred embodiments, jy is 1, 2, 3, 4, or 5.

Independently in some embodiments of jz, and independently in combination with any embodiments of any other relevant substituent classes, jz can be an integer from 1 to 6, 2 to 6, 3 to 6, 4 to 6, 5 to 6, 1 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 4, 2 to 4, 3 to 4, 1 to 3, 2 to 3, or 1 to 2. In preferred embodiments, jz is 1, 2, 3, 4, or 5.

In some embodiments, in Formula VI, R12, R13, R14, R15, R16, and R17are carbon, z is 2, Rdis —O—CH3, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, both R19are hydrogen, and p is 1. In some embodiments, Rdis at positions R14and R15.

In some embodiments, R2is methyl, in Formula IX, R13and R16are oxygen, R12, R14, and R15are carbon, w is 0, the ring of Formula IX has no double bonds, R18is —(CR19R19)p—, both R19are hydrogen, and p is 1.

In some embodiments Rhis absent, j is 3, and each Rgis C(R42R43), wherein R42and R43are hydrogen. In some embodiments Rhis absent, j is 0 to 10, and each Rgis C(R42R43), wherein R42and R43are hydrogen. In some embodiments Rhis absent, j is 3, each Rgis C(R42R43), and Rfis NR48R49R50, wherein R48and R49are —CH3, R50is absent, and R42and R43are hydrogen. In some embodiments Rhis absent, j is 0 to 10, each Rgis C(R42R43), and Rfis NR48R49R50, wherein R48and R49are —CH3, R50is absent, and R42and R43are hydrogen. In some embodiments j is 0. In some embodiments j is 1. In some embodiment j is 2. In some embodiments j is 3. In some embodiment j is 4. In some embodiments j is 5. In some embodiments j is 7. In some embodiment j is 8. In some embodiments j is 9. In some embodiments j is 10.

In some embodiments, R2is methyl, and in Formula VI, R12, R13, R14, R15, R16, and R17are carbon, z is 0, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, both R19are hydrogen, and p is 1.

In some embodiments, in Formula VI, R12, R13, R14, R15, R16, and R17are carbon, z is 0, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, both R19are hydrogen, and p is 1.

In some embodiments R2is methyl, Rhis NR41, j is 6, and Rgis C(R42R43), wherein R41is —C(R56R57R58), wherein R42, R43, R56, R57, and R58are hydrogen. In some embodiments R2is methyl, Rhis NR41, j is 1 to 12, and each Rgis C(R42R43), wherein R41is —C(R56R57R58), wherein R42, R43, R56, R57, and R58are hydrogen. In some embodiments R2is methyl, Rhis NR41, j is 6, Rgis C(R42R43), and Rfis NR48R49R50, wherein R41is —C(R56R57R58), wherein R42, R43, R49, R56, R57, and R58are hydrogen, R48is —CH3, and R50is absent. In some embodiments R2is methyl, Rhis NR41, j is 1 to 12, each Rgis C(R42R43), and Rfis NR48R49R50, wherein R41is —C(R56R57R58), wherein R42, R43, R49, R56, R57, and R58are hydrogen, R48is —CH3, and R50is absent. In some embodiments j is 1. In some embodiment j is 2. In some embodiments j is 3. In some embodiment j is 4. In some embodiments j is 5. In some embodiments j is 7. In some embodiment j is 8. In some embodiments j is 9. In some embodiments j is 10. In some embodiments j is 11. In some embodiments j is 12. In some embodiments R2is hydrogen, methyl, ethyl, or butyl.

In some embodiments Rhis C(R39R40), j is 4 to 16, one Rgis O, and the other Rgare C(R42R43), wherein R39, R40, R42, and R43are hydrogen. In some embodiments the first Rgis O. In some embodiments the second Rgis O. In some embodiments the third Rgis O. In some embodiments the fourth Rgis O. In some embodiments the fifth Rgis O.

In some embodiments the sixth Rgis O. In some embodiments the fifth from the last Rgis O. In some embodiments the fourth from the last Rgis O. In some embodiments the antepenultimate Rgis O. In some embodiments the penultimate Rgis not O. In some embodiments the last Rgis not O. In some embodiments neither the penultimate Rgnor the last Rgis O.

In some embodiments Rhis C(R39R40), j is 4 to 16, one Rgis O, the other Rgare C(R42R43), and Rfis OH, wherein R39, R40, R42, and R43are hydrogen. In some embodiments the first Rgis O. In some embodiments the second Rgis O. In some embodiments the third Rgis O. In some embodiments the fourth Rgis O. In some embodiments the fifth Rgis O. In some embodiments the sixth Rgis O. In some embodiments the fifth from the last Rgis O. In some embodiments the fourth from the last Rgis O. In some embodiments the antepenultimate Rgis O. In some embodiments the penultimate Rgis not O. In some embodiments the last Rgis not O. In some embodiments neither the penultimate Rgnor the last Rgis O.

In some embodiments R2is methyl, Rhis NR41, j is 0 to 10, and Rgis C(R42R43), wherein NR41is —Rhx—(Rgx)jx—Rfxand R42and R43are hydrogen, wherein Rhxis C(R39xR40x), jx=0 to 10, and Rfxis C(R45xR46xR47x), and wherein R39x, R40x, R45x, R46x, R47xare hydrogen. In some embodiments R2is methyl, Rhis NR41, j is 0 to 10, Rgis C(R42R43), and Rfis OH, wherein NR41is —Rhx—(Rgx)jx—Rfxand R42and R43are hydrogen, wherein Rhxis C(R39xR40x), jx=0 to 10, and Rfxis C(R45xR46xR47x), and wherein R39x, R40x, R45x, R46x, R47xare hydrogen. In some embodiment j is 0. In some embodiments j is 1. In some embodiment j is 2. In some embodiments j is 3. In some embodiment j is 4. In some embodiments j is 5. In some embodiments j is 6. In some embodiments j is 7. In some embodiment j is 8. In some embodiments j is 9. In some embodiments j is 10. In some embodiment jx is 0. In some embodiments jx is 1. In some embodiment jx is 2. In some embodiments jx is 3. In some embodiment jx is 4. In some embodiments jx is 5. In some embodiments jx is 6. In some embodiments jx is 7. In some embodiment jx is 8. In some embodiments jx is 9. In some embodiments jx is 10. In some embodiments j=jx. In some embodiments j=jx+4. In some embodiments j=2*jx. In some embodiments R2is hydrogen, methyl, ethyl, or butyl.

In some embodiments R2is methyl, Rhis NR41, j is 0 to 10, and Rgis C(R42R43), wherein NR41is —Rhx—(Rgx)jx—Rfxand R42and R43are hydrogen, wherein Rhxis C(R39xR40x), jx=0 to 10, and Rfxis hydrogen, and wherein R39x, R40x, R45x, R46x, R47xare hydrogen. In some embodiments R2is methyl, Rhis NR41, j is 0 to 10, Rgis C(R42R43), and Rfis OH, wherein NR41is —Rhx—(Rgx)jx—Rfxand R42and R43are hydrogen, wherein Rhxis C(R39xR40x), jx=0 to 10, and Rfxis hydrogen, and wherein R39x, R40x, R45x, R46x, R47xare hydrogen. In some embodiment j is 0. In some embodiments j is 1. In some embodiment j is 2. In some embodiments j is 3. In some embodiment j is 4. In some embodiments j is 5. In some embodiments j is 6. In some embodiments j is 7. In some embodiment j is 8. In some embodiments j is 9. In some embodiments j is 10. In some embodiment jx is 0. In some embodiments jx is 1. In some embodiment jx is 2. In some embodiments jx is 3. In some embodiment jx is 4. In some embodiments jx is 5. In some embodiments jx is 6. In some embodiments jx is 7. In some embodiment jx is 8. In some embodiments jx is 9. In some embodiments jx is 10. In some embodiments j=jx. In some embodiments j=jx+4. In some embodiments j=2*jx. In some embodiments R2is hydrogen, methyl, ethyl, or butyl.

In some embodiments, in Formula VI, R12, R13, R14, R15, R16, and R17are carbon, z is 0, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, both R19are hydrogen, and p is 1.

In some embodiments, in Formula IX, R13is oxygen, R12, R14, R15, and R16are carbon, w is 0, the ring of Formula IX has no double bonds, R18is —(CR19R19)p—, both R19are hydrogen, and p is 1.

In some embodiments, Rhis C(R39R40), j is 0, Rfis C(R45R46R47), wherein R45, R46, and R47are fluorine, wherein R39and R40are hydrogen. In some embodiments, j is an integer from 0 to 5, wherein each Rgis C(R42R43), wherein R42and R43are hydrogen. In some embodiments, j is 1. In some embodiments, j is 2. In some embodiments, j is 3. In some embodiments, j is 4. In some embodiments, j is 5.

In some embodiments Rhis C(R39R40), j is 2, and Rgis C(R42R43), wherein R42and R43are absent and R39and R40are hydrogen. In some embodiments Rhis C(R39R40), j is 2, Rgis C(R42R43), and Rfis hydrogen, wherein R42and R43are absent and R39and R40are hydrogen. In some embodiments Rhis C(R39R40), j is 2 to 12, and Rgis C(R42R43), wherein R42and R43are absent on one pair of adjacent Rg, R42and R43are hydrogen on the other Rg, and R39and R40are hydrogen. In some embodiments Rhis C(R39R40), j is 2 to 12, Rgis C(R42R43), and Rfis hydrogen, wherein R42and R43are absent on one pair of adjacent Rg, R42and R43are hydrogen on the other Rg, and R39and R40are hydrogen. In some embodiments R42and R43are absent on the first and second Rg. In some embodiments R42and R43are absent on the second and third Rg. In some embodiments R42and R43are absent on the third and fourth Rg. In some embodiments R42and R43are absent on the fourth and fifth Rg. In some embodiments R42and R43are absent on the fifth and sixth Rg. In some embodiments R42and R43are absent on the sixth and seventh Rg. In some embodiments R42and R43are absent on the seventh and eighth Rg. In some embodiments R42and R43are absent on the eighth and ninth Rg. In some embodiments R42and R43are absent on the ninth and tenth Rg. In some embodiments R42and R43are absent on the tenth and eleventh Rg. In some embodiments R42and R43are absent on the eleventh and twelfth Rg.

In some embodiments, in Formula IX, R13is oxygen, R12, R14, R15, and R16are carbon, w is 0, the ring of Formula IX has no double bonds, R18is —(CR19R19)p—, both R19are hydrogen, and p is 1.

In some embodiments, in Formula IX, R15and R16are absent, R12, R13, and R14are carbon, w is 3, the ring of Formula IX has no double bonds, R18is —(CR19R19)p—, and p is 0, wherein each Rdis independently —CH3or —CH2—OH. In some embodiments, one Rdis —CH3and two Rdare —CH2—OH. In some embodiments, one Rdis —CH2—OH and two Rdare —CH3. In some embodiments, each Rdis —CH2—OH. In some embodiments, each Rdis —CH3. In some embodiments, w is 4. In some embodiments, w is 3. In some embodiments, w is 2. In some embodiments, w is 1. In some embodiments, w is 0.

In some embodiments, Rhis C(R39R40), j is 0, Rfis C(R45R46R47), wherein R39, R40, R45, R46, and R47are hydrogen. In some embodiments, j is an integer from 0 to 5, wherein each Rgis C(R42R43), wherein R42and R43are hydrogen. In some embodiments, j is 1. In some embodiments, j is 2. In some embodiments, j is 3. In some embodiments, j is 4. In some embodiments, j is 5.

In some embodiments Rhis C(R39R40), and j is 0, wherein R39and R40are hydrogen. In some embodiments Rhis C(R39R40), and j is 0 to 10, wherein R39and R40are hydrogen. In some embodiments Rhis C(R39R40), j is 0, and Rfis C(R45R46R47), wherein R39, R40, R45, R46, and R47are hydrogen. In some embodiments Rhis C(R39R40), j is 0 to 10, and Rfis C(R45R46R47), wherein R39, R40, R45, R46, and R47are hydrogen. In some embodiment j is 0. In some embodiments j is 1. In some embodiment j is 2. In some embodiments j is 3. In some embodiment j is 4. In some embodiments j is 5. In some embodiments j is 6. In some embodiments j is 7. In some embodiment j is 8. In some embodiments j is 9. In some embodiments j is 10.

In some embodiments, R100, R101, and R102are each independently C1-C3alkyl. In some embodiments R42and R43are absent on the first and second Rg. In some embodiments, R100, R101, and R102are each independently C1-C6alkyl, phenyl, aryl, or C5-C6cyclic. In some embodiments, R100, R101, and R102are each independently C1-C3alkyl.

In some embodiments R42and R43are absent on the first and second Rg. In some embodiments R42and R43are absent on the second and third Rg. In some embodiments R42and R43are absent on the third and fourth Rg. In some embodiments R42and R43are absent on the fourth and fifth Rg. In some embodiments R42and R43are absent on the fifth and sixth Rg. In some embodiments R42and R43are absent on the sixth and seventh Rg. In some embodiments R42and R43are absent on the seventh and eighth Rg. In some embodiments R42and R43are absent on the eighth and ninth Rg. In some embodiments R42and R43are absent on the ninth and tenth Rg. In some embodiments R42and R43are absent on the tenth and eleventh Rg. In some embodiments R42and R43are absent on the eleventh and twelfth Rg.

In some embodiments, in Formula VI, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis —OH, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, both R19are hydrogen, and p is 1. In some embodiments, Rdis at position R15.

In some embodiments, in Formula VI, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis —O—CH3, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, both R19are hydrogen, and p is 1. In some embodiments, Rdis at position R15.

In some embodiments, in Formula VI, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis hydroxy, the ring of Formula VI has no double bonds, R18is —(CR19R19)p—, and p is 0. In some embodiments, Rdis at R15. In some embodiments, Rdis at R13. In some embodiments, Rdis at R14. In some embodiments, Rdis at R16. In some embodiments, Rdis at R17.

In some embodiments, in Formula VI, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis —O—CH3, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, and p is 0. In some embodiments, Rdis at R15. In some embodiments, Rdis at R13. In some embodiments, Rdis at R14. In some embodiments, Rdis at R16. In some embodiments, Rdis at R17.

In some embodiments, in Formula IX, R13and R14are oxygen, R12, R15, and R16are carbon, w is 0, the ring of Formula IX has no double bonds, R18is —(CR19R19)p—, both R19are hydrogen, and p is 1.

In some embodiments, in Formula VI, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis —CH2—OH, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, and p is 0. In some embodiments, Rdis at R15. In some embodiments, Rdis at R13. In some embodiments, Rdis at R14. In some embodiments, Rdis at R16. In some embodiments, Rdis at R17.

In some embodiments, in Formula VI, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis methyl, the ring of Formula VI is aromatic, R18is —(CR19R19)p—Xb—(CR19R19)q—, p is 0, q is 0, and Xbis S(O)2.

In some embodiments j=jx. In some embodiments j and jx are 0. In some embodiment j and jx are 2. In some embodiments j and jx are 3. In some embodiments j and jx are 4.

In some embodiments Rhis C(R39R40), and j is 0, wherein R39and R40are hydrogen. In some embodiments Rhis C(R39R40), j is 0 to 10, and each Rgis C(R42R43), wherein R39, R40R42, R43are hydrogen. In some embodiments Rhis C(R39R40), j is 0, and Rfis OH, wherein R39and R40are hydrogen. In some embodiments Rhis C(R39R40), j is 0 to 10, each Rgis C(R42R43), and Rfis OH, wherein R39, R40R42, R43are hydrogen. In some embodiments j is 1. In some embodiment j is 2. In some embodiments j is 3. In some embodiments j is 4.

In some embodiments Rhis C(R39R40), j is 1 to 10, one Rgis O, and the other Rgare C(R42R43), wherein R39, R40, R42, and R43are hydrogen. In some embodiments the last Rgis O. In some embodiments the penultimate Rgis O. In some embodiments the antepenultimate Rgis O. In some embodiments the fourth from the last Rgis O. In some embodiments the fifth from the last Rgis O. In some embodiments the first Rgis O. In some embodiments the second Rgis O. In some embodiments the third Rgis O. In some embodiments the fourth Rgis O. In some embodiments the fifth Rgis O.

In some embodiments Rhis C(R39R40), j is 1 to 10, one Rgis O, the other Rgare C(R42R43), and Rfis C(R45R46R47), wherein R39, R40, R42, R43, R45, R46, and R47are hydrogen. In some embodiments the last Rgis O. In some embodiments the penultimate Rgis O. In some embodiments the antepenultimate Rgis O. In some embodiments the fourth from the last Rgis O. In some embodiments the fifth from the last Rgis O. In some embodiments the first Rgis O. In some embodiments the second Rgis O. In some embodiments the third Rgis O. In some embodiments the fourth Rgis O. In some embodiments the fifth Rgis O.

In some embodiments, R4is —COOH and in Formula VI, R12, R13, R14, R15, R16, and R17are carbon, z is 0, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, and p is 0.

In some embodiments Rhis absent, j is 6, and each Rgis C(R42R43), wherein R42and R43are hydrogen. In some embodiments Rhis absent, j is 1 to 10, and each Rgis C(R42R43), wherein R42and R43are hydrogen. In some embodiments Rhis absent, j is 6, each Rgis C(R42R43), and Rfis C(R45R46R47), wherein R42, R43, R45, R46, and R47are hydrogen. In some embodiments Rhis absent, j is 1 to 10, each Rgis C(R42R43), and Rfis C(R45R46R47), wherein R42, R43, R45, R46, and R47are hydrogen. In some embodiments j is 3. In some embodiment j is 4. In some embodiments j is 5. In some embodiments j is 7. In some embodiment j is 8. In some embodiments j is 9. In some embodiments j is 10.

In some embodiments Rhis C(R39R40), j is 3, the first Rgis O, and the second and third Rgare C(R42R43), wherein R39, R40, R42, and R43are hydrogen. In some embodiments Rhis C(R39R40), j is 1 to 10, one Rgis O, and the other Rgare C(R42R43), wherein R39, R40, R42, and R43are hydrogen. In some embodiments Rhis C(R39R40), j is 3, the first Rgis O, the second and third Rgare C(R42R43), and Rfis OH, wherein R39, R40, R42, and R43are hydrogen. In some embodiments Rhis C(R39R40), j is 1 to 10, one Rgis O, the other Rgare C(R42R43), and Rfis OH, wherein R39, R40, R42, and R43are hydrogen. In some embodiments the first Rgis O. In some embodiments the second Rgis O. In some embodiments the third Rgis O. In some embodiments the fourth Rgis O. In some embodiments the fifth Rgis O. In some embodiments the fifth from the last Rgis O.

In some embodiments the fourth from the last Rgis O. In some embodiments the antepenultimate Rgis O. In some embodiments the penultimate Rgis O. In some embodiments the last Rgis O.

In some embodiments, in Formula VI, R13is O, R12, R14, R15, R16, and R17are carbon, z is 0, the ring of Formula VI has no double bonds, R18is —(CR19R19)p—Xb—(CR19R19)q—, p is 0, q is 1, both R19are hydrogen, and Xbis O.

In some embodiments, in Formula VI, R12, R13, R14, R15, R16, and R17are carbon, z is 0, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, one R19is —OH, the other R19is hydrogen, and p is 1.

In some embodiments, in Formula VI, R14is N, R12, R13, R15, R16, and R17are carbon, z is 0, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, and p is 0).

In some embodiments Rhis C(R39R40), and j is 0, wherein R39and R40are hydrogen. In some embodiments Rhis C(R39R40), j is 0 to 10, and each Rgis C(R42R43), wherein R39, R40, R42, and R43are hydrogen. In some embodiments Rhis C(R39R40), j is 0, and Rfis hydrogen, wherein R39and R40are hydrogen. In some embodiments Rhis C(R39R40), j is 0 to 10, each Rgis C(R42R43), and Rfis hydrogen, wherein R39, R40, R42, and R43are hydrogen. In some embodiments j is 1. In some embodiment j is 2. In some embodiments j is 3. In some embodiment j is 4. In some embodiments j is 5. In some embodiments j is 7. In some embodiment j is 8. In some embodiments j is 9. In some embodiments j is 10.

In some embodiments Rhis C(R39R40), j is 0 to 10, and each Rgis C(R42R43), wherein R39is —Rhx—(Rgx)jx—Rfx, and R40, R42, and R43are hydrogen, wherein Rhxis C(R39xR40x), jx is 0, and Rfxis hydrogen, wherein R39xand R40xare hydrogen. In some embodiments j is 0. In some embodiments j is 1. In some embodiment j is 2. In some embodiments j is 3. In some embodiment j is 4. In some embodiments j is 5. In some embodiments j is 7. In some embodiment j is 8. In some embodiments j is 9. In some embodiments j is 10.

In some embodiments Rhis C(R39R40), j is 0 to 10, and each Rgis C(R42R43), wherein R39is —Rhx—(Rgx)jx—Rfx, and R40, R42, and R43are hydrogen, wherein Rhxis C(R39xR40x), jx is 0, and Rfxis hydrogen, wherein R39xand R40xare hydrogen. In some embodiments Rhis C(R39R40), j is 0 to 10, each Rgis C(R42R43), and Rfis hydrogen, wherein R39is —Rhx—(Rgx)jx—Rfx, and R40, R42, and R43are hydrogen, wherein Rhxis C(R39xR40x), jx is 0, and Rfxis hydrogen, wherein R39xand R40xare hydrogen. In some embodiments j is 1. In some embodiment j is 2. In some embodiments j is 3. In some embodiment j is 4. In some embodiments j is 5. In some embodiments j is 7. In some embodiment j is 8. In some embodiments j is 9. In some embodiments j is 10. In some embodiments jx is 1. In some embodiment jx is 2. In some embodiments jx is 3. In some embodiment jx is 4. In some embodiments jx is 5. In some embodiments jx is 7. In some embodiment jx is 8. In some embodiments jx is 9. In some embodiments jx is 10. In some embodiments j=jx.

In some embodiments, in Formula VI, R12, R13, R14, R15, R16, and R17are carbon, z is 0, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, and p is 0.

In some embodiments Rhis C(R39R40), and j is 0, wherein R39is ═O, and R40is absent. In some embodiments Rhis C(R39R40), j is 0, and Rfis C(R45R46R47), wherein R39is ═O, R40is absent, and R45, R46, and R47are hydrogen. In some embodiments Rhis C(R39R40), j is 0 to 10, and each Rgis C(R42R43), wherein R39is ═O, R40is absent, and R42and R43are hydrogen. In some embodiments Rhis C(R39R40), j is 0 to 10, each Rgis C(R42R43), and Rfis C(R45R46R47), wherein R39is ═O, R40is absent, and R42, R43, R45, R46, and R47are hydrogen. In some embodiments j is 1. In some embodiment j is 2. In some embodiments j is 3. In some embodiment j is 4. In some embodiments j is 5. In some embodiments j is 7. In some embodiment j is 8. In some embodiments j is 9. In some embodiments j is 10.

In some embodiments Rhis C(R39R40), j is 1 to 10, and each Rgis C(R42R43), wherein R42is ═O and R43is absent for one Rg, R42and R43are hydrogen for the other Rg, and R39and R40are hydrogen. In some embodiments Rhis C(R39R40), j is 1 to 10, each Rgis C(R42R43), and Rfis C(R45R46R47), wherein R42is ═O and R43is absent for one Rg, R42and R43are hydrogen for the other Rg, and R39, R40, R45, R46, and R47are hydrogen. In some embodiments R42is ═O and R43is absent for the last Rg. In some embodiments R42is ═O and R43is absent for the penultimate Rg. In some embodiments R42is ═O and R43is absent for the antepenultimate Rg. In some embodiments R42is ═O and R43is absent for the fourth from the last Rg. In some embodiments R42is ═O and R43is absent for the fifth from the last Rg. In some embodiments R42is ═O and R43is absent for the first Rg. In some embodiments R42is ═O and R43is absent for the second Rg. In some embodiments R42is ═O and R43is absent for the third Rg. In some embodiments R42is ═O and R43is absent for the fourth Rg. In some embodiments R42is ═O and R43is absent for the fifth Rg.

In some embodiments, in Formula VI, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis —NH2, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, and p is 0. In some embodiments, Rdis at R15. In some embodiments, Rdis at R13. In some embodiments, Rdis at R14. In some embodiments, Rdis at R16. In some embodiments, Rdis at R17.

In some embodiments Rhis C(R39R40), j is 1 to 10, each Rgis C(R42R43), and Rfis C(R45R46R47), wherein R39, R40, R45, R46, and R47are hydrogen, wherein R42of one Rgis C(R56R57R58), R42of the other Rgare hydrogen, and R43is hydrogen, and, wherein R56is ═O, R57is —OH, and R58is absent. In some embodiments R42of the first Rgis C(R56R57R58). In some embodiments Rhis C(R39R40), j is 1 to 10, and each Rgis C(R42R43), wherein R39and R40are hydrogen, wherein R42of one Rgis C(R56R57R58), R42of the other Rgare hydrogen, and R43is hydrogen, and, wherein R56is ═O, R57is —OH, and R58is absent. In some embodiments R42of the first Rgis C(R56R57R58). In some embodiments R42of the second Rgis C(R56R57R58). In some embodiments R42of the third Rgis C(R56R57R58). In some embodiments R42of the fourth Rgis C(R56R57R58). In some embodiments R42of the fifth Rgis C(R56R57R58). In some embodiments R42of the sixth Rgis C(R56R57R58). In some embodiments R42of the seventh Rgis C(R56R57R58). In some embodiments R42of the eighth Rgis C(R56R57R58). In some embodiments R42of the ninth Rgis C(R56R57R58). In some embodiments R42of the tenth Rgis C(R56R57R58).

In some embodiments where A or R3is Formula VI, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis Rb, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, p is 0 to 10, and R19are independently hydrogen or C1-C3alkyl. In some embodiments, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis Rb, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, p is 1, and R19are hydrogen.

In some embodiments where A or R3is Formula VI, Rdis at R15. In some embodiments, Rdis at R13. In some embodiments, Rdis at R14. In some embodiments, Rdis at R16. In some embodiments, Rdis at R17. In some embodiments, p is 0. In some embodiments p is 1. In some embodiment p is 2. In some embodiments p is 3. In some embodiment p is 4. In some embodiments p is 5. In some embodiments p is 7. In some embodiment p is 8. In some embodiments p is 9. In some embodiments p is 10. In some embodiments all R19are hydrogen. In some embodiments all but one R19are hydrogen. In some embodiments all but two R19are hydrogen. In some embodiments all but three R19are hydrogen. In some embodiments all but four R19are hydrogen.

Preferred compounds are represented by the general formula:
—X—R1Formula Iwherein X is oxygen, sulfur, NR2, or another group compatible with attachment or coupling of the compound to a product or surface;wherein R1is -A-B(—C)δor —R3—Rb;wherein A and R3are —Rh—(Rg)jor

wherein each C, R4, and R5are independently hydrogen or

X is preferably oxygen, sulfur, or NR2.

In some embodiments where A or R3is —Rh—(Rg)j, Rhis C(R39R40), and j is 4 to 31, wherein the first, third, fourth, sixth, seventh, ninth, tenth, twelfth, thirteenth, fifteenth, sixteenth, eighteenth, nineteenth, twenty-first, twenty-second, twenty-fourth, twenty-fifth, twenty-seventh, twenty-eighth, thirtieth, and thirty-first Rg, if present, are C(R42R43) and the second, fifth, eighth, eleventh, fourteenth, seventeenth, twentieth, twenty-third, twenty-sixth, and twenty-ninth, Rg, if present, are O, wherein R39, R40, R42, and R43are hydrogen or C1-C3alkyl. In some embodiments R39and R40are hydrogen. In some embodiments R39is hydrogen and R40is C1-C3alkyl. In some embodiments R39and R40are C1-C3alkyl. In some embodiments all R42are hydrogen. In some embodiments all but one R42are hydrogen. In some embodiments all but two R42are hydrogen. In some embodiments all but three R42are hydrogen. In some embodiments all but four R42are hydrogen. In some embodiments all but five R42are hydrogen. In some embodiments all but six R42are hydrogen. In some embodiments all but seven R42are hydrogen. In some embodiments all but eight R42are hydrogen. In some embodiments all but nine R42are hydrogen. In some embodiments all but ten R42are hydrogen. In some embodiments all but eleven R42are hydrogen. In some embodiments all but twelve R42are hydrogen. In some embodiments all R43are hydrogen. In some embodiments all but one R43are hydrogen. In some embodiments all but two R43are hydrogen. In some embodiments all but three R43are hydrogen. In some embodiments all but four R43are hydrogen. In some embodiments all but five R43are hydrogen. In some embodiments all but six R43are hydrogen. In some embodiments all but seven R43are hydrogen. In some embodiments all but eight R43are hydrogen. In some embodiments all but nine R43are hydrogen. In some embodiments all but ten R43are hydrogen. In some embodiments all but eleven R43are hydrogen. In some embodiments all but twelve R43are hydrogen.

In some embodiments where A or R3is Formula VI, Rdis at R15. In some embodiments, Rdis at R13. In some embodiments, Rdis at R14. In some embodiments, Rdis at R16. In some embodiments, Rdis at R17. In some embodiments, p is 0. In some embodiments p is 1. In some embodiment p is 2. In some embodiments p is 3. In some embodiment p is 4. In some embodiments p is 5. In some embodiments p is 7. In some embodiment p is 8. In some embodiments p is 9. In some embodiments p is 10. In some embodiments all R19are hydrogen. In some embodiments all but one R19are hydrogen. In some embodiments all but two R19are hydrogen. In some embodiments all but three R19are hydrogen. In some embodiments all but four R19are hydrogen.

In some embodiments where A or R3is Formula VI, in such A and R3, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis Rb, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, p is 1, and R19are hydrogen.

In some embodiments where one or more of C, R4, and R5are Formula VI, in such C, R4, and R5: R12is carbon, one or two of nonadjacent R13, R14, R15, R16, and R17are O, the rest of R13, R14, R15, R16, and R17are carbon, z is 0 to 3, Rdare independently C1-C3alkyl, C1-C3alkoxy, amino, C1-C3alkylamino, C1-C3dialkylamino, hydroxy, C1-C3alkenyl, or C1-C3alkynyl, the ring of Formula VI has no double bonds, R18is —(CR19R19)p—Xb—(CR19R19)q—, p is 0 to 5, q is 0 to 5, R19are independently hydrogen or C1-C3alkyl, and Xbis O. In some embodiments R4is hydrogen. In some embodiments, R5is hydrogen. In some embodiments, R13is O and R14, R15, R16, and R17are carbon. In some embodiments, R14is O and R13, R15, R16, and R17are carbon. In some embodiments, R15is O and R13, R14, R16, and R17are carbon. In some embodiments, R16is O and R13, R14, R15, and R17are carbon. In some embodiments, R17is O and R13, R14, R15, and R16are carbon. In some embodiments, R13and R15are O. In some embodiments, R13and R16are O. In some embodiments, R13and R17are O. In some embodiments, R14and R16are O. In some embodiments, R14and R17are O. In some embodiments, R15and R17are O. In some embodiments z is 0. In some embodiments z is 1. In some embodiments z is 2. In some embodiments z is 3. In some embodiments Rdis independently methyl, ethyl, methoxy, ethoxy, amino methyl, amino ethyl, hydroxyl, or amino. In some embodiments, p is 0. In some embodiments p is 1. In some embodiment p is 2. In some embodiments p is 3. In some embodiments p is 4. In some embodiments p is 5. In some embodiments, q is 0. In some embodiments q is 1. In some embodiment q is 2. In some embodiments q is 3. In some embodiments q is 4. In some embodiments q is 5. In some embodiments all R19are hydrogen. In some embodiments all but one R19are hydrogen. In some embodiments all but two R19are hydrogen. In some embodiments all but three R19are hydrogen. In some embodiments all but four R19are hydrogen.

In some embodiments where at least one C is Formula VI, R4is hydrogen, and R5is Formula VI, in such C and R5: R13is O, R12, R14, R15, R16, and R17are carbon, z is 0, the ring of Formula VI has no double bonds, R18is —(CR19R19)p—Xb—(CR19R19)q—, p is 0, q is 1, both R19are hydrogen, and Xbis O.

In some embodiments where one or more of C, R4, and R5are Formula VI, in such C, R4, and R5: R12is N, R15is S(O)2, R13, R14, R16, and R17are carbon, the ring of Formula VI has no double bonds, R18is —(CR19R19)p—, p is 0 to 10, and R19are independently hydrogen or C1-C3alkyl. In some embodiments, p is 0. In some embodiments p is 1. In some embodiment p is 2. In some embodiments p is 3. In some embodiment p is 4. In some embodiments p is 5. In some embodiments p is 7. In some embodiment p is 8. In some embodiments p is 9. In some embodiments p is 10. In some embodiments all R19are hydrogen. In some embodiments all but one R19are hydrogen. In some embodiments all but two R19are hydrogen. In some embodiments all but three R19are hydrogen. In some embodiments all but four R19are hydrogen.

In some embodiments where at least one C is Formula VI, R4is hydrogen, and R5is Formula VI, in such C and R5: R12is N, R15is S(O)2, R13, R14, R16, and R17are carbon, the ring of Formula VI has no double bonds, R18is —(CR19R19)p—, p is 1, and both R19are hydrogen.

In some embodiments where one or more of C, R4, and R5are Formula VI, in such C, R4, and R5: R12, R13, R14, R15, R16, and R17are carbon, z is 0 to 5, Rdare independently C1-C3alkyl, C1-C3alkoxy, amino, C1-C3alkylamino, C1-C3dialkylamino, hydroxy, C1-C3alkenyl, or C1-C3alkynyl, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, p is 0 to 5, and R19are independently hydrogen or C1-C3alkyl. In some embodiments, z is 0. In some embodiments z is 1. In some embodiment z is 2. In some embodiments z is 3. In some embodiment z is 4. In some embodiments z is 5. In some embodiments, p is 0. In some embodiments p is 1. In some embodiment p is 2. In some embodiments p is 3. In some embodiment p is 4. In some embodiments p is 5. In some embodiments all R19are hydrogen. In some embodiments all but one R19are hydrogen. In some embodiments all but two R19are hydrogen. In some embodiments all but three R19are hydrogen. In some embodiments all but four R19are hydrogen. In some embodiments, Rdis at R15. In some embodiments, Rdis at R13. In some embodiments, Rdis at R14. In some embodiments, Rdis at R16. In some embodiments, Rdis at R17.

In some embodiments where at least one C is Formula VI, R4is hydrogen, and R5is Formula VI, in such C and R5: R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis —NH2, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, p is 0, and Rdis at R15.

In some embodiments, the compounds are represented by the general formula:
—X—R1Formula Iwherein X is oxygen, sulfur, NR2, or another group compatible with attachment or coupling of the compound to a product or surface;wherein R1is -A-B(—C)δor —R3—Rb;wherein A and R3are

wherein for A and R3, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis Rb, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, p is 0 to 10, and R19are independently hydrogen or C1-C3alkyl;wherein B and Rbare:

wherein each C, R4, and R5are independently hydrogen or

X is preferably oxygen, sulfur, or NR2.

In some embodiments where A or R3is Formula VI, Rdis at R15. In some embodiments, Rdis at R13. In some embodiments, Rdis at R14. In some embodiments, Rdis at R16. In some embodiments, Rdis at R17. In some embodiments, p is 0. In some embodiments p is 1. In some embodiment p is 2. In some embodiments p is 3. In some embodiment p is 4. In some embodiments p is 5. In some embodiments p is 7. In some embodiment p is 8. In some embodiments p is 9. In some embodiments p is 10. In some embodiments all R19are hydrogen. In some embodiments all but one R19are hydrogen. In some embodiments all but two R19are hydrogen. In some embodiments all but three R19are hydrogen. In some embodiments all but four R19are hydrogen.

In some embodiments where A or R3is Formula VI, in such A and R3, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis Rb, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, p is 1, and R19are hydrogen.

In some embodiments where one or more of C, R4, and R5are Formula VI, in such C, R4, and R5: R12is carbon, one or two of nonadjacent R13, R14, R15, R16, and R17are O, the rest of R13, R14, R15, R16, and R17are carbon, z is 0 to 3, Rdare independently C1-C3alkyl, C1-C3alkoxy, amino, C1-C3alkylamino, C1-C3dialkylamino, hydroxy, C1-C3alkenyl, or C1-C3alkynyl, the ring of Formula VI has no double bonds, R18is —(CR19R19)p—Xb—(CR19R19)q—, p is 0 to 5, q is 0 to 5, R19are independently hydrogen or C1-C3alkyl, and Xbis O. In some embodiments R4is hydrogen. In some embodiments, R5is hydrogen. In some embodiments, R13is O and R14, R15, R16, and R17are carbon. In some embodiments, R14is O and R13, R15, R16, and R17are carbon. In some embodiments, R15is O and R13, R14, R16, and R17are carbon. In some embodiments, R16is O and R13, R14, R15, and R17are carbon. In some embodiments, R17is O and R13, R14, R15, and R16are carbon. In some embodiments, R13and R15are O. In some embodiments, R13and R16are O. In some embodiments, R13and R17are O. In some embodiments, R14and R16are O. In some embodiments, R14and R17are O. In some embodiments, R15and R17are O. In some embodiments z is 0. In some embodiments z is 1. In some embodiments z is 2. In some embodiments z is 3. In some embodiments Rdis independently methyl, ethyl, methoxy, ethoxy, amino methyl, amino ethyl, hydroxyl, or amino. In some embodiments, p is 0. In some embodiments p is 1. In some embodiment p is 2. In some embodiments p is 3. In some embodiments p is 4. In some embodiments p is 5. In some embodiments, q is 0. In some embodiments q is 1. In some embodiment q is 2. In some embodiments q is 3. In some embodiments q is 4. In some embodiments q is 5. In some embodiments all R19are hydrogen. In some embodiments all but one R19are hydrogen. In some embodiments all but two R19are hydrogen. In some embodiments all but three R19are hydrogen. In some embodiments all but four R19are hydrogen.

In some embodiments where at least one C is Formula VI, R4is hydrogen, and R5is Formula VI, in such C and R5: R13is O, R12, R14, R15, R16, and R17are carbon, z is 0, the ring of Formula VI has no double bonds, R18is —(CR19R19)p—Xb—(CR19R19)q—, p is 0, q is 1, both R19are hydrogen, and Xbis O.

wherein each C, R4, and R5are independently hydrogen or

wherein for C, R4, and R5, R12is N, R15is S(O)2, R13, R14, R16, and R17are carbon, the ring of Formula VI has no double bonds, R18is —(CR19R19)p—, p is 0 to 10, and R19are independently hydrogen or C1-C3alkyl;wherein R4and R5are not both hydrogen, wherein at least one C is not hydrogen.

X is preferably oxygen, sulfur, or NR2.

In some embodiments where A or R3is —Rh—(Rg)j, Rhis C(R39R40), and j is 4 to 31, wherein the first, third, fourth, sixth, seventh, ninth, tenth, twelfth, thirteenth, fifteenth, sixteenth, eighteenth, nineteenth, twenty-first, twenty-second, twenty-fourth, twenty-fifth, twenty-seventh, twenty-eighth, thirtieth, and thirty-first Rg, if present, are C(R42R43) and the second, fifth, eighth, eleventh, fourteenth, seventeenth, twentieth, twenty-third, twenty-sixth, and twenty-ninth, Rg, if present, are O, wherein R39, R40, R42, and R43are hydrogen or C1-C3alkyl. In some embodiments R39and R40are hydrogen. In some embodiments R39is hydrogen and R40is C1-C3alkyl. In some embodiments R39and R40are C1-C3alkyl. In some embodiments all R42are hydrogen. In some embodiments all but one R42are hydrogen. In some embodiments all but two R42are hydrogen. In some embodiments all but three R42are hydrogen. In some embodiments all but four R42are hydrogen. In some embodiments all but five R42are hydrogen. In some embodiments all but six R42are hydrogen. In some embodiments all but seven R42are hydrogen. In some embodiments all but eight R42are hydrogen. In some embodiments all but nine R42are hydrogen. In some embodiments all but ten R42are hydrogen. In some embodiments all but eleven R42are hydrogen. In some embodiments all but twelve R42are hydrogen. In some embodiments all R43are hydrogen. In some embodiments all but one R43are hydrogen. In some embodiments all but two R43are hydrogen. In some embodiments all but three R43are hydrogen. In some embodiments all but four R43are hydrogen. In some embodiments all but five R43are hydrogen. In some embodiments all but six R43are hydrogen. In some embodiments all but seven R43are hydrogen. In some embodiments all but eight R43are hydrogen. In some embodiments all but nine R43are hydrogen. In some embodiments all but ten R43are hydrogen. In some embodiments all but eleven R43are hydrogen. In some embodiments all but twelve R43are hydrogen.

In some embodiments where one or more of C, R4, and R5are Formula VI, in such C, R4, and R5: R12is N, R15is S(O)2, R13, R14, R16, and R17are carbon, the ring of Formula VI has no double bonds, R18is —(CR19R19)p—, p is 0 to 10, and R19are independently hydrogen or C1-C3alkyl. In some embodiments, p is 0. In some embodiments p is 1. In some embodiment p is 2. In some embodiments p is 3. In some embodiment p is 4. In some embodiments p is 5. In some embodiments p is 7. In some embodiment p is 8. In some embodiments p is 9. In some embodiments p is 10. In some embodiments all R19are hydrogen. In some embodiments all but one R19are hydrogen. In some embodiments all but two R19are hydrogen. In some embodiments all but three R19are hydrogen. In some embodiments all but four R19are hydrogen.

In some embodiments where at least one C is Formula VI, R4is hydrogen, and R5is Formula VI, in such C and R5: R12is N, R15is S(O)2, R13, R14, R16, and R17are carbon, the ring of Formula VI has no double bonds, R18is —(CR19R19)p—, p is 1, and both R19are hydrogen.

wherein each C, R4, and R5are independently hydrogen or

wherein R12, R13, R14, R15, R16, and R17are carbon, z is 0 to 5, Rdare independently C1-C3alkyl, C1-C3alkoxy, amino, C1-C3alkylamino, C1-C3dialkylamino, hydroxy, C1-C3alkenyl, or C1-C3alkynyl, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, p is 0 to 5, and R19are independently hydrogen or C1-C3alkyl;wherein R4and R5are not both hydrogen, wherein at least one of C is not hydrogen.

X is preferably oxygen, sulfur, or NR2.

In some embodiments where A or R3is —Rh—(Rg)j, Rhis C(R39R40), and j is 4 to 31, wherein the first, third, fourth, sixth, seventh, ninth, tenth, twelfth, thirteenth, fifteenth, sixteenth, eighteenth, nineteenth, twenty-first, twenty-second, twenty-fourth, twenty-fifth, twenty-seventh, twenty-eighth, thirtieth, and thirty-first Rg, if present, are C(R42R43) and the second, fifth, eighth, eleventh, fourteenth, seventeenth, twentieth, twenty-third, twenty-sixth, and twenty-ninth, Rg, if present, are O, wherein R39, R40, R42, and R43are hydrogen or C1-C3alkyl. In some embodiments R39and R40are hydrogen. In some embodiments R39is hydrogen and R40is C1-C3alkyl. In some embodiments R39and R40are C1-C3alkyl. In some embodiments all R42are hydrogen. In some embodiments all but one R42are hydrogen. In some embodiments all but two R42are hydrogen. In some embodiments all but three R42are hydrogen. In some embodiments all but four R42are hydrogen. In some embodiments all but five R42are hydrogen. In some embodiments all but six R42are hydrogen. In some embodiments all but seven R42are hydrogen. In some embodiments all but eight R42are hydrogen. In some embodiments all but nine R42are hydrogen. In some embodiments all but ten R42are hydrogen. In some embodiments all but eleven R42are hydrogen. In some embodiments all but twelve R42are hydrogen. In some embodiments all R43are hydrogen. In some embodiments all but one R43are hydrogen. In some embodiments all but two R43are hydrogen. In some embodiments all but three R43are hydrogen. In some embodiments all but four R43are hydrogen. In some embodiments all but five R43are hydrogen. In some embodiments all but six R43are hydrogen. In some embodiments all but seven R43are hydrogen. In some embodiments all but eight R43are hydrogen. In some embodiments all but nine R43are hydrogen. In some embodiments all but ten R43are hydrogen. In some embodiments all but eleven R43are hydrogen. In some embodiments all but twelve R43are hydrogen.

In some embodiments where one or more of C, R4, and R5are Formula VI, in such C, R4, and R5: R12, R13, R14, R15, R16, and R17are carbon, z is 0 to 5, Rdare independently C1-C3alkyl, C1-C3alkoxy, amino, C1-C3alkylamino, C1-C3dialkylamino, hydroxy, C1-C3alkenyl, or C1-C3alkynyl, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, p is 0 to 5, and R19are independently hydrogen or C1-C3alkyl. In some embodiments, z is 0. In some embodiments z is 1. In some embodiment z is 2. In some embodiments z is 3. In some embodiment z is 4. In some embodiments z is 5. In some embodiments, p is 0. In some embodiments p is 1. In some embodiment p is 2. In some embodiments p is 3. In some embodiment p is 4. In some embodiments p is 5. In some embodiments all R19are hydrogen. In some embodiments all but one R19are hydrogen. In some embodiments all but two R19are hydrogen. In some embodiments all but three R19are hydrogen. In some embodiments all but four R19are hydrogen. In some embodiments, Rdis at R15. In some embodiments, Rdis at R13. In some embodiments, Rdis at R14. In some embodiments, Rdis at R16. In some embodiments, Rdis at R17.

In some embodiments where at least one C is Formula VI, R4is hydrogen, and R5is Formula VI, in such C and R5: R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis —NH2, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, p is 0, and Rdis at R15.

wherein each C, R4, and R5are independently hydrogen or —Rh—(Rg)j,wherein Rhis C(R39R40), j is 1 to 15, and each Rgis C(R42R43), wherein R42is ═O and R43is absent for two Rg, R42and R43are hydrogen for the other Rg, and R39and R40are hydrogen;wherein R4and R5are not both hydrogen, wherein at least one of C is not hydrogen.

X is preferably oxygen, sulfur, or NR2.

In some embodiments where A or R3is —Rh—(Rg)j, Rhis C(R39R40), and j is 4 to 31, wherein the first, third, fourth, sixth, seventh, ninth, tenth, twelfth, thirteenth, fifteenth, sixteenth, eighteenth, nineteenth, twenty-first, twenty-second, twenty-fourth, twenty-fifth, twenty-seventh, twenty-eighth, thirtieth, and thirty-first Rg, if present, are C(R42R43) and the second, fifth, eighth, eleventh, fourteenth, seventeenth, twentieth, twenty-third, twenty-sixth, and twenty-ninth, Rg, if present, are O, wherein R39, R40, R42, and R43are hydrogen or C1-C3alkyl. In some embodiments R39and R40are hydrogen. In some embodiments R39is hydrogen and R40is C1-C3alkyl. In some embodiments R39and R40are C1-C3alkyl. In some embodiments all R42are hydrogen. In some embodiments all but one R42are hydrogen. In some embodiments all but two R42are hydrogen. In some embodiments all but three R42are hydrogen. In some embodiments all but four R42are hydrogen. In some embodiments all but five R42are hydrogen. In some embodiments all but six R42are hydrogen. In some embodiments all but seven R42are hydrogen. In some embodiments all but eight R42are hydrogen. In some embodiments all but nine R42are hydrogen. In some embodiments all but ten R42are hydrogen. In some embodiments all but eleven R42are hydrogen. In some embodiments all but twelve R42are hydrogen. In some embodiments all R43are hydrogen. In some embodiments all but one R43are hydrogen. In some embodiments all but two R43are hydrogen. In some embodiments all but three R43are hydrogen. In some embodiments all but four R43are hydrogen. In some embodiments all but five R43are hydrogen. In some embodiments all but six R43are hydrogen. In some embodiments all but seven R43are hydrogen. In some embodiments all but eight R43are hydrogen. In some embodiments all but nine R43are hydrogen. In some embodiments all but ten R43are hydrogen. In some embodiments all but eleven R43are hydrogen. In some embodiments all but twelve R43are hydrogen.

In some embodiments Rhis C(R39R40), and j is 0, wherein R39is ═O, and R40is absent. In some embodiments Rhis C(R39R40), j is 0 to 10, and each Rgis C(R42R43), wherein R39is ═O, R40is absent, and R42and R43are hydrogen. In some embodiments j is 1. In some embodiment j is 2. In some embodiments j is 3. In some embodiment j is 4. In some embodiments j is 5. In some embodiments j is 7. In some embodiment j is 8. In some embodiments j is 9. In some embodiments j is 10.

In some embodiments Rhis C(R39R40), j is 1 to 10, and each Rgis C(R42R43), wherein R42is ═O and R43is absent for one Rg, R42and R43are hydrogen for the other Rg, and R39and R40are hydrogen. In some embodiments R42is ═O and R43is absent for the last Rg. In some embodiments R42is ═O and R43is absent for the penultimate Rg. In some embodiments R42is ═O and R43is absent for the antepenultimate Rg. In some embodiments R42is ═O and R43is absent for the fourth from the last Rg. In some embodiments R42is ═O and R43is absent for the fifth from the last Rg. In some embodiments R42is ═O and R43is absent for the first Rg. In some embodiments R42is ═O and R43is absent for the second Rg. In some embodiments R42is ═O and R43is absent for the third Rg. In some embodiments R42is ═O and R43is absent for the fourth Rg. In some embodiments R42is ═O and R43is absent for the fifth Rg.

wherein each C, R4, and R5are independently hydrogen or

wherein for C, R4, and R5, R12is carbon, one or two of nonadjacent R13, R14, R15, R16, and R17are O, the rest of R13, R14, R15, R16, and R17are carbon, z is 0 to 3, Rdare independently C1-C3alkyl, C1-C3alkoxy, amino, C1-C3alkylamino, C1-C3dialkylamino, hydroxy, C1-C3alkenyl, or C1-C3alkynyl, the ring of Formula VI has no double bonds, R18is —(CR19R19)p—Xb—(CR19R19)q—, p is 0 to 5, q is 0 to 5, R19are independently hydrogen or C1-C3alkyl, and Xbis O;wherein R4and R5are not both hydrogen, wherein at least one of C is not hydrogen.

X is preferably oxygen, sulfur, or NR2.

In some embodiments where A or R3is —Rh—(Rg)j, Rhis C(R39R40), and j is 4 to 31, wherein the first, third, fourth, sixth, seventh, ninth, tenth, twelfth, thirteenth, fifteenth, sixteenth, eighteenth, nineteenth, twenty-first, twenty-second, twenty-fourth, twenty-fifth, twenty-seventh, twenty-eighth, thirtieth, and thirty-first Rg, if present, are C(R42R43) and the second, fifth, eighth, eleventh, fourteenth, seventeenth, twentieth, twenty-third, twenty-sixth, and twenty-ninth, Rg, if present, are O, wherein R39, R40, R42, and R43are hydrogen or C1-C3alkyl. In some embodiments R39and R40are hydrogen. In some embodiments R39is hydrogen and R40is C1-C3alkyl. In some embodiments R39and R40are C1-C3alkyl. In some embodiments all R42are hydrogen. In some embodiments all but one R42are hydrogen. In some embodiments all but two R42are hydrogen. In some embodiments all but three R42are hydrogen. In some embodiments all but four R42are hydrogen. In some embodiments all but five R42are hydrogen. In some embodiments all but six R42are hydrogen. In some embodiments all but seven R42are hydrogen. In some embodiments all but eight R42are hydrogen. In some embodiments all but nine R42are hydrogen. In some embodiments all but ten R42are hydrogen. In some embodiments all but eleven R42are hydrogen. In some embodiments all but twelve R42are hydrogen. In some embodiments all R43are hydrogen. In some embodiments all but one R43are hydrogen. In some embodiments all but two R43are hydrogen. In some embodiments all but three R43are hydrogen. In some embodiments all but four R43are hydrogen. In some embodiments all but five R43are hydrogen. In some embodiments all but six R43are hydrogen. In some embodiments all but seven R43are hydrogen. In some embodiments all but eight R43are hydrogen. In some embodiments all but nine R43are hydrogen. In some embodiments all but ten R43are hydrogen. In some embodiments all but eleven R43are hydrogen. In some embodiments all but twelve R43are hydrogen.

In some embodiments where one or more of C, R4, and R5are Formula VI, in such C, R4, and R5: R12is carbon, one or two of nonadjacent R13, R14, R15, R16, and R17are O, the rest of R13, R14, R15, R16, and R17are carbon, z is 0 to 3, Rdare independently C1-C3alkyl, C1-C3alkoxy, amino, C1-C3alkylamino, C1-C3dialkylamino, hydroxy, C1-C3alkenyl, or C1-C3alkynyl, the ring of Formula VI has no double bonds, R18is —(CR19R19)p—Xb—(CR19R19)q—, p is 0 to 5, q is 0 to 5, R19are independently hydrogen or C1-C3alkyl, and Xbis O.

In some embodiments where one or more of C, R4, and R5are Formula VI, in such C, R4, and R5: R12is carbon, one or two of nonadjacent R13, R14, R15, R16, and R17are O, the rest of R13, R14, R15, R16, and R17are carbon, z is 0 to 3, Rdare independently C1-C3alkyl, C1-C3alkoxy, amino, C1-C3alkylamino, C1-C3dialkylamino, hydroxy, C1-C3alkenyl, or C1-C3alkynyl, the ring of Formula VI has no double bonds, R18is —(CR19R19)p—Xb—(CR19R19)q—, p is 0 to 5, q is 0 to 5, R19are independently hydrogen or C1-C3alkyl, and Xbis O. In some embodiments R4is hydrogen. In some embodiments, R5is hydrogen. In some embodiments, R13is O and R14, R15, R16, and R17are carbon. In some embodiments, R14is O and R13, R15, R16, and R17are carbon. In some embodiments, R15is O and R13, R14, R16, and R17are carbon. In some embodiments, R16is O and R13, R14, R15, and R17are carbon. In some embodiments, R17is O and R13, R14, R15, and R16are carbon. In some embodiments, R13and R15are O. In some embodiments, R13and R16are O. In some embodiments, R13and R17are O. In some embodiments, R14and R16are O. In some embodiments, R14and R17are O. In some embodiments, R15and R17are O. In some embodiments z is 0. In some embodiments z is 1. In some embodiments z is 2. In some embodiments z is 3. In some embodiments Rdis independently methyl, ethyl, methoxy, ethoxy, amino methyl, amino ethyl, hydroxyl, or amino. In some embodiments, p is 0. In some embodiments p is 1. In some embodiment p is 2. In some embodiments p is 3. In some embodiments p is 4. In some embodiments p is 5. In some embodiments, q is 0. In some embodiments q is 1. In some embodiment q is 2. In some embodiments q is 3. In some embodiments q is 4. In some embodiments q is 5. In some embodiments all R19are hydrogen. In some embodiments all but one R19are hydrogen. In some embodiments all but two R19are hydrogen. In some embodiments all but three R19are hydrogen. In some embodiments all but four R19are hydrogen.

In some embodiments where at least one C is Formula VI, R4is hydrogen, and R5is Formula VI, in such C and R5: R13is O, R12, R14, R15, R16, and R17are carbon, z is 0, the ring of Formula VI has no double bonds, R18is —(CR19R19)p—Xb—(CR19R19)q—, p is 0, q is 1, both R19are hydrogen, and Xbis O.

wherein each C, R4, and R5are independently hydrogen or

wherein for C, R4, and R5, R12, R13, R14, R15, R16, and R17are carbon, z is 0 to 3, Rdare independently C1-C3alkyl, C1-C3alkoxy, amino, C1-C3alkylamino, C1-C3dialkylamino, hydroxy, C1-C3alkenyl, or C1-C3alkynyl, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, and p is 0;wherein R4and R5are not both hydrogen, wherein at least one of C is not hydrogen.

X is preferably oxygen, sulfur, or NR2.

In some embodiments where A or R3is —Rh—(Rg)j, Rhis C(R39R40), and j is 4 to 31, wherein the first, third, fourth, sixth, seventh, ninth, tenth, twelfth, thirteenth, fifteenth, sixteenth, eighteenth, nineteenth, twenty-first, twenty-second, twenty-fourth, twenty-fifth, twenty-seventh, twenty-eighth, thirtieth, and thirty-first Rg, if present, are C(R42R43) and the second, fifth, eighth, eleventh, fourteenth, seventeenth, twentieth, twenty-third, twenty-sixth, and twenty-ninth, Rg, if present, are O, wherein R39, R40, R42, and R43are hydrogen or C1-C3alkyl. In some embodiments R39and R40are hydrogen. In some embodiments R39is hydrogen and R40is C1-C3alkyl. In some embodiments R39and R40are C1-C3alkyl. In some embodiments all R42are hydrogen. In some embodiments all but one R42are hydrogen. In some embodiments all but two R42are hydrogen. In some embodiments all but three R42are hydrogen. In some embodiments all but four R42are hydrogen. In some embodiments all but five R42are hydrogen. In some embodiments all but six R42are hydrogen. In some embodiments all but seven R42are hydrogen. In some embodiments all but eight R42are hydrogen. In some embodiments all but nine R42are hydrogen. In some embodiments all but ten R42are hydrogen. In some embodiments all but eleven R42are hydrogen. In some embodiments all but twelve R42are hydrogen. In some embodiments all R43are hydrogen. In some embodiments all but one R43are hydrogen. In some embodiments all but two R43are hydrogen. In some embodiments all but three R43are hydrogen. In some embodiments all but four R43are hydrogen. In some embodiments all but five R43are hydrogen. In some embodiments all but six R43are hydrogen. In some embodiments all but seven R43are hydrogen. In some embodiments all but eight R43are hydrogen. In some embodiments all but nine R43are hydrogen. In some embodiments all but ten R43are hydrogen. In some embodiments all but eleven R43are hydrogen. In some embodiments all but twelve R43are hydrogen.

In some embodiments, in Formula VI, R12, R13, R14, R15, R16, and R17are carbon, z is 0, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, and p is 0.

wherein each C, R4, and R5are independently hydrogen or

wherein for C, R4, and R5, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis hydroxy, C1-C3alkyl, C1-C3alkoxy, amino, C1-C3alkylamino, C1-C3dialkylamino, hydroxy, C1-C3alkenyl, or C1-C3alkynyl, the ring of Formula VI has no double bonds, R18is —(CR19R19)p—, and p is 0;wherein R4and R5are not both hydrogen, wherein at least one of C is not hydrogen.

X is preferably oxygen, sulfur, or NR2.

In some embodiments where A or R3is —Rh—(Rg)j, Rhis C(R39R40), and j is 4 to 31, wherein the first, third, fourth, sixth, seventh, ninth, tenth, twelfth, thirteenth, fifteenth, sixteenth, eighteenth, nineteenth, twenty-first, twenty-second, twenty-fourth, twenty-fifth, twenty-seventh, twenty-eighth, thirtieth, and thirty-first Rg, if present, are C(R42R43) and the second, fifth, eighth, eleventh, fourteenth, seventeenth, twentieth, twenty-third, twenty-sixth, and twenty-ninth, Rg, if present, are O, wherein R39, R40, R42, and R43are hydrogen or C1-C3alkyl. In some embodiments R39and R40are hydrogen. In some embodiments R39is hydrogen and R40is C1-C3alkyl. In some embodiments R39and R40are C1-C3alkyl. In some embodiments all R42are hydrogen. In some embodiments all but one R42are hydrogen. In some embodiments all but two R42are hydrogen. In some embodiments all but three R42are hydrogen. In some embodiments all but four R42are hydrogen. In some embodiments all but five R42are hydrogen. In some embodiments all but six R42are hydrogen. In some embodiments all but seven R42are hydrogen. In some embodiments all but eight R42are hydrogen. In some embodiments all but nine R42are hydrogen. In some embodiments all but ten R42are hydrogen. In some embodiments all but eleven R42are hydrogen. In some embodiments all but twelve R42are hydrogen. In some embodiments all R43are hydrogen. In some embodiments all but one R43are hydrogen. In some embodiments all but two R43are hydrogen. In some embodiments all but three R43are hydrogen. In some embodiments all but four R43are hydrogen. In some embodiments all but five R43are hydrogen. In some embodiments all but six R43are hydrogen. In some embodiments all but seven R43are hydrogen. In some embodiments all but eight R43are hydrogen. In some embodiments all but nine R43are hydrogen. In some embodiments all but ten R43are hydrogen. In some embodiments all but eleven R43are hydrogen. In some embodiments all but twelve R43are hydrogen.

In some embodiments, in Formula VI, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis hydroxy, the ring of Formula VI has no double bonds, R18is —(CR19R19)p—, and p is 0. In some embodiments, Rdis at R15. In some embodiments, Rdis at R13. In some embodiments, Rdis at R14. In some embodiments, Rdis at R16. In some embodiments, Rdis at R17.

wherein C and R5are independently hydrogen or

wherein C and R4, independently hydrogen or —Rh—(Rg)j,wherein for C and R5, R12, R13, R14, R15, R16, and R17are carbon, z is 0, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, and p is 0; wherein Rhis C(R39R40), and j is 0, wherein R39is ═O and R40is —OH. In some embodiments Rhis absent, j is 0 to 10, and each Rgis C(R42R43), wherein R42and R43are hydrogen;wherein R4and R5are not both hydrogen, wherein at least one of C is not hydrogen.

X is preferably oxygen, sulfur, or NR2.

In some embodiments where A or R3is —Rh—(Rg)j, Rhis C(R39R40), and j is 4 to 31, wherein the first, third, fourth, sixth, seventh, ninth, tenth, twelfth, thirteenth, fifteenth, sixteenth, eighteenth, nineteenth, twenty-first, twenty-second, twenty-fourth, twenty-fifth, twenty-seventh, twenty-eighth, thirtieth, and thirty-first Rg, if present, are C(R42R43) and the second, fifth, eighth, eleventh, fourteenth, seventeenth, twentieth, twenty-third, twenty-sixth, and twenty-ninth, Rg, if present, are O, wherein R39, R40, R42, and R43are hydrogen or C1-C3alkyl. In some embodiments R39and R40are hydrogen. In some embodiments R39is hydrogen and R40is C1-C3alkyl. In some embodiments R39and R40are C1-C3alkyl. In some embodiments all R42are hydrogen. In some embodiments all but one R42are hydrogen. In some embodiments all but two R42are hydrogen. In some embodiments all but three R42are hydrogen. In some embodiments all but four R42are hydrogen. In some embodiments all but five R42are hydrogen. In some embodiments all but six R42are hydrogen. In some embodiments all but seven R42are hydrogen. In some embodiments all but eight R42are hydrogen. In some embodiments all but nine R42are hydrogen. In some embodiments all but ten R42are hydrogen. In some embodiments all but eleven R42are hydrogen. In some embodiments all but twelve R42are hydrogen. In some embodiments all R43are hydrogen. In some embodiments all but one R43are hydrogen. In some embodiments all but two R43are hydrogen. In some embodiments all but three R43are hydrogen. In some embodiments all but four R43are hydrogen. In some embodiments all but five R43are hydrogen. In some embodiments all but six R43are hydrogen. In some embodiments all but seven R43are hydrogen. In some embodiments all but eight R43are hydrogen. In some embodiments all but nine R43are hydrogen. In some embodiments all but ten R43are hydrogen. In some embodiments all but eleven R43are hydrogen. In some embodiments all but twelve R43are hydrogen.

In some embodiments, one C or R4is —Rh—(Rg)j, and one C or R5is, wherein in Formula VI, R12, R13, R14, R15, R16, and R17are carbon, z is 0, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, and p is 0, wherein Rhis C(R39R40), and j is 0, wherein R39is ═O and R40is —OH. In some embodiments Rhis absent, j is 0 to 10, and each Rgis C(R42R43), wherein R42and R43are hydrogen.

wherein each C, R4, and R5are independently hydrogen or

wherein for C, R4, and R5, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis —O—CH3, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, and p is 0. In some embodiments, Rdis at R15;wherein R4and R5are not both hydrogen, wherein at least one of C is not hydrogen.

X is preferably oxygen, sulfur, or NR2.

In some embodiments where A or R3is —Rh—(Rg)j, Rhis C(R39R40), and j is 4 to 31, wherein the first, third, fourth, sixth, seventh, ninth, tenth, twelfth, thirteenth, fifteenth, sixteenth, eighteenth, nineteenth, twenty-first, twenty-second, twenty-fourth, twenty-fifth, twenty-seventh, twenty-eighth, thirtieth, and thirty-first Rg, if present, are C(R42R43) and the second, fifth, eighth, eleventh, fourteenth, seventeenth, twentieth, twenty-third, twenty-sixth, and twenty-ninth, Rg, if present, are O, wherein R39, R40, R42, and R43are hydrogen or C1-C3alkyl. In some embodiments R39and R40are hydrogen. In some embodiments R39is hydrogen and R40is C1-C3alkyl. In some embodiments R39and R40are C1-C3alkyl. In some embodiments all R42are hydrogen. In some embodiments all but one R42are hydrogen. In some embodiments all but two R42are hydrogen. In some embodiments all but three R42are hydrogen. In some embodiments all but four R42are hydrogen. In some embodiments all but five R42are hydrogen. In some embodiments all but six R42are hydrogen. In some embodiments all but seven R42are hydrogen. In some embodiments all but eight R42are hydrogen. In some embodiments all but nine R42are hydrogen. In some embodiments all but ten R42are hydrogen. In some embodiments all but eleven R42are hydrogen. In some embodiments all but twelve R42are hydrogen. In some embodiments all R43are hydrogen. In some embodiments all but one R43are hydrogen. In some embodiments all but two R43are hydrogen. In some embodiments all but three R43are hydrogen. In some embodiments all but four R43are hydrogen. In some embodiments all but five R43are hydrogen. In some embodiments all but six R43are hydrogen. In some embodiments all but seven R43are hydrogen. In some embodiments all but eight R43are hydrogen. In some embodiments all but nine R43are hydrogen. In some embodiments all but ten R43are hydrogen. In some embodiments all but eleven R43are hydrogen. In some embodiments all but twelve R43are hydrogen.

In some embodiments, in Formula VI, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis —O—CH3, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, and p is 0.

In some embodiments, Rdis at R15. In some embodiments, Rdis at R13. In some embodiments, Rdis at R14. In some embodiments, Rdis at R16. In some embodiments, Rdis at R17.

In some embodiments, the compounds are represented by the general formula:
—X—R1Formula Iwherein X is oxygen, sulfur, NR2, or another group compatible with attachment or coupling of the compound to a product or surface;wherein R1is -A-B(—C)δor —R3—Rb;wherein A and R3are

wherein for A and R3, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis Rb, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, p is 0 to 10, and R19are independently hydrogen or C1-C3alkyl;wherein B and Rbare:

wherein each C, R4, and R5are independently hydrogen or

wherein for C, R4, and R5, R12, R13, R14, R15, R16, and R17are carbon, z is 0, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, one R19is —OH, the other R19is hydrogen, and p is 1;wherein R4and R5are not both hydrogen, wherein at least one of C is not hydrogen.

X is preferably oxygen, sulfur, or NR2.

In some embodiments where A or R3is Formula VI, Rdis at R15. In some embodiments, Rdis at R13. In some embodiments, Rdis at R14. In some embodiments, Rdis at R16. In some embodiments, Rdis at R17. In some embodiments, p is 0. In some embodiments p is 1. In some embodiment p is 2. In some embodiments p is 3. In some embodiment p is 4. In some embodiments p is 5. In some embodiments p is 7. In some embodiment p is 8. In some embodiments p is 9. In some embodiments p is 10. In some embodiments all R19are hydrogen. In some embodiments all but one R19are hydrogen. In some embodiments all but two R19are hydrogen. In some embodiments all but three R19are hydrogen. In some embodiments all but four R19are hydrogen.

In some embodiments where A or R3is Formula VI, in such A and R3, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis Rb, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, p is 1, and R19are hydrogen.

In some embodiments, in Formula VI, R12, R13, R14, R15, R16, and R17are carbon, z is 0, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, one R19is —OH, the other R19is hydrogen, and p is 1.

In some embodiments, the compounds are represented by the general formula:
—X—R1Formula Iwherein X is oxygen, sulfur, NR2, or another group compatible with attachment or coupling of the compound to a product or surface;wherein R1is -A-B(—C)δor —R3—Rb;wherein A and R3are

wherein for A and R3, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis Rb, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, p is 0 to 10, and R19are independently hydrogen or C1-C3alkyl;wherein B and Rbare:

wherein each C, R4, and R5are independently hydrogen or

wherein for C, R4, and R5, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis methyl, the ring of Formula VI is aromatic, R18is —(CR19R19)p—Xb—(CR19R19)q—, p is 0, q is 0, and Xbis S(O)2;wherein R4and R5are not both hydrogen, wherein at least one of C is not hydrogen.

X is preferably oxygen, sulfur, or NR2.

In some embodiments where A or R3is Formula VI, Rdis at R15. In some embodiments, Rdis at R13. In some embodiments, Rdis at R14. In some embodiments, Rdis at R16. In some embodiments, Rdis at R17. In some embodiments, p is 0. In some embodiments p is 1. In some embodiment p is 2. In some embodiments p is 3. In some embodiment p is 4. In some embodiments p is 5. In some embodiments p is 7. In some embodiment p is 8. In some embodiments p is 9. In some embodiments p is 10. In some embodiments all R19are hydrogen. In some embodiments all but one R19are hydrogen.

In some embodiments all but two R19are hydrogen. In some embodiments all but three R19are hydrogen. In some embodiments all but four R19are hydrogen.

In some embodiments where A or R3is Formula VI, in such A and R3, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis Rb, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, p is 1, and R19are hydrogen.

In some embodiments, in Formula VI, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis methyl, the ring of Formula VI is aromatic, R18is —(CR19R19)p—Xb—(CR19R19)q—, p is 0, q is 0, and Xbis S(O)2.

In some embodiments, the compounds are represented by the general formula:
—X—R1Formula Iwherein X is oxygen, sulfur, NR2, or another group compatible with attachment or coupling of the compound to a product or surface;wherein R1is -A-B(—C)δor —R3—Rb;wherein A and R3are

wherein for A and R3, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis Rb, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, p is 0 to 10, and R19are independently hydrogen or C1-C3alkyl;wherein B and Rbare:

wherein each C, R4, and R5are independently hydrogen or —Rh—(Rg)j,wherein Rhis C(R39R40), j is 1 to 10, one Rgis O, the other Rgare C(R42R43), and Rfis C(R45R46R47), wherein R39, R40, R42, R43, R45, R46, and R47are hydrogen;wherein R4and R5are not both hydrogen, wherein at least one of C is not hydrogen.

X is preferably oxygen, sulfur, or NR2.

In some embodiments where A or R3is Formula VI, Rdis at R15. In some embodiments, Rdis at R13. In some embodiments, Rdis at R14. In some embodiments, Rdis at R16. In some embodiments, Rdis at R17. In some embodiments, p is 0. In some embodiments p is 1. In some embodiment p is 2. In some embodiments p is 3. In some embodiment p is 4. In some embodiments p is 5. In some embodiments p is 7. In some embodiment p is 8. In some embodiments p is 9. In some embodiments p is 10. In some embodiments all R19are hydrogen. In some embodiments all but one R19are hydrogen. In some embodiments all but two R19are hydrogen. In some embodiments all but three R19are hydrogen. In some embodiments all but four R19are hydrogen.

In some embodiments where A or R3is Formula VI, in such A and R3, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis Rb, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, p is 1, and R19are hydrogen.

In some embodiments Rhis C(R39R40), j is 1 to 10, one Rgis O, the other Rgare C(R42R43), and Rfis C(R45R46R47), wherein R39, R40, R42, R43, R45, R46, and R47are hydrogen. In some embodiments the last Rgis O. In some embodiments the penultimate Rgis O. In some embodiments the antepenultimate Rgis O. In some embodiments the fourth from the last Rgis O. In some embodiments the fifth from the last Rgis O. In some embodiments the first Rgis O. In some embodiments the second Rgis O. In some embodiments the third Rgis O. In some embodiments the fourth Rgis O. In some embodiments the fifth Rgis O.

In some embodiments, the compounds are represented by the general formula:
—X—R1Formula Iwherein X is oxygen, sulfur, NR2, or another group compatible with attachment or coupling of the compound to a product or surface;wherein R1is -A-B(—C)δor —R3—Rb;wherein A and R3are

wherein for A and R3, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis Rb, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, p is 0 to 10, and R19are independently hydrogen or C1-C3alkyl;wherein B and Rbare:

X is preferably oxygen, sulfur, or NR2.

In some embodiments where A or R3is Formula VI, Rdis at R15. In some embodiments, Rdis at R13. In some embodiments, Rdis at R14. In some embodiments, Rdis at R16. In some embodiments, Rdis at R17. In some embodiments, p is 0. In some embodiments p is 1. In some embodiment p is 2. In some embodiments p is 3. In some embodiment p is 4. In some embodiments p is 5. In some embodiments p is 7. In some embodiment p is 8. In some embodiments p is 9. In some embodiments p is 10. In some embodiments all R19are hydrogen. In some embodiments all but one R19are hydrogen. In some embodiments all but two R19are hydrogen. In some embodiments all but three R19are hydrogen. In some embodiments all but four R19are hydrogen.

In some embodiments where A or R3is Formula VI, in such A and R3, R12, R13, R14, R15, R16, and R17are carbon, z is 1, Rdis Rb, the ring of Formula VI is aromatic, R18is —(CR19R19)p—, p is 1, and R19are hydrogen.

In some embodiments Rhis NR41, j is 0 to 10, and each Rgis C(R42R43), wherein R41is —Rhx—(Rgx)jx—Rfx, and R42and R43are hydrogen, wherein Rhxis C(R39xR40x), jx=0 to 10, Rgxis C(R42xR43x), and Rfxis C(R45xR46xR47x), and wherein R39x, R40x, R42x, R43x, R45x, R46x, R47xare hydrogen. In some embodiments j=jx. In some embodiments j and jx are 0. In some embodiment j and jx are 2. In some embodiments j and jx are 3. In some embodiments j and jx are 4.

In some embodiments Rhis C(R39R40), and j is 0, wherein R39and R40are hydrogen. In some embodiments Rhis C(R39R40), j is 0 to 10, and each Rgis C(R42R43), wherein R39, R40R42, R43are hydrogen. In some embodiments j is 1. In some embodiment j is 2. In some embodiments j is 3. In some embodiments j is 4.

wherein each C, R4, and R5are independently hydrogen or —Rh—(Rg)j,wherein Rhis absent, j is 1 to 10, and each Rgis C(R42R43), wherein R42and R43are hydrogen;wherein R4and R5are not both hydrogen, wherein at least one of C is not hydrogen.

X is preferably oxygen, sulfur, or NR2.

In some embodiments where A or R3is —Rh—(Rg)j, Rhis C(R39R40), and j is 4 to 31, wherein the first, third, fourth, sixth, seventh, ninth, tenth, twelfth, thirteenth, fifteenth, sixteenth, eighteenth, nineteenth, twenty-first, twenty-second, twenty-fourth, twenty-fifth, twenty-seventh, twenty-eighth, thirtieth, and thirty-first Rg, if present, are C(R42R43) and the second, fifth, eighth, eleventh, fourteenth, seventeenth, twentieth, twenty-third, twenty-sixth, and twenty-ninth, Rg, if present, are O, wherein R39, R40, R42, and R43are hydrogen or C1-C3alkyl. In some embodiments R39and R40are hydrogen. In some embodiments R39is hydrogen and R40is C1-C3alkyl. In some embodiments R39and R40are C1-C3alkyl. In some embodiments all R42are hydrogen. In some embodiments all but one R42are hydrogen. In some embodiments all but two R42are hydrogen. In some embodiments all but three R42are hydrogen. In some embodiments all but four R42are hydrogen. In some embodiments all but five R42are hydrogen. In some embodiments all but six R42are hydrogen. In some embodiments all but seven R42are hydrogen. In some embodiments all but eight R42are hydrogen. In some embodiments all but nine R42are hydrogen. In some embodiments all but ten R42are hydrogen. In some embodiments all but eleven R42are hydrogen. In some embodiments all but twelve R42are hydrogen. In some embodiments all R43are hydrogen. In some embodiments all but one R43are hydrogen. In some embodiments all but two R43are hydrogen. In some embodiments all but three R43are hydrogen. In some embodiments all but four R43are hydrogen. In some embodiments all but five R43are hydrogen. In some embodiments all but six R43are hydrogen. In some embodiments all but seven R43are hydrogen. In some embodiments all but eight R43are hydrogen. In some embodiments all but nine R43are hydrogen. In some embodiments all but ten R43are hydrogen. In some embodiments all but eleven R43are hydrogen. In some embodiments all but twelve R43are hydrogen.

In some embodiments Rhis absent, j is 6, and each Rgis C(R42R43), wherein R42and R43are hydrogen. In some embodiments Rhis absent, j is 1 to 10, and each Rgis C(R42R43), wherein R42and R43are hydrogen. In some embodiments j is 3. In some embodiment j is 4. In some embodiments j is 5. In some embodiments j is 7. In some embodiment j is 8. In some embodiments j is 9. In some embodiments j is 10.

wherein each C, R4, and R5are independently hydrogen or —Rh—(Rg)j,wherein Rhis C(R39R40), j is 1 to 10, one Rgis O, and the other Rgare C(R42R43), wherein R39, R40, R42, and R43are hydrogen;wherein R4and R5are not both hydrogen, wherein at least one of C is not hydrogen.

X is preferably oxygen, sulfur, or NR2.

In some embodiments where A or R3is —Rh—(Rg)j, Rhis C(R39R40), and j is 4 to 31, wherein the first, third, fourth, sixth, seventh, ninth, tenth, twelfth, thirteenth, fifteenth, sixteenth, eighteenth, nineteenth, twenty-first, twenty-second, twenty-fourth, twenty-fifth, twenty-seventh, twenty-eighth, thirtieth, and thirty-first Rg, if present, are C(R42R43) and the second, fifth, eighth, eleventh, fourteenth, seventeenth, twentieth, twenty-third, twenty-sixth, and twenty-ninth, Rg, if present, are O, wherein R39, R40, R42, and R43are hydrogen or C1-C3alkyl. In some embodiments R39and R40are hydrogen. In some embodiments R39is hydrogen and R40is C1-C3alkyl. In some embodiments R39and R40are C1-C3alkyl. In some embodiments all R42are hydrogen. In some embodiments all but one R42are hydrogen. In some embodiments all but two R42are hydrogen. In some embodiments all but three R42are hydrogen. In some embodiments all but four R42are hydrogen. In some embodiments all but five R42are hydrogen. In some embodiments all but six R42are hydrogen. In some embodiments all but seven R42are hydrogen. In some embodiments all but eight R42are hydrogen. In some embodiments all but nine R42are hydrogen. In some embodiments all but ten R42are hydrogen. In some embodiments all but eleven R42are hydrogen. In some embodiments all but twelve R42are hydrogen. In some embodiments all R43are hydrogen. In some embodiments all but one R43are hydrogen. In some embodiments all but two R43are hydrogen. In some embodiments all but three R43are hydrogen. In some embodiments all but four R43are hydrogen. In some embodiments all but five R43are hydrogen. In some embodiments all but six R43are hydrogen. In some embodiments all but seven R43are hydrogen. In some embodiments all but eight R43are hydrogen. In some embodiments all but nine R43are hydrogen. In some embodiments all but ten R43are hydrogen. In some embodiments all but eleven R43are hydrogen. In some embodiments all but twelve R43are hydrogen.

In some embodiments Rhis C(R39R40), j is 3, the first Rgis O, and the second and third Rgare C(R42R43), wherein R39, R40, R42, and R43are hydrogen. In some embodiments Rhis C(R39R40), j is 1 to 10, one Rgis O, and the other Rgare C(R42R43), wherein R39, R40, R42, and R43are hydrogen. In some embodiments the first Rgis O. In some embodiments the second Rgis O. In some embodiments the third Rgis O. In some embodiments the fourth Rgis O. In some embodiments the fifth Rgis O. In some embodiments the fifth from the last Rgis O. In some embodiments the fourth from the last Rgis O. In some embodiments the antepenultimate Rgis O. In some embodiments the penultimate Rgis O. In some embodiments the last Rgis O.

wherein each C, R4, and R5are independently hydrogen or

wherein for C, R4, and R5, R13and R14are oxygen, R12, R15, and R16are carbon, w is 0, the ring of Formula IX has no double bonds, R18is —(CR19R19)p—, both R19are hydrogen, and p is 1;wherein R4and R5are not both hydrogen, wherein at least one of C is not hydrogen.

X is preferably oxygen, sulfur, or NR2.

In some embodiments where A or R3is —Rh—(Rg)j, Rhis C(R39R40), and j is 4 to 31, wherein the first, third, fourth, sixth, seventh, ninth, tenth, twelfth, thirteenth, fifteenth, sixteenth, eighteenth, nineteenth, twenty-first, twenty-second, twenty-fourth, twenty-fifth, twenty-seventh, twenty-eighth, thirtieth, and thirty-first Rg, if present, are C(R42R43) and the second, fifth, eighth, eleventh, fourteenth, seventeenth, twentieth, twenty-third, twenty-sixth, and twenty-ninth, Rg, if present, are O, wherein R39, R40, R42, and R43are hydrogen or C1-C3alkyl. In some embodiments R39and R40are hydrogen. In some embodiments R39is hydrogen and R40is C1-C3alkyl. In some embodiments R39and R40are C1-C3alkyl. In some embodiments all R42are hydrogen. In some embodiments all but one R42are hydrogen. In some embodiments all but two R42are hydrogen. In some embodiments all but three R42are hydrogen. In some embodiments all but four R42are hydrogen. In some embodiments all but five R42are hydrogen. In some embodiments all but six R42are hydrogen. In some embodiments all but seven R42are hydrogen. In some embodiments all but eight R42are hydrogen. In some embodiments all but nine R42are hydrogen. In some embodiments all but ten R42are hydrogen. In some embodiments all but eleven R42are hydrogen. In some embodiments all but twelve R42are hydrogen. In some embodiments all R43are hydrogen. In some embodiments all but one R43are hydrogen. In some embodiments all but two R43are hydrogen. In some embodiments all but three R43are hydrogen. In some embodiments all but four R43are hydrogen. In some embodiments all but five R43are hydrogen. In some embodiments all but six R43are hydrogen. In some embodiments all but seven R43are hydrogen. In some embodiments all but eight R43are hydrogen. In some embodiments all but nine R43are hydrogen. In some embodiments all but ten R43are hydrogen. In some embodiments all but eleven R43are hydrogen. In some embodiments all but twelve R43are hydrogen.

In some embodiments, in Formula IX, R13and R14are oxygen, R12, R15, and R16are carbon, w is 0, the ring of Formula IX has no double bonds, R18is —(CR19R19)p—, both R19are hydrogen, and p is 1.

The hydrophobicity/hydrophilicity of surfaces of the surface-modified product can be varied by the incorporation of hydrophobic compounds, hydrophilic compounds, or both on the surfaces. In preferred embodiments, the modified surface contains one or more hydrophobic covalently attached compounds. The relative hydrophobicity/hydrophilicity of the surface or a surface of the surface-modified product can be quantitatively assessed by measuring the contact angle of a water droplet on such a surface. In some embodiments, the water droplet has a contact angle of less than 90° (i.e., the surface is hydrophilic). In preferred embodiments, the water droplet has a contact angle greater than or equal to 900 (i.e., the surface is hydrophobic). In some embodiments, the water droplet has a contact angle greater than or equal to 950, 1000, 105°, 110°, 115°, or 120°.

The compounds described herein, provide bioinert surfaces when used to coat the surfaces of products. In some embodiments the surface or a surface of the product is substantially covered with the compounds, wherein the surface or a surface is covalently modified as described herein.

Also contemplated are products containing a surface that has been modified using a compound that renders the surface or a surface bioinert, such as those described above, and another compound that renders the surface or a surface bioactive, such as those described by Franz, Ward and Slee, the contents of which are incorporated herein by reference.

The disclosed products generally can be products that (1) are useful for treating a disease or disorder in a subject and (2) have a surface that can be chemically modified with a compound as disclosed herein. Useful products include, for example, devices, prostheses, and other materials for implantation in a subject or to be in long term contact with biomaterial, such as blood or body fluids, of a subject. A product can have any form, composition, use, and purpose that can be used to treat a subject. A product can include a biological material, such as cells, or other therapeutic agent, such as drugs, antibodies, nucleic acids, vaccines, and hormones.

The surfaces of products can be chemically modified as described herein to any desired density of modifications. The density of modifications is the average number of modifications (that is, attached compounds) per a given area of the surface or a surface of the product. Generally, a density at or above a threshold density can provide a beneficial effect, such as lower foreign body response. In some embodiments, a high density is not required. Without being bound to any particular theory of operation, it is believed that the chemical modifications signal to, indicate to, or are identified by, one or more immune system or other body components to result in a beneficial effect, such as a lower foreign body response. In some embodiments, a lower density of modifications can be effective for this purpose.

It has been discovered that coverage of products need not be at the same or at an even density. For example, in some embodiments, the density can vary over all or part of the product or surface, can be patchy, or can be uneven. Thus, in some embodiments, density can be referred to as the average over the entire product or surface or a portion or component of the product or surface. Density can be characterized as or by the local density of a portion of the product or surface. In such cases, other portions of the product or surface can have densities that are the same or different from the referenced local density (in other words, reference to the density of a portion of the product or surface does not preclude density of other parts of the product or surface from being the same or different). In some embodiments, the product, surface, or portions thereof, can also have smooth or uneven gradients of density. Gradients of density can vary through any of the density ranges disclosed herein.

In some embodiments, the density of the modifications on a surface, surfaces, or portions of a surface(s) of a product that, when the product is administered to (e.g., implanted in the body of) a subject, would be in contact with fluid(s), cell(s), tissue(s), other component(s), or a combination thereof of the subject's body is greater than the density of the modifications on other surfaces of the product.

Density can also be expressed in terms of the concentration of the surface modifications as measured by X-ray photoelectron spectroscopy (XPS). XPS is a surface-sensitive quantitative spectroscopic technique that measures the elemental composition at the parts per thousand range of the elements that exist within a material. XPS spectra are obtained by irradiating a material with a beam of X-rays while simultaneously measuring the kinetic energy and number of electrons that escape from the top 0 to 10 nm of the material being analyzed. By measuring all elements present on the surface, the percentage of the elements that come from the surface modifications can be calculated. This can be accomplished by, for example, taking the percentage of nitrogen (and/or other elements in the surface modifications) in the total elemental signal measured. Nitrogen is a useful indicator for the surface modification because many substrated and materials forming the product contain little nitrogen. For convenience, the percent of the element(s) used to indicate the surface modifications can be stated as the percent surface modifications. Also for convenience, the percent surface modifications can be referred to as the concentration of surface modifications. Examples of XPS analysis and concentrations of surface modifications are shown in Tables 4-7.

Useful materials that can constitute all or a part of a product (e.g., that includes its surface) include a variety of different substrates and substances that the disclosed chemical compounds can be, for example, applied to, absorbed into, or coupled to. Examples of suitable materials include metals, metallic materials, ceramics, polymers, fibers, inert materials such as silicon, and combinations thereof.

Suitable ceramic materials include, but are not limited to, oxides, carbides, or nitrides of the transition elements such as titanium oxides, hafnium oxides, iridium oxides, chromium oxides, aluminum oxides, and zirconium oxides. Silicon based materials, such as silica, may also be used.

In some embodiments, the polymer is alginate, e.g., a polysaccharides made up of β-D-mannuronic acid (M) and α-L-guluronic acid (G) linked together. In some embodiments, alginate is a high guluronic acid (G) alginate. In some embodiments, the alginate is a high mannuronic acid (M) alginate. In some embodiments, the ratio of M:G is about 1. In some embodiments, the ratio of M:G is less than 1. In some embodiments, the ratio of M:G is greater than 1.

The polymer can be covalently or non-covalently associated with the surface; however, in particular embodiments, the polymer is non-covalently associated with the surface. The polymer can be applied by a variety of techniques in the art including, but not limited to, spraying, wetting, immersing, dipping, such as dip coating (e.g., intraoperative dip coating), painting, or otherwise applying a hydrophobic, polycationic polymer to a surface of the implant.

B. Product Forms

A product can have any form, composition, use, and purpose that can be used to treat a subject. For example, useful products include devices, prostheses, and other components for implantation or incorporation into a subject. Products useful for surface modification include any types of medical devices used, at least in part, for implantation in the body, or in long term contact with biomaterial, of a patient or subject in need thereof. Examples include, but are not limited to, implants, implantable medical products, implantable devices, catheters and other tubes (including urological and biliary tubes, endotracheal tubes, wound drain tubes, needle injection catheters, peripherably insertable central venous catheters, dialysis catheters, long term tunneled central venous catheters peripheral venous catheters, short term central venous catheters, arterial catheters, pulmonary catheters, Swan-Ganz catheters, urinary catheters, peritoneal catheters), vascular catheter ports, blood clot filters, urinary devices (including long term urinary devices, tissue bonding urinary devices, artificial urinary sphincters, urinary dilators), shunts (including ventricular or arterio-venous shunts, stent transplants, biliary stents, intestinal stents, bronchial stents, esophageal stents, ureteral stents, and hydrocephalus shunts), cannulas, (including intravenous cannulas and nasal cannulas), balloons, pacemakers, implantable defibrillators, orthopedic products (including pins, plates, screws, and implants), transplants (including organs, vascular transplants, vessels, aortas, heart valves, and organ replacement parts), prostheses (including breast implants, penile prostheses, vascular grafting prostheses, heart valves, artificial joints, artificial larynxes, otological implants, artificial hearts, artificial blood vessels, and artificial kidneys), aneurysm-filling coils and other coil devices, transmyocardial revascularization devices, percutaneous myocardial revascularization devices, tubes, fibers, hollow fibers, membranes, blood containers, titer plates, adsorber media, dialyzers, connecting pieces, sensors, valves, endoscopes, filters, pump chambers, scalpels, needles, scissors (and other devices used in invasive surgical, therapeutic, or diagnostic procedures), and other medical products and devices intended to have anti-fibrotic properties. The expression “medical products” is broad and refers in particular to products that come in contact with blood briefly (e.g., endoscopes) or permanently (e.g., stents).

Useful medical products are balloon catheters and endovascular prostheses, in particular stents. Stents of a conventional design have a filigree support structure composed of metallic struts. The support structure is initially provided in an unexpanded state for insertion into the body, and is then widened into an expanded state at the application site. The stent can be coated before or after it is crimped onto a balloon. A wide variety of medical endoprostheses or medical products or implants for highly diverse applications and are known. They are used, for example, to support vessels, hollow organs, and ductal systems (endovascular implants), to attach and temporarily affix tissue implants and tissue transplants, and for orthopedic purposes such as pins, plates, or screws.

Substrates can be in the form of, or form part of, films, particles (nanoparticles, microparticles, or millimeter diameter beads), fibers (wound dressings, bandages, gauze, tape, pads, sponges, including woven and non-woven sponges and those designed specifically for dental or ophthalmic surgeries), sensors, pacemaker leads, catheters, stents, contact lenses, bone implants (hip replacements, pins, rivets, plates, bone cement, etc.), or tissue regeneration or cell culture devices, or other medical devices used within or in contact with the body.

Implants with surface modifications are described herein. “Implants” are any object intended for placement in the body of a mammal, such as a human, that is not a living tissue. Implants are a form of medical product. Implants include naturally derived objects that have been processed so that their living tissues have been devitalized. As an example, bone grafts can be processed so that their living cells are removed, but so that their shape is retained to serve as a template for ingrowth of bone from a host. As another example, naturally occurring coral can be processed to yield hydroxyapatite preparations that can be applied to the body for certain orthopedic and dental therapies. An implant can also be an article comprising artificial components. The term “implant” can be applied to the entire spectrum of medical devices intended for placement in a human body or that of a mammal, including orthopedic applications, dental applications, ear, nose, and throat (“ENT”) applications, and cardiovascular applications.

In some embodiments, “implant” as used herein refers to a macroscopic composition including a device for implantation or a surface of a device for implantation with a covalently modified surface. In some embodiments, the implant a device for implantation or a surface of a device for implantation and a modified alginate polymer coating. In these embodiments, the term “implant” does not encompass nanoparticles and/or microparticles. “Macroscopic” as used herein generally refers to devices, implants, or compositions that can be viewed by the unaided eye. In some embodiments the implant is extravascular. In some embodiments the implant is intravascular.

Examples of implantable medical devices and medical devices and mechanical structures that can use a bio-compatible coating include, but are not limited to, stents, conduits, scaffolds, cardiac valve rings, cardiovascular valves, pacemakers, hip replacement devices, implanted sensor devices, esophageal stents, heart implants, bio-compatible linings for heart valves, dialysis equipment and oxygenator tubing for heart-lung by-pass systems.

In general, a stent is a device, typically tubular in shape, that is inserted into a lumen of the body, such as a blood vessel or duct, to prevent or counteract a localized flow constriction. The purpose of a stent, in some cases, is to mechanically prop open a bodily fluid conduit. Stents are often used to alleviate diminished blood flow to organs and extremities in order to maintain adequate delivery of oxygenated blood. The most common use of stents is in coronary arteries, but they are also widely used in other bodily conduits, such as, for example, central and peripheral arteries and veins, bile ducts, the esophagus, colon, trachea, large bronchi, ureters, and urethra. Frequently, stents inserted into a lumen are capable of being expanded after insertion or are self-expanding. For example, metal stents are deployed into an occluded artery using a balloon catheter and expanded to restore blood flow. For example, stainless steel wire mesh stents are commercially available from Boston Scientific, Natick, Mass.

In some embodiments, the implant is an orthopedic implant. An “orthopedic implant” is defined as an implant which replaces bone or provides fixation to bone, replaces articulating surfaces of a joint, provides abutment for a prosthetic, or combinations thereof or assists in replacing bone or providing fixation to bone, replacing articulating surfaces of a joint, providing abutment for a prosthetic, and combinations thereof.

Orthopedic implants can be used to replace bone or provide fixation to bone, replace articulating surfaces of a joint, provide abutment for a prosthetic, or combinations thereof or assist in replacing bone or providing fixation to bone, replacing articulating surfaces of a joint, providing abutment for a prosthetic, including dental applications, and combinations thereof.

In other embodiments, the implant is an ear, nose, and/or throat (“ENT”) implant. Exemplary ENT implants include, but are not limited to, ear tubes, endotracheal tubes, ventilation tubes, cochlear implants and bone anchored hearing devices.

In other embodiments, the implant is a cardiovascular implant. Exemplary cardiovascular implants are cardiac valves or alloplastic vessel wall supports, total artificial heart implants, ventricular assist devices, vascular grafts, stents, electrical signal carrying devices such as pacemaker and neurological leads, defibrillator leads, and the like.

In some embodiments, products can be surface modified artificial organs and organ-repair implants. For example, surface modified substrate material surfaces that are used in the preparation of scaffolds and/or matrices that are subsequently used to fabricate surgical implants for diseased or impaired organs or used to grow whole, artificial organs. A variety of materials have been used in scaffold applications such as, but not limited to, tubular, fibrous, filamentous, and woven polymers, and natural materials. Other starting material configurations suitable for scaffold fabrication include woven or knitted items, micro- or nano-spheres (i.e., fullerenes), micro- or nano-tubes, cobweb-like configurations or foams/sponge-like forms. Any of these materials may be surface modified as disclosed herein.

In some embodiments, products can be chemically modified cardiovascular, vascular and associated implant devices. For example, surface modified cardiovascular or vascular implants can be used to improve the biocompatibility of medical devices meant to be implanted into the body. In those cases where the implant's surface interfaces with blood, other body fluids and/or tissue, these surfaces can be modified. Such modifications can be combined with other chemical and/or biological coating of cardiovascular implants useful to prevent formation of thrombi, aggregation, and ultimately emboli.

Implants can be prepared from a variety of materials. In some embodiments, the material is biocompatible. In some embodiments, the material is biocompatible and non-biodegradable. Exemplary materials include metallic materials, metal oxides, polymeric materials, including degradable and non-degradable polymeric materials, ceramics, porcelains, glass, allogeneic, xenogenic bone or bone matrix; genetically engineered bone; and combinations thereof.

Spheres, spheroids, and ellipsoids are shapes with curved surfaces that can be defined by rotation of circles, ellipses, or a combination around each of the three perpendicular axes, a, b, and c. For a sphere, the three axes are the same length. For oblate spheroids (also referred to as oblate ellipsoids of rotation), the length of the axes are a=b>c. For prolate spheroids (also referred to as prolate ellipsoids of rotation), the length of the axes are a=b<c. For tri-axial ellipsoids (also referred to as scalene ellipsoids), the length of the axes are a>b>c. Stadiumoids are rotational shapes of stadiums. Cylinders are rotational shapes of rectangles rotated on the long axis. Disks are squashed cylinders where the diameter is greater than the height. Rods are elongated cylinders where the long axis is ten or more times the diameter.

Generally, a sphere-like shape is an ellipsoid (for its averaged surface) with semi-principal axes within 10% of each other. The diameter of a sphere or sphere-like shape is the average diameter, such as the average of the semi-principal axes. Generally, a spheroid-like shape is an ellipsoid (for its averaged surface) with semi-principal axes within 100% of each other. The diameter of a spheroid or spheroid-like shape is the average diameter, such as the average of the semi-principal axes. Generally, an ellipsoid-like shape is an ellipsoid (for its averaged surface) with semi-principal axes within 100% of each other. The diameter of an ellipsoid or ellipsoid-like shape is the average diameter, such as the average of the semi-principal axes. Generally, a stadiumoid-like shape is a stadiumoid (for its averaged surface) with semi-principal axes of the ends within 20% of each other. The diameter of a stadiumoid or stadiumoid-like shape is the average diameter, such as the average of the semi-principal axes. Alternatively, the size of a stadiumoid or stadiumoid-like shape can be given as the average of the long axis. Generally, a cylinder-like shape is a cylinder (for its averaged surface) with semi-principal axes within 20% of each other. The diameter of a cylinder or cylinder-like shape is the average diameter, such as the average of the semi-principal axes. Alternatively, the size of a cylinder or cylinder-like shape can be given as the average of the long axis. Generally, a rod-like shape is a rod (for its averaged surface) with semi-principal axes within 10% of each other. The diameter of a rod or rod-like shape is the average diameter, such as the average of the semi-principal axes. Alternatively, the size of a rod or rod-like shape can be given as the average of the long axis. Generally, a cube-like shape is a cube (for its averaged surface) with sides within 10% of each other. The diameter of a cube or cube-like shape is the average side length. Generally, a cuboid-like shape is a cuboid (for its averaged surface) with matching sides within 10% of each other. The diameter of a cuboid or cuboid-like shape is the average side length. Generally, a torus-like shape is a torus (for its averaged surface) with semi-principal axes within 10% of each other. The diameter of a torus or torus-like shape is the average diameter, such as the average of the semi-principal axes. Alternatively, the size of a torus or torus-like shape can be given as the diameter across the ring.

“Flat side” refers to a contiguous area of more than 5% of a surface that has a curvature of 0.

“Sharp angle” refers to a location on a surface across which the tangent to the surface changes by more than 10% over a distance of 2% or less of the circumference of the surface. Edges, corners, grooves, and ridges in a surface are all forms of sharp angles.

Preferred products can be made of biocompatible materials, have a diameter of at least 1 mm and less than 10 mm, has a spheroid-like shape, and have one or more of the additional characteristics: surface pores of the products greater than 0 nm and less than m; surface of the products neutral or hydrophilic; curvature of the surface or a surface of the products at least 0.2 and is not greater than 2 on all points of the surface; and surface of the products lacking flat sides, sharp angles, grooves, or ridges. Generally, the products elicit less of a fibrotic reaction after implantation than the same products lacking one or more of these characteristics that are present on the products.

In some embodiments, the product is provided as a preparation and at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the products in the preparation have a shape characteristic described herein, e.g., have a spheroid-like shape, or have a curvature of the surface of at least 0.2 to 2.0 on all points of the surface.

In some embodiments, the products have a mean diameter or size that is greater than 1 mm, preferably 1.5 mm or greater. In some embodiments, the products can be as large as 8 mm in diameter or size. For example, the products is in a size range of 1 mm to 8 mm, 1 mm to 6 mm, 1 mm to 5 mm, 1 mm to 4 mm, 1 mm to 3 mm, 1 mm to 2 mm, 1 mm to 1.5 mm, 1.5 mm to 8 mm, 1.5 mm to 6 mm, 1.5 mm to 5 mm, 1.5 mm to 4 mm, 1.5 mm to 3 mm, 1.5 mm to 2 mm, 2 mm to 8 mm, 2 mm to 7 mm, 2 mm to 6 mm, 2 mm to 5 mm, 2 mm to 4 mm, 2 mm to 3 mm, 2.5 mm to 8 mm, 2.5 mm to 7 mm, 2.5 mm to 6 mm, 2.5 mm to 5 mm, 2.5 mm to 4 mm, 2.5 mm to 3 mm, 3 mm to 8 mm, 3 mm to 7 mm, 3 mm to 6 mm, 3 mm to 5 mm, 3 mm to 4 mm, 3.5 mm to 8 mm, 3.5 mm to 7 mm, 3.5 mm to 6 mm, 3.5 mm to 5 mm, 3.5 mm to 4 mm, 4 mm to 8 mm, 4 mm to 7 mm, 4 mm to 6 mm, 4 mm to 5 mm, 4.5 mm to 8 mm, 4.5 mm to 7 mm, 4.5 mm to 6 mm, 4.5 mm to 5 mm, 5 mm to 8 mm, 5 mm to 7 mm, 5 mm to 6 mm, 5.5 mm to 8 mm, 5.5 mm to 7 mm, 5.5 mm to 6 mm, 6 mm to 8 mm, 6 mm to 7 mm, 6.5 mm to 8 mm, 6.5 mm to 7 mm, 7 mm to 8 mm, or 7.5 mm to 8 mm. In some embodiments, the product has a mean diameter or size between 1 mm to 8 mm. In some embodiments, the product has a mean diameter or size between 1 mm to 4 mm. In some embodiments, the product has a mean diameter or size between 1 mm to 2 mm.

In some embodiments, the products are provided as a preparation and at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the products in the preparation, have a diameter or size in a size range described herein.

In some embodiments, the products are provided as a preparation and at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the products in the preparation have pores in a size range described herein.

In some embodiments, the chemical derivatizations of the surface or a surface of the products are expressed as a density, i.e., average number of attached compounds per given area. In some embodiments, the density is at least, is less than, or is 0.1, 0.2, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 320, 340, 360, 380, 400, 420, 440, 460, 480, 500, 550, 600, 650, 700, 750, 800, 850, 900, or 1000 chemical derivatizations per μm2on the surface or a surface of the products, in the interior of the products, or both. In some embodiments, the density is at least 100 chemical derivatizations per μm2on the surface or a surface of the products, in the interior of the products, or both. In some embodiments, the density is at least 1000 chemical derivatizations per μm2on the surface oe a surface of the products, in the interior of the products, or both.

In some embodiments the density is in the range of 70 to 75, 70 to 80, 70 to 85, 70 to 90, 70 to 95, 70 to 100, 70 to 110, 70 to 120, 70 to 130, 70 to 140, 70 to 150, 70 to 160, 70 to 170, 70 to 180, 70 to 190, 70 to 200, 70 to 210, 70 to 220, 70 to 230, 70 to 240, 70 to 250, 70 to 260, 70 to 270, 70 to 280, 70 to 290, 70 to 300, 70 to 320, 70 to 340, 70 to 360, 70 to 380, 70 to 400, 70 to 420, 70 to 440, 70 to 460, 70 to 480, 70 to 500, 70 to 550, 70 to 600, 70 to 650, 70 to 700, 70 to 750, 70 to 800, 70 to 850, 70 to 900, and 70 to 1000 chemical derivatizations per μm2on the surface or a surface of the products, in the interior of the products, or both.

In some embodiments the density is in the range of 80 to 85, 80 to 90, 80 to 95, 80 to 100, 80 to 110, 80 to 120, 80 to 130, 80 to 140, 80 to 150, 80 to 160, 80 to 170, 80 to 180, 80 to 190, 80 to 200, 80 to 210, 80 to 220, 80 to 230, 80 to 240, 80 to 250, 80 to 260, 80 to 270, 80 to 280, 80 to 290, 80 to 300, 80 to 320, 80 to 340, 80 to 360, 80 to 380, 80 to 400, 80 to 420, 80 to 440, 80 to 460, 80 to 480, 80 to 500, 80 to 550, 80 to 600, 80 to 650, 80 to 700, 80 to 750, 80 to 800, 80 to 850, 80 to 900, and 80 to 1000 chemical derivatizations per μm2on the surface or a surface of the products, in the interior of the products, or both.

In some embodiments the density is in the range of 90 to 95, 90 to 100, 90 to 110, 90 to 120, 90 to 130, 90 to 140, 90 to 150, 90 to 160, 90 to 170, 90 to 180, 90 to 190, 90 to 200, 90 to 210, 90 to 220, 90 to 230, 90 to 240, 90 to 250, 90 to 260, 90 to 270, 90 to 280, 90 to 290, 90 to 300, 90 to 320, 90 to 340, 90 to 360, 90 to 380, 90 to 400, 90 to 420, 90 to 440, 90 to 460, 90 to 480, 90 to 500, 90 to 550, 90 to 600, 90 to 650, 90 to 700, 90 to 750, 90 to 800, 90 to 850, 90 to 900, and 90 to 1000 chemical derivatizations per μm2on the surface or a surface of the products, in the interior of the products, or both.

In some embodiments the density is in the range of 100 to 110, 100 to 120, 100 to 130, 100 to 140, 100 to 150, 100 to 160, 100 to 170, 100 to 180, 100 to 190, 100 to 200, 100 to 210, 100 to 220, 100 to 230, 100 to 240, 100 to 250, 100 to 260, 100 to 270, 100 to 280, 100 to 290, 100 to 300, 100 to 320, 100 to 340, 100 to 360, 100 to 380, 100 to 400, 100 to 420, 100 to 440, 100 to 460, 100 to 480, 100 to 500, 100 to 550, 100 to 600, 100 to 650, 100 to 700, 100 to 750, 100 to 800, 100 to 850, 100 to 900, and 100 to 1000 chemical derivatizations per μm2on the surface or a surface of the products, in the interior of the products, or both.

In some embodiments the density is in the range of 200 to 210, 200 to 220, 200 to 230, 200 to 240, 200 to 250, 200 to 260, 200 to 270, 200 to 280, 200 to 290, 200 to 300, 200 to 320, 200 to 340, 200 to 360, 200 to 380, 200 to 400, 200 to 420, 200 to 440, 200 to 460, 200 to 480, 200 to 500, 200 to 550, 200 to 600, 200 to 650, 200 to 700, 200 to 750, 200 to 800, 200 to 850, 200 to 900, and 200 to 1000 chemical derivatizations per μm2on the surface or a surface of the products, in the interior of the products, or both.

In some embodiments the density is in the range of 300 to 320, 300 to 340, 300 to 360, 300 to 380, 300 to 400, 300 to 420, 300 to 440, 300 to 460, 300 to 480, 300 to 500, 300 to 550, 300 to 600, 300 to 650, 300 to 700, 300 to 750, 300 to 800, 300 to 850, 300 to 900, and 300 to 1000 chemical derivatizations per μm2on the surface or a surface of the products, in the interior of the products, or both.

In some embodiments the density is in the range of 400 to 420, 400 to 440, 400 to 460, 400 to 480, 400 to 500, 400 to 550, 400 to 600, 400 to 650, 400 to 700, 400 to 750, 400 to 800, 400 to 850, 400 to 900, and 400 to 1000 chemical derivatizations per μm2on the surface or a surface of the products, in the interior of the products, or both.

In some embodiments the density is in the range of 500 to 550, 500 to 600, 500 to 650, 500 to 700, 500 to 750, 500 to 800, 500 to 850, 500 to 900, and 500 to 1000 chemical derivatizations per μm2on the surface or a surface of the products, in the interior of the products, or both.

In some embodiments the density is in the range of 600 to 650, 600 to 700, 600 to 750, 600 to 800, 600 to 850, 600 to 900, and 600 to 1000 chemical derivatizations per μm2on the surface or a surface of the products, in the interior of the products, or both.

In some embodiments the density is in the range of 700 to 750, 700 to 800, 700 to 850, 700 to 900, and 700 to 1000 chemical derivatizations per μm2on the surface or a surface of the products, in the interior of the products, or both.

In some embodiments the density is in the range of 800 to 850, 800 to 900, and 800 to 1000 chemical derivatizations per μm2on the surface or a surface of the products, in the interior of the products, or both.

In some embodiments the density is in the range of 900 to 1000 chemical derivatizations per μm2on the surface or a surface of the products, in the interior of the products, or both.

In some embodiments, the product is provided as a preparation and at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the products in the preparation have a density of attached compounds described herein.

In some embodiments the concentration of surface modifications is in the range of 10 to 11, 10 to 12, 10 to 13, 10 to 14, 10 to 15, 10 to 16, 10 to 17, 10 to 18, 10 to 19, 10 to 20, 10 to 25, 10 to 30, 10 to 35, 10 to 40, 10 to 45, 10 to 50, 10 to 55, 10 to 60, 10 to 65, 10 to 70, 10 to 75, 10 to 80, 10 to 85, 10 to 90, 10 to 95, 10 to 100 percent surface modifications. In some embodiments, the concentration of surface modifications is in the range of 10 to 100 percent surface modifications.

In some embodiments the concentration of surface modifications is in the range of 20 to 25, 20 to 30, 20 to 35, 20 to 40, 20 to 45, 20 to 50, 20 to 55, 20 to 60, 20 to 65, 20 to 70, 20 to 75, 20 to 80, 20 to 85, 20 to 90, 20 to 95, 20 to 100 percent surface modifications.

In some embodiments the concentration of surface modifications is in the range of 30 to 35, 30 to 40, 30 to 45, 30 to 50, 30 to 55, 30 to 60, 30 to 65, 30 to 70, 30 to 75, 30 to 80, 30 to 85, 30 to 90, 30 to 95, 30 to 100 percent surface modifications.

In some embodiments the concentration of surface modifications is in the range of 40 to 45, 40 to 50, 40 to 55, 40 to 60, 40 to 65, 40 to 70, 40 to 75, 40 to 80, 40 to 85, 40 to 90, 40 to 95, 40 to 100 percent surface modifications.

In some embodiments the concentration of surface modifications is in the range of 50 to 55, 50 to 60, 50 to 65, 50 to 70, 50 to 75, 50 to 80, 50 to 85, 50 to 90, 50 to 95, 50 to 100 percent surface modifications.

In some embodiments the concentration of surface modifications is in the range of 60 to 65, 60 to 70, 60 to 75, 60 to 80, 60 to 85, 60 to 90, 60 to 95, 60 to 100 percent surface modifications.

In some embodiments the concentration of surface modifications is in the range of 70 to 75, 70 to 80, 70 to 85, 70 to 90, 70 to 95, 70 to 100 percent surface modifications.

In some embodiments the concentration of surface modifications is in the range of 80 to 85, 80 to 90, 80 to 95, 80 to 100 percent surface modifications.

In some embodiments the concentration of surface modifications is in the range of 90 to 95, 90 to 100 percent surface modifications.

In some embodiments, the product is provided as a preparation and at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the products in the preparation have a concentration of attached compounds described herein.

In some embodiments, the product is provided as a preparation and at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the products in the preparation have a combination of diameter and pore size described herein.

In some embodiments, the product is provided as a preparation and at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the products in the preparation have a combination of product size or diameter and derivatization density described herein.

In some embodiments, the products have a mean diameter or size that is greater than 1 mm and less than 8 mm, greater than 1.5 mm and less than 8 mm, greater than 2 mm and less than 8 mm, greater than 2.5 mm and less than 8 mm, greater than 3 mm and less than 8 mm, greater than 3.5 mm and less than 8 mm, greater than 4 mm and less than 8 mm, greater than 4.5 mm and less than 8 mm, greater than 5 mm and less than 8 mm, greater than 5.5 mm and less than 8 mm, greater than 6 mm and less than 8 mm, greater than 6.5 mm and less than 8 mm, greater than 7 mm and less than 8 mm, or greater than 7.5 mm and less than 8 mm, and, independently, the concentration of surface modifications is at least, is less than, or is 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, and 100 percent.

In some embodiments, the product is provided as a preparation and at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the products in the preparation have a combination of product size or diameter and concentrations of surface modifications described herein.

In some embodiments, the product is provided as a preparation and at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the products in the preparation have a combination of pore size and derivatization density or concentration of surface modifications described herein.

In some embodiments, the product is provided as a preparation and at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% of the products in the preparation have a combination of product size or diameter, pore size, and derivatization density or concentration of surface modifications described herein.

C. Properties of Surface-Modified Products

In preferred embodiments, the surface modified product shows an improved beneficial effect. In further embodiments, the improved beneficial effect involves enhanced biocompatibility such that the fluorescence response normalized to a corresponding unmodified product measured using the in vivo biocompatibility assay described herein is less than 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, or 40%. In preferred embodiments, the surface modified product induces a lower foreign body response than the corresponding unmodified product. This is indicated by fluorescence response normalized to unmodified surface of less than 100%. In some embodiments, the surface modified product is biocompatible such that the fluorescence response normalized a corresponding unmodified product measured using the in vivo biocompatibility assay described herein is less than 75%, more preferably less than 65%, and most preferably less than 50%.

A surface of a product adapted for use in a medical environment can be capable of sterilization using autoclaving, biocide exposure, irradiation, or gassing techniques, like ethylene oxide exposure. Surfaces found in medical environments include the inner and outer aspects of various instruments and devices, whether disposable or intended for repeated uses.

D. Therapeutic Agents Included in Products

The disclosed surface modified products can include one or more therapeutic agents. Therapeutic agents are any compound, composition, conjugate, or construct that can be used to treat a disease, disorder, condition, symptom, etc. Examples of therapeutic agents include cells, tissues, cell products, tissue products, proteins, antibodies, vaccines, vaccine components, antigens, epitopes, drugs, salts, nutrients, buffers, acids, and bases. In some embodiments, the therapeutic agent can be a biological material.

In some embodiments, the product can include a cell or tissue, e.g., a living cell or tissue, which in some embodiments is encapsulated in, or coated with, a polymer. In such embodiments, the surface or a surface of the polymer encapsulation or coating is modified with moieties or compounds disclosed herein. In some embodiments, the cell can include an exogenous nucleic acid that encodes a therapeutic or diagnostic polypeptide. In some embodiments the cell or engineered cell is autologous, allogenic, or zenogeneic.

In some embodiments, the cell is a genetically engineered cell that secretes a therapeutic agent, such as a protein or hormone for treating a disease or other condition. In some embodiments, the cell is a genetically engineered cell that secretes a diagnostic agent. In some embodiments, the cell is a stem cell, e.g., an embryonic stem cell, mesenchymal stem cell, hepatic stem cell, or bone marrow stem cell.

1. Biological Materials

Biological material for inclusion in the disclosed products can be any biological substance. For example, the biological material can be tissue, cells, biological micromolecules, or biological macromolecules. Examples of biological macromolecules include nucleotides, amino acids, cofactors, and hormones. Examples of biological macromolecules include nucleic acids, polypeptides, proteins, and polysaccharides. Examples of proteins include enzymes, receptors, secretory proteins, structural proteins, signaling proteins, hormones, and ligands. Any class, type, form, or particular biological material can be used together with any other classes, types, forms, or particular biological materials.

The cell type chosen for inclusion in the disclosed products depends on the desired therapeutic effect. The cells may be from the patient (autologous cells), from another donor of the same species (allogeneic cells), or from another species (xenogeneic). Xenogeneic cells are easily accessible, but the potential for rejection and the danger of possible transmission of viruses to the patient restricts their clinical application. Any of these types of cells can be from natural sources, stem cells, derived cells, or genetically engineered cell.

In some embodiments, the cells secrete a therapeutically effective substance, such as a protein or nucleic acid. In some embodiments, the cells produce a metabolic product. In some embodiments, the cells metabolize toxic substances. In some embodiments, the cells form structural tissues, such as skin, bone, cartilage, blood vessels, or muscle. In some embodiments, the cells are natural, such as islet cells that naturally secrete insulin, or hepatocytes that naturally detoxify. In some embodiments, the cells are genetically engineered to express a heterologous protein or nucleic acid and/or overexpress an endogenous protein or nucleic acid. In some embodiments, the cells are genetically engineered to produce a new or different product, which can be an expression product of the engineered gene(s) or another product, such as a metabolite, produced because of the engineered gene(s).

Types of cells for inclusion in the disclosed products include cells from natural sources, such as cells from xenotissue, cells from a cadaver, and primary cells; stem cells, such as embryonic stem cells, mesenchymal stem cells, and induced pluripotent stem cells; derived cells, such as cells derived from stem cells, cells from a cell line, reprogrammed cells, reprogrammed stem cells, and cells derived from reprogrammed stem cells; and genetically engineered cells, such as cells genetically engineered to express a protein or nucleic acid, cells genetically engineered to produce a metabolic product, and cells genetically engineered to metabolize toxic substances.

A preferred cell type is a pancreatic islet cell or other insulin-producing cell. Hormone-producing cells can produce one or more hormones, such as insulin, parathyroid hormone, anti-diuretic hormone, oxytocin, growth hormone, prolactin, thyroid stimulating hormone, adrenocorticotropic hormone, follicle-stimulating hormone, lutenizing hormone, thyroxine, calcitonin, aldosterone, cortisol, epinephrine, glucagon, estrogen, progesterone, and testosterone. Genetically engineered cells are also suitable for inclusion in the disclosed products. In some embodiments, the cells are engineered to produce one or more hormones, such as insulin, parathyroid hormone, anti-diuretic hormone, oxytocin, growth hormone, prolactin, thyroid stimulating hormone, adrenocorticotropic hormone, follicle-stimulating hormone, lutenizing hormone, thyroxine, calcitonin, aldosterone, cortisol, epinephrine, glucagon, estrogen, progesterone, and testosterone. In some embodiments, the cells are engineered to secrete blood clotting factors (e.g., for hemophilia treatment) or to secrete growth hormones. In some embodiments, the cells are contained in natural or bioengineered tissue. For example, the cells for inclusion in the disclosed products are in some embodiments a bioartificial renal glomerulus. In some embodiments, the cells are suitable for transplantation into the central nervous system for treatment of neurodegenerative disease.

Cells can be obtained directly from a donor, from cell culture of cells from a donor, or from established cell culture lines. In the preferred embodiments, cells are obtained directly from a donor, washed and implanted directly in combination with the polymeric material. The cells are cultured using techniques known to those skilled in the art of tissue culture.

Cell viability can be assessed using standard techniques, such as histology and fluorescent microscopy. The function of the implanted cells can be determined using a combination of these techniques and functional assays. For example, in the case of hepatocytes, in vivo liver function studies can be performed by placing a cannula into the recipient's common bile duct. Bile can then be collected in increments. Bile pigments can be analyzed by high pressure liquid chromatography looking for underivatized tetrapyrroles or by thin layer chromatography after being converted to azodipyrroles by reaction with diazotized azodipyrroles ethylanthranilate either with or without treatment with P-glucuronidase. Diconjugated and monoconjugated bilirubin can also be determined by thin layer chromatography after alkalinemethanolysis of conjugated bile pigments. In general, as the number of functioning transplanted hepatocytes increases, the levels of conjugated bilirubin will increase. Simple liver function tests can also be done on blood samples, such as albumin production. Analogous organ function studies can be conducted using techniques known to those skilled in the art, as required to determine the extent of cell function after implantation. For example, pancreatic islet cells and other insulin-producing cells can be implanted to achieve glucose regulation by appropriate secretion of insulin. Other endocrine tissues and cells can also be implanted.

The site, or sites, where cells are to be implanted is determined based on individual need, as is the requisite number of cells. For cells replacing or supplementing organ or gland function (for example, hepatocytes or islet cells), the mixture can be injected into the mesentery, subcutaneous tissue, retroperitoneum, properitoneal space, and intramuscular space.

The amount and density of cells included in the disclosed products will vary depending on the choice of cell and site of implantation. In some embodiments, the single cells are present in the product at a concentration of 0.1×106to 4×106cells/ml, preferred 0.5×106to 2×106cells/ml. In other embodiments, the cells are present as cell aggregates. For example, islet cell aggregates (or whole islets) preferably contain about 1500-2000 cells for each aggregate of 150 μm diameter, which is defined as one islet equivalent (IE). Therefore, in some embodiments, islet cells are present at a concentration of 100-10000 IE/ml, preferably 200-3,000 IE/ml, more preferably 500-1500 IE/ml.

i. Islet Cells and Other Insulin-Producing Cells

In preferred embodiments, the disclosed compositions contain islet cells or other insulin-producing cells. Methods of isolating pancreatic islet cells are known in the art. Field et al.,Transplantation61:1554 (1996); Linetsky et al.,Diabetes46:1120 (1997). Fresh pancreatic tissue can be divided by mincing, teasing, comminution and/or collagenase digestion. The islets can then be isolated from contaminating cells and materials by washing, filtering, centrifuging or picking procedures. Methods and apparatus for isolating and purifying islet cells are described in U.S. Pat. No. 5,447,863 to Langley, U.S. Pat. No. 5,322,790 to Scharp et al., U.S. Pat. No. 5,273,904 to Langley, and U.S. Pat. No. 4,868,121 to Scharp et al. The isolated pancreatic cells may optionally be cultured prior to inclusion in the product using any suitable method of culturing islet cells as is known in the art. See e.g., U.S. Pat. No. 5,821,121 to Brothers. Isolated cells may be cultured in a medium under conditions that helps to eliminate antigenic components. Insulin-producing cells can also be derived from stem cells and cell lines and can be cells genetically engineered to produce insulin.

2. Genetically Engineered Cells

In some embodiments, the disclosed compositions contain cells genetically engineered to produce a protein or nucleic acid (e.g., a therapeutic protein or nucleic acid). In these embodiments, the cell can be, for example, a stem cell (e.g., pluripotent), a progenitor cell (e.g., multipotent or oligopotent), or a terminally differentiated cell (i.e., unipotent). Any of the disclosed cell types can be genetically engineered. The cell can be engineered, for example, to contain a nucleic acid encoding, for example, a polynucleotide such miRNA or RNAi or a polynucleotide encoding a protein. The nucleic acid can be, for example, integrated into the cells genomic DNA for stable expression or can be, for example, in an expression vector (e.g., plasmid DNA). The polynucleotide or protein can be selected based on the disease to be treated (or effect to be achieved) and the site of transplantation or implantation. In some embodiments, the polynucleotide or protein is anti-neoplastic. In other embodiments, the polynucleotide or protein is a hormone, growth factor, or enzyme.

Therapeutic agents for secretion by genetically engineered cells include, for example, thyroid stimulating hormone; beneficial lipoproteins such as Apo1; prostacyclin and other vasoactive substances, anti-oxidants and free radical scavengers; soluble cytokine receptors, for example soluble transforming growth factor (TGF) receptor, or cytokine receptor antagonists, for example IL1ra; soluble adhesion molecules, for example ICAM-1; soluble receptors for viruses, e.g. CD4, CXCR4, CCR5 for HIV; cytokines; elastase inhibitors; bone morphogenetic proteins (BMP) and BMP receptors 1 and 2; endoglin; serotonin receptors; tissue inhibiting metaloproteinases; potassium channels or potassium channel modulators; anti-inflammatory factors; angiogenic factors including vascular endothelial growth factor (VEGF), transforming growth factor (TGF), hepatic growth factor, and hypoxia inducible factor (HIF); polypeptides with neurotrophic and/or anti-angiogenic activity including ciliary neurotrophic factor (CNTF), glial-derived neurotrophic factor (GDNF), nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3, nurturin, fibroblast growth factors (FGFs), endostatin, ATF, fragments of thrombospondin, variants thereof and the like. More preferred polypeptides are FGFs, such as acidic FGF (aFGF), basic FGF (bFGF), FGF-1 and FGF-2 and endostatin.

In some embodiments, the active agent is a protein or peptide. Examples of protein active agents include, but are not limited to, cytokines and their receptors, as well as chimeric proteins including cytokines or their receptors, including, for example tumor necrosis factor alpha and beta, their receptors and their derivatives; renin; lipoproteins; colchicine; prolactin; corticotrophin; vasopressin; somatostatin; lypressin; pancreozymin; leuprolide; alpha-1-antitrypsin; clotting factors such as factor VIIIC, factor IX, tissue factor, and von Willebrands factor; anti-clotting factors such as Protein C; atrial natriuretic factor; lung surfactant; a plasminogen activator other than a tissue-type plasminogen activator (t-PA), for example a urokinase; bombesin; thrombin; hemopoietic growth factor; enkephalinase; RANTES (regulated on activation normally T-cell expressed and secreted); human macrophage inflammatory protein (MIP-1-alpha); a serum albumin such as human serum albumin; mullerian-inhibiting substance; relaxin A-chain; relaxin B-chain; prorelaxin; mouse gonadotropin-associated peptide; chorionic gonadotropin; a microbial protein, such as beta-lactamase; DNase; inhibin; activin; receptors for hormones or growth factors; integrin; protein A or D; rheumatoid factors; platelet-derived growth factor (PDGF); epidermal growth factor (EGF); transforming growth factor (TGF) such as TGF-α and TGF-β, including TGF-β1, TGF-β2, TGF-β3, TGF-β4, or TGF-β5; insulin-like growth factor-I and -II (IGF-I and IGF-II); des(1-3)-IGF-I (brain IGF-I), insulin-like growth factor binding proteins; CD proteins such as CD-3, CD-4, CD-8, and CD-19; erythropoietin; osteoinductive factors; immunotoxins; an interferon such as interferon-alpha (e.g., interferon.alpha.2A), -beta, -gamma, -lambda and consensus interferon; colony stimulating factors (CSFs), e.g., M-CSF, GM-CSF, and G-CSF; interleukins (ILs), e.g., IL-1 to IL-10; superoxide dismutase; T-cell receptors; surface membrane proteins; decay accelerating factor; transport proteins; homing receptors; addressins; fertility inhibitors such as the prostaglandins; fertility promoters; regulatory proteins; antibodies (including fragments thereof) and chimeric proteins, such as immunoadhesins; precursors, derivatives, prodrugs and analogues of these compounds, and pharmaceutically acceptable salts of these compounds, or their precursors, derivatives, prodrugs and analogues. Suitable proteins or peptides may be native or recombinant and include, e.g., fusion proteins.

Hormones to be included in the disclosed products or, most preferably, produced from cells included in the disclosed products can be any hormone of interest.

Examples of endocrine hormones include Anti-diuretic Hormone (ADH), which is produced by the posterior pituitary, targets the kidneys, and affects water balance and blood pressure; Oxytocin, which is produced by the posterior pituitary, targets the uterus, breasts, and stimulates uterine contractions and milk secretion; Growth Hormone (GH), which is produced by the anterior pituitary, targets the body cells, bones, muscles, and affects growth and development; Prolactin, which is produced by the anterior pituitary, targets the breasts, and maintains milk secretions; Growth Hormone-Releasing Hormone (GHRH), which is a releasing hormone of GH and is produced in the arcuate nucleas of the hypothalamus; Thyroid Stimulating Hormone (TSH), which is produced by the anterior pituitary, targets the thyroid, and regulates thyroid hormones; Thyrotropin-Release Hormone (TRH), which is produced by the hypothalamus and stimulates the release of TSH and prolactin from the anterior pituitary; Adrenocorticotropic Hormone (ACTH), which is produced by the anterior pituitary, targets the adrenal cortex, and regulates adrenal cortex hormones; Follicle-Stimulating Hormone (FSH), which is produced by the anterior pituitary, targets the ovaries/testes, and stimulates egg and sperm production; Lutenizing Hormone (LH), which is produced by the anterior pituitary, targets the ovaries/testes, and stimulates ovulation and sex hormone release; Luteinizing Hormone-Releasing Hormone (LHRH), also known as Gonadotropin-Releasing Hormone (GnRH), which is synthesized and released from GnRH neurons within the hypothalamus and is a trophic peptide hormone responsible for the release of FSH and LH; Thyroxine, which is produced by the thyroid, targets the body cells, and regulates metabolism; Calcitonin, which is produced by the thyroid, targets the adrenal cortex, and lowers blood calcium; Parathyroid Hormone, which is produced by the parathyroid, targets the bone matrix, and raises blood calcium; Aldosterone, which is produced by the adrenal cortex, targets the kidney, and regulates water balance; Cortisol, which is produced by the adrenal cortex, targets the body cells, and weakens immune system and stress responses; Epinephrine, which is produced by the adrenal medulla, targets the heart, lungs, liver, and body cells, and affects primary “fight or flight” responses; Glucagon, which is produced by the pancreas, targets the liver body, and raises blood glucose level; Insulin, which is produced by the pancreas, targets body cells, and lowers blood glucose level; Estrogen, which is produced by the ovaries, targets the reproductive system, and affects puberty, menstrual, and development of gonads; Progesterone, which is produced by the ovaries, targets the reproductive system, and affects puberty, menstrual cycle, and development of gonads; and Testosterone, which is produced by the adrenal gland, testes, targets the reproductive system, and affects puberty, development of gonads, and sperm.

In some embodiments, the protein is a growth hormone, such as human growth hormone (hGH), recombinant human growth hormone (rhGH), bovine growth hormone, methione-human growth hormone, des-phenylalanine human growth hormone, and porcine growth hormone; insulin, insulin A-chain, insulin B-chain, and proinsulin; or a growth factor, such as vascular endothelial growth factor (VEGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), epidermal growth factor (EGF), transforming growth factor (TGF), and insulin-like growth factor-I and -II (IGF-I and IGF-II).

The disclosed products and materials can also be used to provide vaccine components. For example, cells expressing vaccine antigens can be included in the product or material. A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains the same antigens (or parts of antigents) from a microorganism that causes disease. For example, measles vaccine contains measles virus. However, the antigens in vaccines are either killed, or weakened to the point that the do not cause disease but they are strong enough to stimulate the body's immune system so that the immune system can readily recognize and kill any of microorganisms that it later encounters (immunity).

An antigen can include any protein or peptide that is foreign to the subject organism. Preferred antigens can be presented at the surface of antigen presenting cells (APC) of a subject for surveillance by immune effector cells, such as leucocytes expressing the CD4 receptor (CD4 T cells) and Natural Killer (NK) cells. Typically, the antigen is of viral, bacterial, protozoan, fungal, or animal origin. In some embodiments the antigen is a cancer antigen. Cancer antigens can be antigens expressed only on tumor cells and/or required for tumor cell survival.

Certain antigens are recognized by those skilled in the art as immuno-stimulatory (i.e., stimulate effective immune recognition) and provide effective immunity to the organism or molecule from which they derive. Antigens can be peptides, proteins, polysaccharides, saccharides, lipids, nucleic acids, or combinations thereof. The antigen can be derived from a virus, bacterium, parasite, plant, protozoan, fungus, tissue or transformed cell such as a cancer or leukemic cell and can be a whole cell or immunogenic component thereof, e.g., cell wall components or molecular components thereof. Suitable antigens are known in the art and are available from commercial government and scientific sources. The antigens may be purified or partially purified polypeptides derived from tumors or viral or bacterial sources. The antigens can be recombinant polypeptides produced by expressing DNA encoding the polypeptide antigen in a heterologous expression system. The antigens can be DNA encoding all or part of an antigenic protein. Antigens may be provided as single antigens or may be provided in combination. Antigens may also be provided as complex mixtures of polypeptides or nucleic acids.

Viral Antigens

Bacterial Antigens

Parasite Antigens

Allergens and Environmental Antigens

The antigen can be an allergen or environmental antigen, such as, but not limited to, an antigen derived from naturally occurring allergens such as pollen allergens (tree-, herb, weed-, and grass pollen allergens), insect allergens (inhalant, saliva and venom allergens), animal hair and dandruff allergens, and food allergens. Important pollen allergens from trees, grasses and herbs originate from the taxonomic orders of Fagales, Oleales, Pinales and platanaceae including i.a. birch (Betula), alder (Alnus), hazel (Corylus), hornbeam (Carpinus) and olive (Olea), cedar (CryptomeriaandJuniperus), Plane tree (Platanus), the order of Poales including i.e. grasses of the generaLolium, Phleum, Poa, Cynodon, Dactylis, Holcus, Phalaris, Secale, andSorghum, the orders of Asterales and Urticales including i.a. herbs of the generaAmbrosia, Artemisia, andParietaria. Other allergen antigens that may be used include allergens from house dust mites of the genusDermatophagoidesandEuroglyphus, storage mite e.g.Lepidoglyphys, GlycyphagusandTyrophagus, those from cockroaches, midges and fleas e.g.Blatella, Periplaneta, ChironomusandCtenocepphalides, those from mammals such as cat, dog and horse, birds, venom allergens including such originating from stinging or biting insects such as those from the taxonomic order of Hymenoptera including bees (superfamily Apidae), wasps (superfamily Vespidea), and ants (superfamily Formicoidae). Still other allergen antigens that may be used include inhalation allergens from fungi such as from the generaAlternariaandCladosporium.

Tumor Antigens

The disclosed products and materials can also be used to provide antibodies. For example, cells expressing antibodies can be included in the product or material. Antibodies that function by binding directly to one or more epitopes, other ligands or accessory molecules at the surface of eukaryote cells, are described. Typically, the antibody or antigen binding fragment thereof has affinity for a receptor at the surface of a specific cell type, such as a receptor expressed at the surface of macrophage cells.

In some embodiments, the antibody or antigen binding fragment binds specifically to an epitope. The epitope can be a linear epitope. The epitope can be specific to one cell type or can be expressed by multiple different cell types. In other embodiments, the antibody or antigen binding fragment thereof can bind a conformational epitope that includes a 3-D surface feature, shape, or tertiary structure at the surface of the target cell.

In some embodiments, the antibody or antigen binding fragment that binds specifically to an epitope on the target cell can only bind if the protein epitope is not bound by a ligand or small molecule.

Various types of antibodies and antibody fragments can be used in the described compositions and methods, including whole immunoglobulin of any class, fragments thereof, and synthetic proteins containing at least the antigen binding variable domain of an antibody. The antibody can be an IgG antibody, such as IgG1, IgG2, IgG3, or IgG4. An antibody can be in the form of an antigen binding fragment including a Fab fragment, F(ab′)2 fragment, a single chain variable region, and the like. Antibodies can be polyclonal or monoclonal (mAb). Monoclonal antibodies include “chimeric” antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they specifically bind the target antigen and/or exhibit the desired biological activity (U.S. Pat. No. 4,816,567; and Morrison, et al.,Proc. Natl. Acad. Sci. USA,81: 6851-6855 (1984)). The described antibodies can also be modified by recombinant means, for example by deletions, additions or substitutions of amino acids, to increase efficacy of the antibody in mediating the desired function. Substitutions can be conservative substitutions. For example, at least one amino acid in the constant region of the antibody can be replaced with a different residue (see, e.g., U.S. Pat. Nos. 5,624,821; 6,194,551; WO 9958572; and Angal, et al., Mol. Immunol. 30:105-08 (1993)). In some cases changes are made to reduce undesired activities, e.g., complement-dependent cytotoxicity. The antibody can be a bi-specific antibody having binding specificities for at least two different antigenic epitopes. In one embodiment, the epitopes are from the same antigen. In another embodiment, the epitopes are from two different antigens. Bi-specific antibodies can include bi-specific antibody fragments (see, e.g., Hollinger, et al.,Proc. Natl. Acad. Sci. U.S.A.,90:6444-48 (1993); Gruber, et al.,J. Immunol.,152:5368 (1994)).

Antibodies can be generated by any means known in the art. Exemplary descriptions means for antibody generation and production include Delves, Antibody Production: Essential Techniques (Wiley, 1997); Shephard, et al., Monoclonal Antibodies (Oxford University Press, 2000); Goding, Monoclonal Antibodies: Principles And Practice (Academic Press, 1993); and Current Protocols In Immunology (John Wiley & Sons, most recent edition). Fragments of intact Ig molecules can be generated using methods well known in the art, including enzymatic digestion and recombinant means.

V. Methods of Making

The surfaces of the products described herein, can be modified using procedures known in the art.

For example, stainless steel and glass can be derivatized using the following procedure. Material to be derivatized is stirred in piranha solution for 1 h at room temperature. The material is washed by ultra-sonication in water, then ethanol, then acetone for 10 min each and then dried by blowing nitrogen over them. Immediate after drying the material is stirred in a 10% (v/v) silane/toluene solution for 48 h at 55° C. The material is cleaned by ultra-sonication in Toluene and Dichloromethane for 5 min each. The material is dried under Argon and cured in an oven at 70° C. for 3 h to prevent air oxidation.

The material is stirred in water and succinic acid, 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) and N-methylmorpholine (NMM) were added. The suspension was stirred at 55° C. overnight. The material is washed with water, methanol, and acetone to remove unreacted components.

The material is stirred in a water/acetonitrile solution and E9, CDMT, and NMM was added. The material is stirred overnight at 55° C. The material is washed with water, methanol, and acetone.

Polystyrene-COOH, PMMA-COOH and other similar materials can be derivatized by the following procedure. To PS/PMMA material in water/acetonitrile (3:2), E9 NMM and a spatula tip of CDMT is added. The solution is overhead stirred at 50° C. overnight. The material is washed three times with methanol and then three times with ethanol. The material is dried under reduced pressure.

Plastics, ceramics, and metals can be derivatized by treating with plasma. Materials are plasma treated for 1 min on each side and immediately dropped into a 0.2 mol solution of E9 in 5% DMSO in toluene. The reaction is stirred for 90 min and the materials are washed three times in methanol and three times in ethanol. The materials are dried under high vacuum overnight.

A. Compounds Used to Modify Surfaces

Compounds that can be used to modify the surfaces of the products include all of the compounds disclosed herein. Useful compounds include, but are not limited to, alcohols, thiols, amines, and combinations thereof.

Preferred alcohols for use as reagents in esterification include those shown below.

Preferred amines that can be used to modify the surfaces of the products include, but are not limited to,

Preferred thiols that can be used to modify the surfaces of the products include, but are not limited to,

d. Derivatization Via Click Chemistry

In some embodiments, the surfaces of the products are covalently modified initially to introduce a functional group which can be further reacted via click chemistry.

In preferred embodiments, the alcohols, amines or thiols are used to introduce a functional group which can further reacted using a 1,3-dipolar cycloaddition reaction (i.e., a Huisgen cycloaddition reaction). In a 1,3-dipolar cycloaddition reaction, a first molecule containing an azide moiety is reacted with a second molecule containing a terminal or internal alkyne. As shown below, the azide and the alkyne groups undergo an intramolecular 1,3-dipolar cycloaddition reaction, coupling the two molecules together and forming a 1,2,3-triazole ring.

The regiochemistry of 1,3-dipolar cycloadditions reaction can be controlled by addition of a copper(I) catalyst (formed in situ by the reduction of CuSO4with sodium ascorbate) or a ruthenium catalyst (such as Cp*RuCl(PPh3)2, Cp*Ru(COD), or Cp*[RuCl4]). For example, using a copper catalyst, azides and terminal alkynes can be reacted to exclusively afford the 1,4-regioisomers of 1,2,3-triazoles. Similarly, in the presence of a suitable ruthenium catalyst, azides can be reacted with internal or terminal alkynes to form exclusively the 1,5-regioisomers of 1,2,3-triazoles.

In some embodiments, the alcohol, amine or thiol containing an alkyne moiety is used to modify the surface initially. In these embodiments, the alkyne moiety present on the surface can be further reacted with a second molecule containing an azide functional group. Upon reaction, the azide and the alkyne groups undergo an intramolecular 1,3-dipolar cycloaddition reaction forming a 1,2,3-triazole ring, coupling the second molecule to the covalently modified surface.

In some embodiments,

wherein z is an integer from 1-11; wherein Rdis independently U2, U2+Q1, U2+Q2, U2+Q3, U2+Q1+Q2, U2+Q1+Q3, U2+Q2+Q3, U2+Q1+Q2+Q3, U3+Q1, U3+Q2, U3+Q3, U3+Q1+Q2, U3+Q1+Q3, U3+Q2+Q3, or U3+Q1+Q2+Q3(preferably, in these embodiments, U3+Q1+Q3); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring; wherein one instance of Rdis or contains Xa; wherein R12, R13, R14, R15, R16, and R17are independently C, O, N, S, S(O), or S(O)2, wherein the bonds between adjacent R12to R17are double or single according to valency, and wherein R12to R17are bound to none, one, or two hydrogens according to valency; and wherein R18is independently —(CR19R19)p— or —(CR19R19)p—Xb—(CR19R19)q—, wherein p and q are independently integers from 0 to 5, wherein Xbis absent, —O—, —S—, —S(O)—, —S(O)2—, or NR20, wherein each R19is, as valency permits, independently absent, hydrogen, ═O, ═S, —OH, —SH, or —NR20, wherein R20is U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1+Q3);wherein R6, R9, R10, and R11are independently present or absent according to valency, and wherein the ring bonds are double or single according to valency;(B) —(CH2)s—R34, wherein s is an integer from 0 to 20; wherein R34is —Xa, —O—R35, —S—R35, —(CH2)r—R35, —CO—R35, or —CHR36R37, wherein r is an integer from 0 to 19; wherein R35is —Xa, —(CH2)u—R38, wherein u is an integer from 0 to 18; wherein R36is —(CH2)t—R38, R37is —(CH2)v—R38, and t and v are integers from 0 to 18, wherein t and v together total 0 to 18; wherein R38is —Xa, methyl, —OH, —SH, or —COOH; Rxis hydrogen or —(CH2)s—R34, wherein s is an integer from 0 to 20; wherein R26is —O—R35, —S—R35, —(CH2)r—R35, —CO—R35, or —CHR35R36, wherein r is an integer from 0 to 19; wherein R35is —(CH2)u—R38, wherein u is an integer from 0 to 18; wherein R36is —(CH2)t—R38, R37is —(CH2)v—R38, and t and v are integers from 0 to 18, wherein t and v together total 0 to 18; wherein R38is methyl, —OH, —SH, or —COOH; wherein Rzand Rxare not both hydrogen; and wherein Rxcan be hydrogen.

wherein z is an integer from 0-11; wherein Rdis independently U2, U2+Q1, U2+Q2, U2+Q3, U2+Q1+Q2, U2+Q1+Q3, U2+Q2+Q3, U2+Q1+Q2+Q3, U3, U3+Q1, U3+Q2, U3+Q3, U3+Q1+Q2, U3+Q1+Q3, U3+Q2+Q3, or U3+Q1+Q2+Q3(preferably, in these embodiments, U3+Q1+Q3); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring; wherein R12, R13, R14, R15, R16, and R17are independently C, O, N, S, S(O), or S(O)2, wherein the bonds between adjacent R12to R17are double or single according to valency, and wherein R12to R17are bound to none, one, or two hydrogens according to valency; and wherein R18is independently —(CR19R19)p— or —(CR19R19)p—Xb—(CR19R19)q—, wherein p and q are independently integers from 0 to 5, wherein Xbis absent, —O—, —S—, —S(O)—, —S(O)2—, or NR20, wherein each R19is, as valency permits, independently absent, hydrogen, ═O, ═S, —OH, —SH, or —NR20, wherein R20is U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1+Q3);wherein R6, R9, R10, and R11are independently present or absent according to valency, and wherein the ring bonds are double or single according to valency;(B) —(CH2)s—R34, wherein s is an integer from 0 to 20; wherein R34is —O—R35, —S—R35, —(CH2)r—R35, —CO—R35, or —CHR36R37, wherein r is an integer from 0 to 19; wherein R35is —(CH2)u—R38, wherein u is an integer from 0 to 18; wherein R28is —(CH2)t—R38, R37is —(CH2)v—R38, and t and v are integers from 0 to 18, wherein t and v together total 0 to 18; wherein R38is methyl, —OH, —SH, or —COOH; wherein Rzand Rxare not both hydrogen; and wherein Rxcan be hydrogen; and Rxis hydrogen or —(CH2)s—R34, wherein s is an integer from 0 to 20; wherein R34is —O—R35, —S—R35, —(CH2)r—R35, —CO—R35, or —CHR36R37, wherein r is an integer from 0 to 19; wherein R35is —(CH2)u—R38, wherein u is an integer from 0 to 18; wherein R36is —(CH2)t—R38, R37is —(CH2)v—R38, and t and v are integers from 0 to 18, wherein t and v together total 0 to 18; wherein R38is methyl, —OH, —SH, or —COOH; wherein Rzand Rxare not both hydrogen; and wherein Rxcan be hydrogen;

In some embodiments, Rwis

In alternative embodiments, an alcohol, amine or thiol, containing an azide moiety is used to modify the surface. In these embodiments, the azide moiety present on the covalently modified surface can be further reacted with a second molecule containing a terminal or internal alkyne. Upon reaction, the azide and the alkyne groups undergo an intramolecular 1,3-dipolar cycloaddition reaction forming a 1,2,3-triazole ring, coupling the second molecule to the covalent modification.

In some embodiments, Xcis not —NH2and Rwis not —CH2—Ar— or —CH2—CH2—(O—CH2—CH2)3—.

In some embodiments, Rwis

wherein z is an integer from 1-11; wherein Rdis independently U2, U2+Q1, U2+Q2, U2+Q3, U2+Q1+Q2, U2+Q1+Q3, U2+Q2+Q3, U2+Q1+Q2+Q3, U3, U3+Q1, U3+Q2, U3+Q3, U3+Q1+Q2, U3+Q1+Q3, U3+Q2+Q3, or U3+Q1+Q2+Q3(preferably, in these embodiments, U3+Q1+Q3); or together with the carbon atom to which they are attached, form a 3- to 8-membered unsubstituted or substituted carbocyclic or heterocyclic ring; wherein one instance of Rdis or contains Xa; wherein R12, R13, R14, R15, R16, and R17are independently C, O, N, S, S(O), or S(O)2, wherein the bonds between adjacent R12to R17are double or single according to valency, and wherein R12to R17are bound to none, one, or two hydrogens according to valency; and wherein R18is independently —(CR19R19)p— or —(CR19R19)p—Xb—(CR19R19)q—, wherein p and q are independently integers from 0 to 5, wherein Xbis absent, —O—, —S—, —S(O)—, —S(O)2—, or NR20, wherein each R19is, as valency permits, independently absent, hydrogen, ═O, ═S, —OH, —SH, or —NR20, wherein R20is U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1+Q3);wherein R6, R9, R10, and R11are independently present or absent according to valency, and wherein the ring bonds are double or single according to valency;(B) —(CH2)s—R34, wherein s is an integer from 0 to 20; wherein R34is —O—R35, —S—R35, —(CH2)r—R35, —CO—R35, or —CHR36R37, wherein r is an integer from 0 to 19; wherein R35is —(CH2)u—R38, wherein u is an integer from 0 to 18; wherein R28is —(CH2)t—R38, R37is —(CH2)v—R38, and t and v are integers from 0 to 18, wherein t and v together total 0 to 18; wherein R38is methyl, —OH, —SH, or —COOH; wherein Rzand Rxare not both hydrogen; and wherein Rxcan be hydrogen; and Rxis hydrogen or —(CH2)s—R34, wherein s is an integer from 0 to 20; wherein R34is —O—R35, —S—R35, —(CH2)r—R35, —CO—R35, or —CHR36R37, wherein r is an integer from 0 to 19; wherein R35is —(CH2)u—R38, wherein u is an integer from 0 to 18; wherein R36is —(CH2)t—R38, R37is —(CH2)v—R38, and t and v are integers from 0 to 18, wherein t and v together total 0 to 18; wherein R38is methyl, —OH, —SH, or —COOH; wherein Rzand Rxare not both hydrogen; and wherein Rxcan be hydrogen;

In some embodiments, the azide moiety can be added to a covalently modified surface that has a compound containing a leaving group, such as I, Br, OTs, OMs. In some embodiments, the alcohol, amine or thiol containing the leaving group used to covalently modify the surface. Examples of the leaving group-containing alcohol, amine or thiol reactant include Xc—Rw-L, where Xcis —OH or —NH2, L is the leaving group, and Rwis U1, U1+Q1, U1+Q2, U1+Q3, U1+Q1+Q2, U1+Q1+Q3, U1+Q2+Q3, or U1+Q1+Q2+Q3(preferably, in these embodiments, U1+Q1+Q2+Q3).

In some embodiments, Xcis not —NH2and Rwis not —CH2—Ar— or —CH2—CH2—(O—CH2—CH2)3—.

In some embodiments, Rwis

In some embodiments, Xcis not —NH2and Rwis not —CH2—Ar— or —CH2—CH2—(O—CH2—CH2)3—.

In preferred embodiments, an amine containing an azide moiety is used to covalently modify the surface initially. Subsequently, the azide moiety present on the covalently modified surface is reacted with a second molecule containing a terminal or internal alkyne, forming a 1,2,3-triazole ring and coupling the second molecule to the covalent modification.

Different strategies can be employed to prepare covalently modified surfaces containing an azide moiety. For example, the surface can be modified by reaction with an amine substituted with an azide moiety (for example, 11-Azido-3,6,9-trioxaundecan-1-amine) in a single synthetic step. Alternatively, the surface can be amidated by reaction with an amine substituted with any moiety which can be readily transformed into an azide. For example, the surface can be amidated by reaction with 4-iodobenzylamine. The iodine moiety can then be readily converted to the azide, for example by treatment with sodium azide.

Subsequently, the azide-functionalized surfaces can be reacted with a molecule containing an alkyne functionality in the presence of a copper(I) catalyst (formed in situ by the reduction of CuSO4with sodium ascorbate).

Preferred alkynes for use as reagents in 1,3-dipolarcycloaddition reactions include those shown below.

Preferred compounds for modifying products include compounds having the structure:

The terminal amine can differ in other preferred compounds depending on the attachment chemistry that is used.
B. Chemical Modification of Products and Surfaces

Methods for attaching compounds to materials and surfaces are well established. For example, compounds can be attached to aminated surfaces, carboxylated surfaces or hydroxylated surfaces using standard immobilization chemistries. As another example, products and surfaces can be modified via a variety of methods to possess functional groups designed to covalently attach compounds. Examples of attachment groups include thiol, silane, carboxylate, methyl acrylate, phosphonate, nitrile, isonitrile, hydroxamate, acid chloride, anhydride, sulfonyl, phosphoryl, hydroxyl, amino acid, cyanogen bromide, succinimide, aldehydes (such as glutaraldehyde), tosyl chloride, photocrosslinkable agents, epoxides and maleimides. In some preferred embodiments, the attachment group is a thiol. In some embodiments, the attachment group contains a single functionality therein that can attach to the surface, for example, an amine or dimethyl-methoxysilane moiety. Any art recognized attachment group can be used to anchor a compound can be used to chemically modify products. For example, organosilanes, carboxylic acids, sulfur-containing anchor groups, may be used as attachments. Products and surfaces of products formed from metals such as gold, silver, copper, cadmium, zinc, palladium, platinum, mercury, lead, iron, chromium, manganese, tungsten, and alloys of these can be patterned, for example, by forming thiol, sulfide, and disulfide bonds with compounds having sulfur-containing attachment groups. In addition, compounds be attached to aluminum via a phosphonic acid (PO32−) anchor group. Nitriles and isonitriles, for example, can be used to attach compounds to platinum and palladium, and copper and aluminum can be chemically modified via a hydroxamic acid or hydroxamic acid-containing attachment group. Other functional groups suitable for attachment include, but are not limited to, acid chlorides, anhydrides, sulfonyl groups, phosphoryl and phosphonic groups, hydroxyl groups, and amino acid groups.

Free amine groups of compounds can also be attached to products and surfaces containing reactive amine groups via homobifunctional linkers. Linkers such as dithiobis(succinimidylpropionate) (DSP, 8-atom spacer), disuccinimidyl suberate (DSS, 8-atom spacer), glutaraldehyde (4-atom spacer), Bis[2-(succinimidyloxycarbonyloxy)ethyl]sulfone (BSOCOES, 9-atom spacer), all requiring high pH, can be used for this purpose. Examples of homobifunctional sulfhydryl-reactive linkers include, but are not limited to, 1,4-Di-[3′-2′-pyridyldithio)propion-amido]butane (DPDPB, 16-atom spacer) and Bismaleimidohexane (BMH, 14-atom spacer). For example, these homobifunctional linkers are first reacted with a thiolated surface in aqueous solution (for example PBS, pH 7.4), and then in a second step, the thiolated antibody or protein is joined by the link. Homo- and heteromultifunctional linkers can also be used.

Compounds can be directly attached to thiol, amine, or carboxylic acid functional groups on products or surfaces or, conversely, compounds with thiol, amine, or carboxylic acid functional groups can be attached to products or surfaces via these functional groups.

Amino groups can be added to the products and surfaces to, for example, increase the density of compounds on the products and surfaces.

Compounds can be attached to products and surfaces by several different mechanisms. Products and surfaces can be modified via a variety of methods to possess functional groups designed to covalently attach compounds.

Passive adsorption consists of primarily hydrophobic interactions or hydrophobic/ionic interactions between the biomolecules and the surface. Typical nomenclature for passive binding surfaces includes medium binding for hydrophobic surfaces and high binding for surfaces that are modified to have a small number of ionic carboxyl groups resulting in a slightly ionic, hydrophobic surface.

Covalent immobilization to products and surfaces can be accomplished through several means. On surfaces that are aminated or carboxylated, covalent coupling can be achieved using bifunctional crosslinkers that couple the amine or carboxyl group on the surface to a functional group, such as an amine or sulfhydryl, on the biomolecule. Selection of the crosslinker determines the type of covalent bond that will be formed. Functional and covalently reactive groups, such as N-oxysuccinimide, maleimide and hydrazide groups, can also be grafted onto a product or surface. These reactive groups are coupled to the products and surfaces via a photolinkable spacer arm resulting in a stable, yet reactive surface.

Surfaces that are hydrophilic and neutrally charged are considered low binding. Since some compounds passively adsorb to surfaces through hydrophobic and ionic interactions, a surface lacking these characteristics naturally inhibits nonspecific immobilization via these forces.

Some non-modified products and surfaces, such as plastices, are hydrophobic in nature and can bind compounds through passive interactions. This type of surface is referred to as medium binding and is primarily suitable for the immobilization of large molecules that have large hydrophobic regions that can interact with the surface.

Some products and surfaces, such as plastics having benzene rings, can be modified to be what is considered high binding via the use of radiation. The radiation effectively incorporates carboxylic acid on the accessible carbons of the benzene ring. The resulting surface is primarily hydrophobic with intermittent carboxyl groups capable of ionic interactions with positively charged groups on biomolecules. The mechanism of immobilization is passive adsorption through hydrophobic and ionic interactions. This is considered a general purpose surface capable of binding compounds that possess ionic groups and/or hydrophobic regions.

Products and surfaces can also be modified to possess positively charged amine groups. This type of surface lacks hydrophobic character and is strictly ionic in nature. Using the appropriate buffers and pH, this surface can be used to ionically couple to small negatively charged compounds. Such products and surfaces can be used with bifunctional crosslinkers (i.e., glutaraldehyde, carbodiimide) to covalently couple to functional groups (primary amines, thiols, carboxyls) on biomolecules.

The modifying compounds can also be linked to each other (e.g., oligomerized or polymerized) prior to, as part of, or following attachment to the product or surface. For example, methacrylate attachment of compounds can result in both polymerization of modifying compounds (via a polymethacrylate backbone) and attachment to the product or surface. Many other oligomerizable or polymerizable attachment groups can be used in a similar manner. The modifying compounds can also be oligomerized or polymerized ia a separate reaction from the attachment to the product or surface.

Products and surfaces can also be chemically modified by, for example, employing techniques established for producing microarrays. For example, compounds can be spotted or printed. Positioning and localization can also be achieved by specific location and distribution of attachment groups on the product or surface. If photoactivated crosslinkers are used, different compounds or different patterns could be generated by use of activating wavelengths at different stages of the modification. Alternatively, masks can be used to achieve the same effect with a single type of photoactivatable crosslinker. Etching of the product or surface can also be used to create patterns of attachment. Use of such techniques allows more precision in the location, density, and gradient of chemical modification on the products and surfaces.

Every compound within the description and definitions herein is intended to be and should be considered to be specifically disclosed herein. Further, every subgroup that can be identified within the above definition is intended to be and should be considered to be specifically disclosed herein. As a result, it is specifically contemplated that any compound or subgroup of compounds can be either specifically included for or excluded from use or included in or excluded from a list of compounds. For example, as one option, a group of compounds is contemplated where each compound is as defined herein but where R6is not substituted alkenyl or alkynyl. As another example, a group of compounds is contemplated where each compound is as defined herein and has a specific beneficial effect.

Any type or form of modified alginate, any type or form of alginate modification, and any type or form of reagent for modifying alginate can be, independently and in any combination, specifically included or excluded in any of the disclosed modified alginates, alginate modifications, reagents for alginate modifications, methods, and kits, and in any context, combination, or use. For example, any type or form of esterification reagent, amidation reagent, click reagent, alkyne-containing reagent, azide-containing reagent, phosphorylating reagent, and ketone reagent, such as those described above and in the examples, can be, independently and in any combination, specifically included or excluded from use to modify alginates, and any alginate modifications and any modified alginates that include or are based on such reagents can be, independently and in any combination, specifically included or excluded in any of the disclosed modified alginates, alginate modifications, reagents for alginate modifications, methods, and kits, and in any context, combination, or use.

VI. Methods of Assessing Biocompatibility

Biocompatibility of the disclosed products and materials can be assessed using any suitable techniques. Examples of useful techniques are described below.

The cytotoxicity of the disclosed surface modified products and materials can be evaluated on HeLa cells. The surface modified products and materials can be loaded into containers, such as wells of 96-well plates. The containers can be coated with an attachment molecule, such as poly-L-lysine, if appropriate. Unmodified product and material and saline can be loaded into containers as controls. HeLa cells can then be seeded into the wells and incubated for 3 days at 37° C. in a humidified chamber.

A cell viability assay using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) can then be performed, in which the media is aspirated from all containers and an appropriate volume (such as 100 μl for 96-well plate wells) of DMEM media without phenol red and an appropriate volume (such as 10 μl for 96-well plate wells) of MTT (5 mg/ml) added to all of the containers. The containers can then be incubated for 4 hours at 37° C. in a humidified chamber. After incubation, an appropriate volume (such as 85 μl for 96-well plate wells) of solution is aspirated and an appropriate volume (such as 100 μl for 96-well plate wells) of DMSO is added. Purple formazan crystals form during the assay in proportion to the number of viable HeLa cells present in each container. The contents of each container can be pipetted up and down to solubilize the formazan crystals prior to measurement. The containers can then be incubated at 37° C. for 10 minutes after which the bubbles from agitation are removed. The plate can be read using a UV/Vis reader at 540 nm with a reference at 700 nm. The viability can be normalized to cells seeded in containers with no product or material.

B. Assessing Foreign Body Response/Inflammatory Response

Cathepsin activity, which can be detected by fluorescence, can be used as an indicator of foreign body response (a form of inflammatory response). Mice, such as 8-12 week old male SKH1 mice, can be used to assess foreign body response of the disclosed products and materials. After injection or implantation of the product of material, cathepsin activity can be measured using an in vivo fluorescence assay at various times after injection or implantation. For example, imaging can be taken at 7 days after injection or implantation. 24 hours before in vivo fluorescence imaging, 2 nmol of ProSense-680 (VisEn Medical, Woburn, MA, excitation wavelength 680±10 nm, emission 700±10 nm) can be dissolved in 150 μl sterile PBS and injected into the tail vein of each mouse to image cathepsin activity.

In vivo fluorescence imaging can be performed with an in vivo fluorescence imaging system, such as the IVIS-Spectrum measuremeMAstem (Xenogen, Hopkinton, MA). The can be maintained under inhaled anesthesia during imaging, using, for example, 1-4% isoflurane in 100% oxygen at a flow rate of 2.5 L/min. Images and data can be collected as appropriate for the imaging device being use. As an example, images can be presented in fluorescence efficiency, which is defined as the ratio of the collected fluorescent intensity to an internal standard of incident intensity at the selected imaging configuration. Regions of interest (ROIs) can be designated around the site of each injection.

Relative cathepsin activity at the point of injection or implantation of products and materials can be imaged. The fluorescence intensity can be measured and normalized to the fluorescence response measured using the unmodified form of the product or material in order to quantify the biocompatibility of the surface modified products and materials as compared to unmodified products and materials.

Inflammatory response can also be assessed by detecting and measuring a suite of cytokines. The cytokine levels can indicate a high or low inflammatory response. For example, low protein levels of, for example, TNF-α, IL-13, IL-6, G-CSF, GM-CSF, IL-4, CCL2, and CCL4 which are known mediators of the foreign body response and fibrosis (Rodriguez et al.,J. Biomed. Mater. Res. A89:152-159 (2009)), can indicate a lack of or lower foreign body response.

FACS analysis can be performed on retrieved products and materials and appropriate times after implantation to characterize the different immune populations that are recruited to the products and materials compared to control product or material. For example, the presence of macrophages, neutrophils, myofibroblasts, of a combination thereto, on products and materials or at the location of the products and materials indicate a fibrotic response. Cells were tagged with markers for macrophages (CD11b+, CD68+), neutrophils (CD11b+, Ly6g+), or myofibroblasts (SMA). FACS was used to determine the levels of these fibrosis-associated cell types in proximity to the product or material.

D. qPCR Analysis of Innate Immune and Firbrosis Markers

Total RNA is isolated from a source—such as capsules or products retrieved from an animal after implantation for a period of time (or tissues removed from an animal)—by snap freezing in liquid nitrogen immediately following excision, using, for example,CAl (Invitrogen; Carlsbad, CA) according to the manufacturer's instructions. In addition, to help ensure complete tissue disruption, strong mechanical disruption with a Polytron homogenizer can also be employed. By this process, gene expression signatures are proportional and representative of the entire cell population present on and/or around retrieved materials. Before reverse transcription using, for example, the High Capacity cDNA Reverse Transcription kit (Cat. #4368814; ApCABiosystems, Foster City, CA), all samples are first normalized for comparison by loading the same input total RNA in a set volume (1 μg total RNA in a volume of 20 μl, for example) for each sample. cDNA (4.8 μl; 1:20 dilution in a total volume of 16 μl, for example), including a nucleic acid stain, such as SYBR Green, and PCR primers, is amplified by qPCR with the following appropriate primers (such as the primers shown in Table 1). These primers (Table 1) were designed using Primer Express software (Applied Biosystems, Carlsbad, CA, USA) and evaluated using LaserGene software (DNAStar, Madison, WI, USA) to ensure either mouse or rat (host)-specificity. Other primers can be designed by similar or equivalent analysis. Samples are incubated, for example, at 95° C. for 10 min followed by 40 cycles of 95° C. for 15 sec and 60° C. for 1 min in, for example, an ABI PRISM 7900HT Sequence Detection System (Applied Biosystems). Results are analyzed using a suitable method, such as the comparative CT(DDCT) method as described by Applied Biosystems. Results are presented, for example, as relative RNA levels compared to the RNA expression in either mock-implanted control cell samples (peripheral intraperitoneal fat tissue, or free floating intraperitoneal lavage cells) after normalization to the β-actin RNA content of each sample.

Single-cell suspensions from capsules or products freshly excised from an animal after implantation for a period of time (or of tissues freshly excised from an animal) are prepared using, for example, a gentleMACS Dissociator (Miltenyi Biotec, Auburn, CA) according to the manufacturer's protocol. Single-cell suspensions are prepared in a passive PEB dissociation buffer (1×PBS, pH 7.2, 0.5% BSA, and 2 mM EDTA) and suspensions are passed through 70 μm filters (for example, Cat. #22363548, Fisher Scientific, Pittsburgh, PA). This process removes the majority of cells adhered to the surface (>90%). The single-cell populations thus derived are then subjected to red blood cell lysis with 5 ml of 1×RBC lysis buffer (Cat. #00-4333, eBioscience, San Diego, CA, USA) for 5 min at 4° C. The reaction is terminated by the addition of 20 ml of sterile 1×PBS. The cells remaining are centrifuged at 300-400 g at 4° C. and resuspended in a minimal volume (˜50 μl) of, for example, eBioscience Staining Buffer (Cat. #00-4222) for antibody incubation. All samples are then co-stained in the dark for 25 min at 4° C. with fluorescently tagged monoclonal antibodies specific for the appropriate cell markers, such as for CD68 (for example, CD68-Alexa647, Clone FA-11, Cat. #11-5931, BioLegend at 1 μl (0.5 rig) per sample), Ly-6G (Gr-1) (for example, Ly-6G-Alexa-647, Clone RB6-8C5, Cat. #108418, BioLegend at 1 μl (0.5 rig) per sample), or CD11b (for example, CD11b-Alexa-488, Clone M1/70, Cat. #101217, BioLegend at 1 μl (0.2 rig) per sample). Two ml of, for example, eBioscience Flow Cytometry Staining Buffer (Cat. #00-4222, eBioscience) is then added, and the samples are centrifuged at 400-500 g for 5 min at 4° C. Supernatants are removed by aspiration, and this wash step is repeated two more times with staining buffer. Following the third wash, each sample is resuspended in 500 μp of, for example, FlowCytometry Staining Buffer and run through a 40 μm filter (for example, Cat. #22363547, Fisher Scientific) for eventual FACS analysis using a FACS machine (for example, BD FACSCalibur (cat. #342975), BD Biosciences, San Jose, CA, USA). For proper background and laser intensity settings, unstained, single antibody, and IgG (labeled with, for example, Alexa-488 or Alexa-647, BioLegend) controls can also be run.

F. Fabrication of Alginate Hydrogel Capsules and Cell Encapsulation

All buffers are sterilized by autoclave and alginate solutions are sterilized by filtration through a 0.2 um filter. After solutions are sterilized, aseptic processing is implemented by performing capsule formation in a type II class A2 biosafety cabinet to maintain sterility of manufactured microcapsules/spheres for subsequent implantation. The hydrogel capsules are formed by the following protocol.

To solubilize alginates, SLG20 (NovaMatrix, Sandvika, Norway) is dissolved at 1.4% weight to volume in 0.8% saline. TMTD alginate is initially dissolved at 5% weight to volume in 0.8% saline, and then blended with 3% weight to volume SLG100 (also dissolved in 0.8% saline) at a volume ratio of 80% TMTD alginate to 20% SLG100.

Forming different sized capsules: for 300 μm diameter capsules, a 30 gauge blunt tipped needle (SAI Infusion Technologies) is used with a voltage of 7-8 kV. For 500 μm diameter capsules, a 25 gauge blunt tipped needle (SAI Infusion Technologies) is used with a voltage of 5-7 kV. For 1.5 mm capsules, an 18 gauge blunt tipped needle (SAI Infusion Technologies) is used with a voltage of 5-7 kV.

Cells, such as human islet cells or cultured human cells, are used for encapsulation. Immediately prior to encapsulation, the cultured human cell clusters are centrifuged at 1,400 rpm for 1 minute and washed with Ca-free Krebs-Henseleit (KH) Buffer (4.7 mM KCl, 25 mM HEPES, 1.2 mM KH2PO4, 1.2 mM MgSO4×7H2O, 135 mM NaCl, pH≈7.4, ≈290 mOsm). After washing, the human cells are centrifuged again and all supernatant is aspirated. The human cell pellet is then re-suspended in the SLG20 or TMTD alginate solutions at cluster densities of 1,000, 250, and 100 clusters per 0.5 ml alginate solution.

An electrostatic droplet generator is set up as follows: an ES series 0-100 KV, 20 Watt high voltage power generator (Gamma ES series, Gamma High Voltage Research, FL, USA) is connected to the top and bottom of a blunt tipped needle (SAI Infusion Technologies, IL, USA). This needle is attached to a 5 mL lure lock syringe (BD, NJ, USA) which is clipped to a syringe pump (Pump 11 Pico Plus, Harvard Apparatus, MA, USA) that is oriented vertically. The syringe pump pumps alginate out into a glass dish containing a 20 mM barium 5% mannitol solution (Sigma Aldrich, MO, USA). The settings of the PicoPlus syringe pump are 12.06 mm diameter and 0.2 mL/min flow rate. Immediately after crosslinking, the encapsulated human cell clusters are washed 4 times with 50 mL of CMRLM media and cultured overnight in a spinner flask at 37° C. prior to transplantation. Due to an inevitable loss of human cell clusters during the encapsulation process, the total number of encapsulated clusters are recounted post-encapsulation.

G. Analysis of Cell Viability of Encapsulated Cells and/or Protein Secreted from Encapsulated Cells

Encapsulated cells are added in 3 ml of fresh medium to each well of a six-well tissue-culture polystyrene plate. Culturing of encapsulated cells is maintained for four days. Afterwards, supernatant samples can be collected and frozen at −20° C. for future analysis, such as by Western blot or ELISA. Encapsulated cells are collected into new plates. Both encapsulated cells are washed in HEPES buffer and subjected to live-dead fluorescent staining (Invitrogen) for viability assessment. The proportion of encapsulated cells that are viable (live) can be calculated. The secretion level of one or more proteins of interest, such as insulin form islet cells or a protein of interest secreted by a recombinant cell, can be assessed by analyzing the supernatant by Western blot or ELISA. The level of secretion can be assessed by, for example, raw level, normalized level (normalized to the level of a housekeeping secreted protein, for example), or either of these compared to the level measured form control cells.

H. Insulin Secretion Analysis

Encapsulated islet cell insulin responses are assessed by loading capsules or product containing encapsulated islet cells into a microfluidic device modified for encapsulated islets (Nourmohammadzadeh et al., Analytical Chem. 85:11240-11249 (2013)). The encapsulated islet cells can be, for example, newly encapsulated or retrieved after implantation into a subject, such as a mouse. Perifusate samples are collected every minute (500 μL/min) by an automated fraction collector (Gilson, model 203B, WI, USA). Insulin concentrations are quantified every other minute using, for example, a chemiluminescent insulin ELISA (Alpco, NH, USA). The following perifusion protocol is used: (1) KRB2 (0-20 min); (2) 20 mM glucose or 30 mM KCl (20-55 min); (3) KRB2 (55-100 min). An appropriate measure of the secreted insulin can be calculated. For example, the area under the curve for each insulin curve can be calculated in order to statistically compare groups using one-way ANOVA (p<0.05 as significant).

Biological and temporal characteristics of the disclosed products can be assessed by any suitable analysis. For example, the length of time a product implanted into a subject remains acceptably free of fibrotic effects, produces a desired effect, maintains encapsulated cell viability, or combinations thereof can be assessed. Analogously, the suitability of surface modifications for facilitating desirable biological and temporal characteristics of the disclosed products can be assessed in similar ways. In some embodiments, a product with surface modifications as described herein, if implanted into and retrieved from an immunocompetent animal, such as a C57BL/6J mouse, as described herein, can have one or more of the following properties:(a) expression of one or more immune and fibrosis markers on the product will be less than 3-fold higher, 2.5-fold higher, 2-fold higher, or 1.5-fold higher than in untreated control tissue at least 14 days, 30 days, 60 days, 120 days, 240 days, or 360 days after implantation into the immunocompetent animal as determined by, for example, Western blot analysis, ELISA, or qPCR analysis as known in the art or as described herein;(b) expression of one or more immune and fibrosis markers on the product will be less than 3-fold higher, 2.5-fold higher, 2-fold higher, or 1.5-fold higher than in untreated control tissue at least 14 days, 30 days, 60 days, 120 days, 240 days, or 360 days after implantation into the immunocompetent animal as determined by, for example, Western blot analysis, ELISA, or qPCR analysis as known in the art or as described herein;(c) the cell population of one or more immune- and fibrosis-associated cells on the product will be less than 20%, 18%, 15%, 12%, 10%, of 5% of the cell population observed for a control similar product lacking the surface modification at least 14 days, 30 days, 60 days, 120 days, 240 days, or 360 days after implantation into the immunocompetent animal as determined by, for example, FACS analysis or ELISA as known in the art or as described herein;(d) expression of a cell viability marker from cells encapsulated in the product will be more than 2-fold higher, 3-fold higher, 3.5-fold higher, 4-fold higher, 5-fold higher, or 10-fold higher observed for similar encapsulated cells comprised in a control similar product lacking the surface modification at least 14 days, 30 days, 60 days, 120 days, 240 days, or 360 days after implantation into the immunocompetent animal as determined by, for example, FACS analysis, Western blot analysis, ELISA, histology, or qPCR analysis as known in the art or as described herein;(e) secretion of a protein of interest from cells encapsulated in the product will be detectable at least 14 days, 30 days, 60 days, 120 days, 240 days, or 360 days after implantation into the immunocompetent animal as determined by, for example, Western blot analysis or ELISA as known in the art or as described herein;(f) secretion of insulin from islet cells encapsulated in the product will be detectable at least 14 days, 30 days, 60 days, 120 days, 240 days, or 360 days after implantation into the immunocompetent animal as determined by, for example, Western blot analysis or ELISA as known in the art or as described herein; and(g) at least 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, or 10% of the cells encapsulated in the product will be viable for at least 14 days, 30 days, 60 days, 120 days, 240 days, or 360 days after implantation into the immunocompetent animal as determined by, for example, cell viability analysis as known in the art or as described herein.

The compounds used for the surface modification can be assessed for facilitating desirable biological and temporal characteristics on products by, for example, fabricating aliginate capsules modified with the compound to encapsulate human islet cells, implanting the alginate capsules into and retrieving the alginate capsules from a C57BL/6J mouse as described herein, and assessing a suitable property of the retrieved alginate capsules. In some embodiments, the retrieved alginate capsules can have one or more of the following properties:(a) expression of an islet cell viability marker from the alginate capsules will be more than 2-fold higher, 3-fold higher, 3.5-fold higher, 4-fold higher, 5-fold higher, or 10-fold higher observed for a control similar alginate capsule lacking the surface modification at least 14 days, 30 days, 60 days, 120 days, 240 days, or 360 days after implantation into the immunocompetent animal as determined by, for example, FACS analysis, Western blot analysis, ELISA, histology, or qPCR analysis as known in the art or as described herein;(b) secretion of insulin from the islet cells encapsulated in the alginate capsule will be detectable at least 14 days, 30 days, 60 days, 120 days, 240 days, or 360 days after implantation into the immunocompetent animal as determined by, for example, Western blot analysis or ELISA as known in the art or as described herein;(c) expression of one or more immune and fibrosis markers on the alginate capsule will be less than 3-fold higher, 2.5-fold higher, 2-fold higher, or 1.5-fold higher than in untreated control tissue at least 14 days, 30 days, 60 days, 120 days, 240 days, or 360 days after implantation into the immunocompetent animal as determined by, for example, Western blot analysis, ELISA, or qPCR analysis as known in the art or as described herein;(d) expression of one or more immune and fibrosis markers on the alginate capsule will be less than 3-fold higher, 2.5-fold higher, 2-fold higher, or 1.5-fold higher than in untreated control tissue at least 14 days, 30 days, 60 days, 120 days, 240 days, or 360 days after implantation into the immunocompetent animal as determined by, for example, Western blot analysis, ELISA, or qPCR analysis as known in the art or as described herein;(e) the cell population of one or more immune- and fibrosis-associated cells on the alginate capsule will be less than 20%, 18%, 15%, 12%, 10%, of 5% of the cell population observed for a control similar product lacking the surface modification at least 14 days, 30 days, 60 days, 120 days, 240 days, or 360 days after implantation into the immunocompetent animal as determined by, for example, FACS analysis or ELISA as known in the art or as described herein;(f) expression of a cell viability marker from the islet cells encapsulated in the alginate capsule will be more than 2-fold higher, 3-fold higher, 3.5-fold higher, 4-fold higher, 5-fold higher, or 10-fold higher observed for similar encapsulated cells comprised in a control similar product lacking the surface modification at least 14 days, 30 days, 60 days, 120 days, 240 days, or 360 days after implantation into the immunocompetent animal as determined by, for example, FACS analysis, Western blot analysis, ELISA, histology, or qPCR analysis as known in the art or as described herein;(g) secretion of a protein of interest from the islet cells encapsulated in the alginate capsule will be detectable at least 14 days, 30 days, 60 days, 120 days, 240 days, or 360 days after implantation into the immunocompetent animal as determined by, for example, Western blot analysis or ELISA as known in the art or as described herein; and(h) at least 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, or 10% of the islet cells encapsulated in the product will be viable for at least 14 days, 30 days, 60 days, 120 days, 240 days, or 360 days after implantation into the immunocompetent animal as determined by, for example, cell viability analysis as known in the art or as described herein.

In some embodiments of the product, a similar product, if implanted into and retrieved from a C57BL/6J mouse as described herein has the following property: expression of one or more immune and fibrosis markers on the product will be less than 3-fold higher than in untreated control tissue at least 30 days after implantation into the C57BL/6J mouse as determined by, for example, Western blot analysis, ELISA, or qPCR analysis as known in the art or as described herein.

In some embodiments of the product, a similar product, if implanted into and retrieved from a C57BL/6J mouse as described herein has the following property: the cell population of one or more immune- and fibrosis-associated cells on the product will be less than 20% of the cell population observed for an identical product lacking the surface modification at least 14 days after implantation into the C57BL/6J mouse as determined by, for example, FACS analysis, Western blot analysis, ELISA, or histology as known in the art or as described herein.

In some embodiments of the product, alginate capsules, (a) fabricated as described herein to encapsulate human islet cells and (b) having the surface modification of the product on the outer surface of alginate capsules at a similar density as on the surface or a surface of the product, provides encapsulated human islet cells that, if implanted into and retrieved from a C57BL/6J mouse as described herein has the following property: expression of an islet cell viability marker from the alginate capsules will be more than 2-fold higher observed for an identical alginate capsule lacking the surface modification at least 30 days after implantation into the C57BL/6J mouse as determined by, for example, FACS analysis, Western blot analysis, ELISA, histology, or qPCR analysis as known in the art or as described herein.

In some embodiments of the product, alginate capsules, (a) fabricated as described herein to encapsulate human islet cells and (b) having the surface modification of the product on the outer surface of alginate capsules at a similar density as on the surface or a surface of the product, provides encapsulated human islet cells that, if implanted into and retrieved from a C57BL/6J mouse as described herein has the following property: the encapsulated islet cells will be able to secrete detectable levels of insulin at least 30 days after implantation into the C57BL/6J mouse as determined by, for example, Western blot analysis or ELISA as known in the art or as described herein.

In some embodiments of the product, the product includes encapsulated cells, where the encapsulated cells, if implanted, via implantation of the product, into and retrieved from a C57BL/6J mouse as described herein has the following property: expression of a cell viability marker from the encapsulated cells will be more than 2-fold higher observed for similar encapsulated cells included in an identical product lacking the surface modification at least 30 days after implantation into the C57BL/6J mouse as determined by, for example, FACS analysis, Western blot analysis, ELISA, histology or qPCR analysis as known in the art or as described herein.

In some embodiments of the product, the product includes encapsulated cells expressing and secreting a protein of interest, where the encapsulated cells, if implanted, via implantation of the product, into and retrieved from a C57BL/6J mouse as described herein has the following property: the encapsulated islet cells will be able to secrete detectable levels of the protein of interest at least 30 days after implantation into the C57BL/6J mouse as determined by, for example, Western blot analysis or ELISA as known in the art or as described herein.

For testing of a product of interest, suitable products can be, for example, a product identical to the product of interest, a corresponding product to the product of interest, a similar product to the product of interest, a product having identical surface modification as the product of interest, a product having a corresponding surface modification as the product of interest, or a product having a similar surface modification as the product of interest. For testing of a compound, chemical modification, or surface modification of interest, suitable products can be, for example, a product surface modified with the compound of interest, a product with the chemical modification of interest, or a product with the surface modification of interest.

VII. Methods of Using

The products described herein, can be used in applications where improved biocompatibility and physical properties (such as being anti-fibrotic), as compared to other commercially available products, are useful or preferred. These include, but are not limited to tissue engineering, invasive sensors, drug delivery, gene transfection systems, medical nanotechnology and biotechnology, implantable medical devices.

The products described herein can be used to treat a broad spectrum of diseases, disorders, and conditions. For example, products that include cells or tissues can be used to treat disorders characterized by a need for a product produced by the cell or tissue or of a reaction mediated by a product of the cell. For example, the cell or cell product can metabolize glucocerebroside or detoxify compounds. For type I and III Gaucher's disease, enzyme replacement treatment with intravenous recombinant glucocerebrosidase is generally used to hydrolyze the beta-glucosidic linkage of, an intermediate in glyclipid metabolism. Toxin-specific antibodies can be used in prophylaxis or treatment of infections caused by bacteria such asBacillus anthracisandClostridium difficile. In some embodiments, the cell or tissue can produce a product useful to treat a disorder. For example, where the cell is an islet cell and the disorder is diabetes. In some embodiments, the product can include a cell that metabolizes or modifies a substrate produced by the subject.

TABLE 3List of products and devices that can be used to treat the disorder.ProductDisorderBioartificial liver devicesLiver diseasesHeart pacemakersAny conditions that case abnormalheart rhythmsBreast implantsMisshaped breastsSpine screws, rods and artificialSpinal fusion surgeriesdiscsIntra-uterine devicesArtificial kneesDisability associated with knee cap orjointsCoronary stentsUnstable angina or heart attach due toblacked arteriesArtificial eye lensesCataractMetal screws, pins, plates and rodsBone fracturesArtificial hipsDisability associated with hipsIntestinal stentsBowl obstruction

EXAMPLES

It was discovered that alginates modified with the Z2-Y12, Z1-Y15, or Z1-Y19 moieties exhibit lower foreign body responses. It has now been discovered that carboxy-polystyrene (C-PS) exhibits lower foreign body responses when modified with Z2-Y12, Z1-Y15, or Z1-Y19 moieties. 500 μm carboxy-polystyrene (C-PS) beads were modified with the following moieties:

After purification, the beads were implanted into the intraperitoneal (IP) space of C57BL/6J mice. After 14 days post-implantation, the beads were retrieved and the amounts of fibrotic or collagenous overgrowth/encapsulation on the implants were analyzed.
Results

Compared to unmodified control C-PS beads, modified C-PS beads showed no clumping or collagenous encapsulation. The control implants showed extreme levels of clumping and fibrotic deposition between beads/capsules. These results mimic similar studies with alginate microcapsules, and show that the chemical derivatizations can successfully mitigate immunological and fibrotic reactions to other biomedical device-relevant materials. These results are surprising, given that the environment on the surface of the beads or device and surface densities of the chemical derivatizations are different from that in the modified alginate polymer.

The materials presented here represent a key advancement in the development of fibrosis-resistant materials. While these compounds have been developed in the context of cell encapsulation and bead surface modification, the compounds are broadly applicable as anti-fibrotic coatings for other biomedical devices.

This example shows that various materials, including synthetic materials, exhibit lower foreign body responses when modified with E9 (Z2-Y12). The surfaces of polystyrene, glass, PDMS, and medical-grade silicone have been modified successfully with the E9 molecule, and after 2 weeks implantation into the intraperitoneal space of a C57BL/6 mouse show dramatically reduced foreign body responses. Since many of these very same materials are used for implantable medical devices, such as implanted catheters in the brain, these results have profound implications for medical device composition and manufacture.

Beads were stirred in piranha solution for 1 h at room temperature. Beads were washed by ultra-sonication in water, then ethanol, then acetone for 10 min each and then dried by blowing nitrogen over them. Immediate after drying the beads were stirred in a 10% (v/v) silane/toluene solution for 48 h at 55° C. Cleaning was done by ultra-sonication in Toluene and Dichloromethane for 5 min each. The beads were dried under Argon and cured in an oven at 70° C. for 3 h to prevent air oxidation.

The beads were stirred in water and succinic acid, 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) and N-methylmorpholine (NMM) were added. The suspension was stirred at 55° C. overnight. The beads were washed with water, methanol, and acetone to remove unreacted material.

The beads were stirred in a water/acetonitrile solution and E9, CDMT, and NMM was added. The beads were stirred overnight at 55° C. Beads were washed with water, methanol, and acetone. The conjugation was analyzed by X-ray photoelectron spectroscopy (XPS).

To PS/PMMA beads in water/acetonitrile (3:2), E9 NMM and a spatula tip of CDMT was added. The solution was overhead stirred at 50° C. overnight. The beads were washed three times with methanol and then three times with ethanol. The beads were dried under reduced pressure. Materials are characterized via XPS.

Materials were plasma treated for 1 min on each side and immediately dropped into a 0.2 mol solution of E9 in 5% DMSO in toluene. The reaction was stirred for 90 min and the materials were washed three times in methanol and three times in ethanol. The materials are dried under high vacuum overnight. Materials are characterized via XPS.

XPS analysis of glass shows the ratios of the elements present on the surfaces of the glass. Table 4 shows a quantitative measure of the amount of each element present, the numbers being derived from the corresponding areas under the peaks in the FIGURE. In this case, the data show that the surface of the glass samples have carbon, oxygen, sodium, magnesium and silicon, which is indicative of the presence of surface modifications. From the standard deviations, one can determine that the elemental variations between the three glass samples are small.

XPS analysis of unmodified polydimethylsiloxane (PDMS) and PDMS modified with compound E9 (Z2-Y12) show that there is a significantly higher amount of elemental nitrogen on the surface of E9-modified PDMS compared to unmodified PDMS (Table 5). For example, (i) the amount of elemental nitrogen in the E9-modified PDMS sample is 7.66, much higher than the value of 1.06 in the unmodified PDMS sample; and (ii) the standard deviation of elemental nitrogen (4.67) is higher than the average amount of nitrogen (4.36) between the samples. Also worth noting is the difference between detected amounts of silicon in the two samples: the values are 10.04 and 18.38 in E9-modified PDMS and in unmodified PDMS, respectively. The lower value in E9-modified PDMS indicates that the surface of the sample has been coated.

Analysis of the atomic concentration of elemental nitrogen present on the surface of a 1300×1300 μm section of a E9-modified PDMS sample indicates that some areas have a high amount of elemental nitrogen compared to other areas.

XPS analysis of E9-modified silicone show that the surfaces of the silicone samples have been successfully modified with E9 (Table 6). In particular, the averages and standard deviations of elemental nitrogen indicate similar densities of surface E9 in the three samples.

XPS analysis of glass shows that the surface of the glass samples have carbon, oxygen, sodium, magnesium and silicon (Table 7), which is indicative of the presence of surface modifications. From the standard deviations, one can determine that the elemental variations between the two glass samples are small.

Grafting E9 to the surface of carboxylic acid terminated polystyrene microspheres (300-500 μm in diameter) reduces fibrosis. Carboxylic acid modified polystyrene or E9 surface modified polystyrene were implanted to the intraperitoneal space of C57BL/6 mice for 14 days. Bright field images of retrieved microspheres revealed extensive clumping and fibrotic coating of the unmodified microspheres and no clumping or coating for the modified microspheres.

Grafting E9 to the surface of PDMS or medical grade silicone cylinders (5 mm diameter×1 mm height) reduces fibrosis. Bright field images obtained from unmodified PDMS cylinders or E9 modified PDMS cylinders after retrieval from the intraperitoneal space of C57BL/6 mice (14-day implantation study) reveal extensive fibrotic coating of unmodified cylinders and no visible coating of modified cylinders. Bright field images obtained from E9 modified or unmodified PDMS cylinders and E9 modified or unmodified medical grade silicone cylinders after retrieval from the intraperitoneal space of C57BL/6 mice (14-day implantation study) reveal extensive fibrotic coating of both unmodified PDMS cylinders and unmodified silicon cylinders and no visible coating of modified PDMS cylinders and modified silicon cylinders. E9 modified or unmodified PDMS cylinders and E9 modified or unmodified medical grade silicone cylinders after retrieval from the intraperitoneal space of C57BL/6 mice (14-day implantation study) were stained for cellular deposition (DAPI, F-actin) and myofibroblasts (α-SMA), the presence of which indicate fibrotic reaction. Confocal immunofluorescence images reveal extensive staining for all three markers on both unmodified PDMS cylinders and unmodified silicon cylinders and minimal staining of modified PDMS cylinders and modified silicon cylinders.

Disclosed are compounds, materials, compositions, and components that can be used for, can be used in conjunction with, can be used in preparation for, or are products of the disclosed method and compositions. These and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed that while specific reference of each various individual and collective combinations and permutation of these compounds may not be explicitly disclosed, each is specifically contemplated and described herein. For example, if a compound is disclosed and discussed and a number of modifications that can be made to a number of molecules including the compound are discussed, each and every combination and permutation of compound and the modifications that are possible are specifically contemplated unless specifically indicated to the contrary. Thus, if a class of molecules A, B, and C are disclosed as well as a class of molecules D, E, and F and an example of a combination molecule, A-D is disclosed, then even if each is not individually recited, each is individually and collectively contemplated. Thus, is this example, each of the combinations A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D. Likewise, any subset or combination of these is also specifically contemplated and disclosed. Thus, for example, the sub-group of A-E, B-F, and C-E are specifically contemplated and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D. Further, each of the materials, compositions, components, etc. contemplated and disclosed as above can also be specifically and independently included or excluded from any group, subgroup, list, set, etc. of such materials. These concepts apply to all aspects of this application including, but not limited to, steps in methods of making and using the disclosed compositions. Thus, if there are a variety of additional steps that can be performed it is understood that each of these additional steps can be performed with any specific embodiment or combination of embodiments of the disclosed methods, and that each such combination is specifically contemplated and should be considered disclosed.

It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to “a compound” includes a plurality of such compounds, reference to “the compound” is a reference to one or more compounds and equivalents thereof known to those skilled in the art, and so forth.

Throughout the description and claims of this specification, the word “comprise” and variations of the word, such as “comprising” and “comprises,” means “including but not limited to,” and is not intended to exclude, for example, other additives, components, integers or steps.

Although the description of materials, compositions, components, steps, techniques, etc. may include numerous options and alternatives, this should not be construed as, and is not an admission that, such options and alternatives are equivalent to each other or, in particular, are obvious alternatives. Thus, for example, a list of different compounds does not indicate that the listed compounds are obvious one to the other, nor is it an admission of equivalence or obviousness.